Investigating the functional significance of an FGFR2 intronic SNP in Breast Cancer by Robbez-Masson, Luisa
Investigating the functional significance of an FGFR2 intronic SNP in
Breast Cancer
Robbez-Masson, Luisa
 
 
 
 
 
The copyright of this thesis rests with the author and no quotation from it or information
derived from it may be published without the prior written consent of the author
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/8539
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
1 
 
 
 
 
 
 
 
Investigating the functional significance of 
an FGFR2 intronic SNP in Breast Cancer 
Luisa Robbez-Masson 
 
 
 
 
Submitted in partial fulfillment of the requirements for  
the Degree of 
Doctor of Philosophy  
 
 
 
May 2013 
Queen Mary University 
Centre for Tumour Biology 
Barts Cancer Institute 
John Vane Science Centre, Charterhouse Square 
EC1M 6BQ   London, UK 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Declaration of authorship 
 
I hereby declare that the material presented in this thesis is the result of original 
work done by the author, Luisa Robbez-Masson, at the Centre for Tumour Biology, 
Barts Cancer Institute, Queen Mary University of London. All the external sources 
have been properly acknowledged.    
3 
 
 
Acknowledgments 
 
I would like to express my extreme gratitude to my supervisor Dr Richard Grose 
and thank him for making me a member of his research group, giving me well 
needed guidance, advice and encouragement throughout my three years PhD. I 
would like to thank my dear friends Dr Athina-Myrto Chioni, Stacey Coleman and 
Abbie Fearon for being great lab mates and friends and making the FGF group such 
a special place to work in.   
My gratitude also goes to Prof Ian Hart, for leading the Centre for Tumour Biology 
with such enthusiasm and providing us with high standards of work ethic and great 
motivation. Thank you also to Dr Jude Fitzgibbon and Dr Csaba Bodor for providing 
much advice on SNP genotyping and reagents. Thank you to Prof Helen Hurst for 
her advice and input on ER biology and molecular biology techniques.  I owe many 
thanks to the people of Prof Bruce Ponder’s lab in CRUK, for their help and advice 
on ChIP, particularly Dr Kerstin Meyer and Dr Martin O’Reilly. I would like to 
acknowledge all of my colleagues from Barts Cancer Institute and office G28, 
especially Hector, Müge, Wasfi, Mo, and Carine.  
I will always be indebted to my partner Yoann, for his support and encouragement 
throughout my PhD, who has helped me maintain my focus, be more optimistic 
and believe in myself and without whom I would not have completed this thesis. 
I also want to thank my family in France, especially my parents Cathie and Frank as 
well as my sister Victoria and brother Lucas for their support, care and love.  
Lastly I would like to thank Queen Mary University for the funding provided which 
allowed me to pursue my dream of starting an academic career in London.  
 
 
 
4 
 
 
“Somewhere, something incredible is waiting to be known.” 
Carl Sagan 
 
“We are survival machines – robot vehicles blindly programmed to preserve the 
selfish molecules known as genes. This is a truth which still fills me with 
astonishment.” 
 
The selfish gene 
Richard Dawkins 
 
 
 
“Behind every man now alive stand thirty ghosts, for that is the ratio by which the 
dead outnumber the living. Since the dawn of time, roughly a hundred billion 
human beings have walked the planet Earth. 
 
Now this is an interesting number, for by a curious coincidence there are 
approximately a hundred billion stars in our local universe, the Milky Way.  
So for every man who has ever lived, in this Universe there shines a star. 
 
But every one of those stars is a sun, often far more brilliant and glorious than the 
small, nearby star we call the Sun. And many--perhaps most--of those alien suns 
have planets circling them. So almost certainly there is enough land in the sky to 
give every member of the human species, back to the first ape-man, his own 
private,  
world-sized heaven—or hell. 
 
2001: A Space Odyssey 
Arthur C. Clarke  
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Abstract 
 
Single nucleotide polymorphisms present in the second intron of the fibroblast 
growth factor receptor 2 (FGFR2) gene have been linked with increased risk of 
breast cancer in several genome wide association studies. The potential effect of 
those SNPs appeared to be mediated through the differential binding of cis-
regulatory elements, such as transcription factors, since all the SNPs in linkage 
disequilibrium were located in a regulatory DNA region. Preliminary studies have 
shown that a Runx2 binding site is functional only in the minor, disease associated 
allele of rs2981578, resulting in increased expression of FGFR2 in cancers from 
patients homozygous for that allele. Moreover, the increased risk conferred by the 
minor FGFR2 allele is associated most strongly in oestrogen receptor alpha positive 
(ERα) breast tumours, suggesting a potential interaction between ERα and FGFR 
signalling. Here, we have developed a human cell line model system to study the 
effect of those SNPs on cell behaviour. In an ERα positive breast cancer cell line, 
rs2981578 was edited using Zinc Finger Nucleases. Unexpectedly, the acquisition 
of the single risk allele in MCF7 cells failed to affect proliferation or cell cycle 
progression. Binding of Runx2 to the risk allele was not observed. However FOXA1 
binding, an important ERα partner, appeared decreased at the rs2981578 locus in 
the risk allele cells. Additionally, differences in allele specific expression (ASE) of 
FGFR2 were not observed in a panel of 72 ERα positive breast cancer samples. 
Thus, the apparent increased risk of developing ERα positive breast cancer is not 
caused by rs2981578 alone.  Rather, the observed increased risk of developing 
breast cancer might be the result of a coordinated effect of multiple SNPs forming 
a risk haplotype in the second intron of FGFR2.    
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1. Introduction 
1.1. Breast Cancer 
1.1.1. Incidence and mortality 
Breast cancer is the most common cancer in women in the UK with 48,700 new 
cases diagnosed in 2009 (Data and Statistics, 2012). It is now the second most 
common cause of cancer-related death in European women, after lung cancer 
(WHO, 2008). Between 1971 and 2010, the incidence rate has increased by 90%, 
while overall mortality has decreased, however different trends can be observed 
over this period (Fig. 1.1A). 
Female breast cancer age-standardised incidence rate increased steadily by around 
1 to 2% each year from the mid-1970s (Data and Statistics, 2012). The apparent 
increase between 1980 and 1987 coincides with increased mammographic 
screening, with a national screening programme introduced in the UK in 1988 for 
women aged between 50 and 64 years old, following the recommendations of the 
Forrest Committee (Forrest P, 1986). By the mid-1990s, the increase in incidence 
rates returned to the pre-screening pace and continued this way until the mid 
2000s, after which time the rate has remained relatively stable. The decrease in 
mortality observed from 1990 can be attributed both to improvement in 
treatments and the benefits of large scale screening, i.e. early detection. 
Breast cancer can also affect males but is much less common, affecting just one in 
100,000 men in England (Gomez-Raposo et al, 2010). This represents about one 
man for every 130 women diagnosed in the UK.  
1.1.2. Pathology and progression 
Like most solid cancers, primary breast cancers usually (but not necessarily) 
progress  from local disease that can originate from the breast lobules or ducts 
(Lobular and Ductal carcinoma in situ, LCIS and DCIS respectively) to more invasive 
disease (Stages I to IV) leading to systemic metastasis (Fig. 1.1B) (Kufe et al, 2003). 
However, the natural history and prognosis vary considerably from patient 
16 
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Figure 1.1: Breast cancer incidence and normal breast with ductal carcinoma in situ 
(DCIS) progression 
A) Female breast cancer, European Age-Standardised Incidence and Mortality Rates, 
England from 1971 to 2010. UK National screening began in 1988 as represented by the 
vertical dashed line. B) General breast morphology and early stages of breast cancer 
development. Source: Data from UK National Statistics (2012) and image from 
breastcancer.org (Bryson, 2012).  
A 
B 
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to patient. Some patients have a very slow progressing disease that can be cured 
by local therapy and can survive for many years even after developing metastases. 
Historically, it even was established that a small percentage of patients survived 
more than 10 years without any treatment (Kufe et al, 2003). In other patients, the 
disease follows an aggressive, rapidly progressing course that is refractory to 
treatment (e.g. Triple-negative and Basal-like tumours) (Kufe et al, 2003).  
Early-stage invasive breast cancer can be managed successfully with either 
mastectomy or breast conservation therapy (Fisher et al, 1989; Fisher et al, 2002). 
The results of the long term (20 years) follow up study by Fisher et al (2002) 
showed that additional adjuvant chemotherapy (hormonal or cytotoxic) or 
radiotherapy in surgery patients, implemented in the 1980s, led to significantly 
lower recurrence rates compared to those who underwent surgery alone. In 
addition, axillary lymph node staging (presence of metastasis in the axillary lymph 
nodes, particularly in the sentinel lymph node) is a powerful prognostic factor 
(Krag et al, 2010), and remains one of the most reliable prognostic factors for 
decisions about treatment plans.  
Due to the very heterogeneous nature of breast cancer, it is crucial to identify 
subgroups of patients with different risk factors and establish individual 
benefit/risk ratios in order to tailor breast cancer treatments and management.  
1.1.3. Risk factors 
1.1.3.1. Environmental risk factors 
Similarly to most solid cancers, cases of breast cancer peak in the 60 to 64 age 
group, with age being one of the known risk factors. The second risk factor is 
gender, and relates to the female patient lifetime exposure to oestrogens (Kufe et 
al, 2003). Indeed breast cancer risk is influenced predominantly by gynaecological 
events in a woman’s lifetime; an early menarche, a late first pregnancy, fewer 
births and a late menopause can all cause an increase in risk (Kelsey and 
Berkowitz, 1988). Oral contraceptives, hormone replacement therapy (HRT) and 
lifestyle factors, such as obesity and alcohol consumption, also have been 
identified as risk factors. For instance it has been established that 6% of UK female 
18 
    
breast cancer can be attributed to alcohol intake, a study on obesity has 
established that weight gain post-menopause of 22Ibs (9.9kg) leads to increase in 
risk of 18% and, finally, that the risk from passive smoking could lead to an 
increase in risk of up to 70% (Calle and Kaaks, 2004; Zhang et al, 2007; Kelsey and 
Berkowitz, 1988). 
The changes in lifestyle observed in Western populations over the last 50 years 
have led to an increase in occurrence of most of these environmental risk factors, 
as well as a change in the approach to motherhood (fewer births, later in life), 
which might explain the increase in incidence observed in those countries (White, 
1987; Parkin, 2011). Additionally, part of this increase has been caused by more 
cancer being detected by the implementation of routine mammographic 
screening. This increase in occurrence however has been associated with a 
decrease in mortality (Fig. 1.1A), attributed both to improvement in breast cancer 
treatments and the benefits of large scale screening, i.e. early detection. 
1.1.3.2. Genetic risk factors 
One of the strongest risk factors for developing breast cancer is family history of 
the disease. A woman’s lifetime risk of developing breast cancer with no family 
history of the disease is estimated to be 8 to 10% but this risk can increase up to 
87% in families with affected members. This risk is correlated with closeness of 
kinship with affected relatives (female or male), number of affected relatives, and 
age at onset of breast cancer in affected relatives (Eisen and Irwin, 2002). 
Interestingly, it was recently established that the relative risk of breast cancer for a 
woman with an affected brother is approximately 30% higher than for a female 
with an affected sister (Bevier et al, 2012).  
BRCA mutations 
BRCA1 and BRCA2, the two most important breast cancer susceptibility genes, 
were identified by linkage analysis and first cloned in the mid 1990s (Hall et al, 
1990; Miki et al, 1994; Wooster et al, 1995). Approximately 20 to 25% of 
hereditary breast cancers are characterised by germline mutations in BRCA1 (60 to 
65% of cases) or BRCA2 (35 to 40% of cases) with the prevalence of mutations 
19 
    
varying according to patient ethnicity, age and family history (Thompson and 
Easton, 2004). These mutations are rare in the general population but confer high 
risk of ovarian and breast cancer for the carriers (Antoniou et al, 2003), with a 
lifetime risk of 47 to 87% for breast cancer, together with an earlier onset of the 
disease (Fackenthal and Olopade, 2007). Genetic testing for mutations in these 
genes is now well established in high-risk families (Walsh et al, 2006). 
The BRCA1 gene encodes a nuclear phosphoprotein that plays a role in maintaining 
genomic stability, thus acting as a tumour suppressor. BRCA1 protein combines 
with other DNA damage proteins to form a large multi-subunit protein complex 
known as the BRCA1-associated genome surveillance complex (BASC) and plays a 
role in transcription, repair of double-stranded DNA breaks, and recombination 
(Wang et al, 2000). In patients with BRCA mutant breast cancer, a deficiency in 
DNA damage repair is observed. Inhibition of poly ADP ribose polymerase (PARP), 
which results in increased double stranded DNA damage specifically in cancer cells 
lacking BRCA, is a successful treatment strategy relying on the principle of 
synthetic lethality (Farmer et al, 2005; Fong et al, 2009).   
Familial syndromes 
The primary syndrome associated with the highest risk of breast cancer is 
hereditary breast and ovarian cancer syndrome, caused by mutations in the DNA 
repair genes BRCA1 and BRCA2. However there are other hereditary cancer 
syndromes also associated with an increased risk of breast cancer and 
characterised by mutations uncommon in the general population. These include Li-
Fraumeni syndrome, associated with germline mutations in TP53 (Varley, 2003), 
Cowden disease, associated with germline mutation in PTEN (Marsh et al, 1999), 
Peutz-Jeghers syndrome, associated with truncation mutations in LKB1 (Jenne et 
al, 1998). In addition to these genes, two other genes are associated with familial 
syndrome with a more moderate risk of breast cancer. Germline mutations in the 
ATM gene are found in patients suffering from ataxia-telangiectasia (de Jong et al, 
2002). It has also been shown that a truncated variant of CHEK2, 1100delC, confers 
a two-fold increased relative risk for developing breast cancer (Meijers-Heijboer et 
al, 2002).   
20 
    
Low penetrance risk factors 
Classical breast cancer susceptibility genes, such as BRCA1 and BRCA2, have been 
estimated to account for only 25% of the familial breast cancer risk (Peto et al, 
1999; Thompson and Easton, 2004; Antoniou and Easton, 2006). When including 
other known susceptibility genes and potential environmental factors, only a small 
portion of the familial cases of breast cancer are accounted for (Hopper and Carlin, 
1992; Thompson and Easton, 2004), indicating that the majority of the risk factors 
remain undiscovered.  
A new class of susceptibility genes or risk variants (discussed in more detail later in 
section 1.3), that confer a low disease risk to the individual but occur at high 
frequencies in the general population, was unearthed by advances in genomic 
analysis. These variants were identified with the emergence of large scale genome-
wide association studies (GWAS), together with new statistical and bioinformatics 
tools. GWAS involve scanning a set number of markers (notably single nucleotide 
polymorphisms) across the complete genomes of two groups of individuals, 
patients with a certain disease (cases) and matched controls, in order to find 
genetic loci associated with the particular disease. The major advantage compared 
to linkage analysis was that high risk families were not required and the number of 
cases involved (thousands in each group) led to a greater power to discover risk 
factors (Mavaddat et al, 2010). Therefore we now see breast cancer as a polygenic 
disease, where a large contribution to the development of a tumour may be 
attributed to low penetrance factors such as particular polymorphisms. However 
the majority of the risk-associated SNPs occur in non coding regions of the genome 
complicating any attempt to investigate the function of those risk variants.   
1.1.4. Breast cancer biomarkers and classification 
Breast cancer is an heterogeneous disease, which encompasses a variety of 
distinct cellular abnormalities with distinct morphological features and clinical 
behaviours. Once diagnosed, carcinomas of the breast are described 
predominantly by their histological presentation and several biomarkers that have 
been found to be predictive of the treatment outcome, or patient survival. 
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Receptor status 
Both oestrogen receptor alpha (ERα) and progesterone receptor (PR) have a 
prognostic value in breast cancer patients, although their ability to discriminate 
between low and high risk patients remains quite limited (Stewart et al, 1982). 
Patients with ER-positive tumours tend to have less aggressive disease with 
metastases targeting the bones and soft tissues (James et al, 2003), unlike ER 
negative patients, who tend to have earlier relapses and metastases in the liver, 
lung and central nervous system (Tham et al, 2006). However, differences between 
the two groups decrease as the disease progresses, with most ER positive tumours 
leading to ER negative metastases (Lower et al, 2005). ER positive tumours are 
often well differentiated and are associated with better prognosis, despite the fact 
that estradiol is a potent mitogen for receptor positive cells, as they can respond 
to endocrine therapy with Tamoxifen, an ERα antagonist (Heel et al, 1978). The 
best use of steroid hormone receptors is therefore not in the determination of 
prognosis but in the prediction of response to endocrine therapy and, therefore, 
the selection of optimal treatments. 
Similarly the HER2/neu receptor is used in patient screening in order to determine 
the best treatment options. Amplification or overexpression of the HER2 gene 
occurs in approximately 30% of early stage breast cancer and is associated with an 
unfavourable prognosis and high recurrence rate (Coussens et al, 1985; Yarden, 
2001). However, HER2 positive breast cancer is now being treated successfully 
with several blocking antibodies (trastuzamab and pertuzamab) that target the 
HER2/neu receptor, in combination with chemotherapy, and these approaches 
have provided a five year increase in disease-free survival of patients (Romond et 
al, 2005).  
Another subgroup of breast cancers are characterised as triple negative breast 
cancer as they lack active ERα, PR and HER2 receptors, and account for 10 to 17% 
of all breast carcinomas (Dent et al, 2007). These patients have the worst 
prognosis because of a lack of targeted therapy. Triple negative disease frequently 
affects younger patients (<50 years), is more prevalent in African-American women 
(Bauer et al, 2007) and is significantly more aggressive than other subtypes.  
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Molecular classification 
Advances in molecular biology and high throughput technologies  have permited 
the establishment of a new taxonomy for breast cancer based on gene expression 
profiles as examplified by the seminal Perou and Sorlie molecular classification of 
breast cancer (Perou et al, 2000; Sorlie et al, 2001). This classification regroups six 
molecular breast cancer subtypes : Luminal A, Luminal B, Luminal C, normal breast 
like, HER2 and basal-like. Some of these subgroups were, to some extent, already 
known by conventional histological classification and some degree of controversy 
about the reliability of this new classification has failed to generate internationally 
accepted definitions for some of these breast cancer groups, such as the basal-like 
group, which is generally defined as triple negative breast cancer (Badve et al, 
2011).  
1.1.5. Conclusion 
Over 11, 500 women are expected to die of breast cancer in the UK this year (Data 
and Statistics, 2012). Breast cancer is still the second most common cancer related 
death among women in the UK, after lung cancer, despite several decades of 
research that have led to improvement in the screening, diagnosis and treatment 
of the disease. It has now been esablished that only 28% of the genetic risk factors 
for breast cancer are known (Michailidou K, 2013). This calls for a more thorough 
understanding of the genetics and molecular mechanisms that trigger and sustain 
cancer development, and will be key to the development of targeted therapies and 
the improvement of patient survival.  
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1.2. Fibroblast growth factors and their receptors 
1.2.1. Fibroblast growth factors (FGFs) 
The mammalian fibroblast growth factor (FGFs) family is composed of 22 members 
of intercellular and intracellular signalling molecules (from 17 to 34 kDa), 18 of 
which are functional ligands (FGF1 to 10 and FGF16 to 23) for the fibroblast growth 
factor receptors (FGFRs). They can be grouped according to their sequence 
homology and receptor binding affinity into seven different FGF subfamilies (Fig. 
1.2A) (Itoh and Ornitz, 2008). FGF1 is the most promiscuous ligand that can bind to 
multiple receptors. This promiscuity in binding is in contrast to specific ligands, like 
FGF7 for instance, which is specific for FGFR2b (Fig. 1.2B) (Ornitz et al, 1996).  
The structure and function of the FGF family of ligands are conserved throughout 
vertebrate evolution, with 13 to 71% amino acid identity (Ornitz and Itoh, 2001), 
and they are found in a wide range of organisms from nematodes to humans. The 
large number of FGFs is thought to have evolved through phases of global gene 
duplication in the period before the emergence of vertebrates (Coulier et al, 1997). 
Most FGFs share an internal region of similarity, with 28 highly conserved and 6 
identical amino acids. Not surprisingly, ten of these residues are responsible for 
interactions with their receptor (Plotnikov et al, 2000). Most FGFs, with the 
exception of FGF1 and FGF2 (Mignatti et al, 1992), are secreted proteins and 
include amino-terminal signal peptides for trafficking via the endoplasmic 
reticulum and the Golgi apparatus (Ornitz and Itoh, 2001). In addition, FGFs can 
bind heparin and heparan sulphate-proteoglycans (HSPG) present at the cell 
surface and in the extracellular matrix (Fig. 1.3C). HSPGs behave as low affinity 
receptors for the FGFs and are believed to protect them against degradation by 
proteases or thermal denaturation (Copeland et al, 1991) but also to facilitate the 
assembly and activation of the FGFR/FGF complex  by physically anchoring them in 
close proximity at the plasma membrane (Rapraeger et al, 1991). In cell culture, 
FGFs can stimulate cell growth, migration and differentiation (Eswarakumar et al, 
2005). In vivo, they are responsible for many different cellular functions, principally 
during development. FGFs are widely expressed but follow a strict spatial and 
temporal pattern in the embryo, where they are crucial for development and
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Isoforms Ligands 
FGFR2 
b 
FGF1, FGF3, FGF7, FGF10, 
FGF22 
c 
FGF1, FGF2, FGF4, FGF5, 
FGF6, FGF8, FGF9, FGF16, 
FGF17, FGF18, FGF20 
 
Figure 1.2: The fibroblast growth factor family 
A) Phylogenetic tree of the fibroblast growth factors showing seven subgroups of closely 
related peptides (adapted from (Itoh and Ornitz, 2008)). B) FGFR2 isoforms and ligand 
specificity. 
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differentiation of highly hierarchical organs such as the skeleton, lungs, and the 
circulatory and central nervous systems (Ciruna and Rossant, 2001).  They also play 
important roles in the adult organism in wound healing, tissue repair, angiogenesis 
and as homeostatic factors (Turner and Grose, 2010). 
1.2.2. Fibroblast growth factor receptors (FGFRs) 
Fibroblast growth factor receptor genes (FGFRs) encode transmembrane receptor 
tyrosine kinases (RTKs). They contain two or three immunoglobulin-like domains 
and a heparin-binding domain in their extracellular portion (Fig. 1.3A). Alternative 
mRNA splicing of the second half of the third immunoglobulin-like domain in 
FGFR1-3 gives rise to various FGFR isoforms that differ in their ligand binding 
affinities (Fig. 1.3B) (Zhang et al, 2006). This alternative splicing event is mostly 
tissue and cell type specific: the IIIb isoforms are more commonly expressed on 
cells from epithelial lineage and the IIIc isoform, in the mesenchymal lineage (Orr-
Urtreger et al, 1993).  In conjunction, expression of their specific ligands occurs in 
adjacent tissues, leading to directional paracrine signalling between epithelial and 
mesenchymal cells. A fifth related receptor, FGFR5 (also known as FGFRL1), can 
bind FGFs but lacks a tyrosine kinase domain, thus potentially acting as a negative 
regulator of FGF signalling (Steinberg et al, 2009). Although the different FGF 
receptors have overlapping expression patterns and functional similarities, they 
also mediate very specific effects depending on cellular differentiation and context 
(Dailey et al, 2005).  
1.2.2.1. Signalling 
Upon interaction with a ligand, stabilised by the cell surface HSPGs and dimeric 
Grb2 (Lin et al, 2012), a conformational shift in receptor dimer structure elicits 
transphosphorylation of the intracellular kinase domains (Furdui et al, 2006; 
Mohammadi et al, 1996). The phosphorylated tyrosine residues of the cytoplasmic 
portion of the receptor can then act as a docking site for adaptor proteins 
containing Src homology-2 (SH2) and phosphotyrosine-binding (PTB) domains (Fig. 
1.3C) (Mohammadi et al, 1996).  FGFRs signal through four pathways that regulate 
cell proliferation, survival and differentiation: the MAPK, the PI3K/AKT, the 
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Figure 1.3: FGF receptor structure and organisation at the plasma membrane  
A) The basic structure of the FGF–FGFR complex comprises two receptor molecules, two 
FGFs and one heparan sulphate proteoglycan chain. The FGFR consist of three 
extracellular immunoglobulin (Ig) domains, a single transmembrane domain and an 
intracellular split tyrosine kinase domain. The second and third Ig domains form the 
ligand-binding pocket and have distinct domains that bind both FGFs and HSPGs. B) 
Ligand-binding specificity is generated by alternative splicing of the Ig III domain. The first 
half of Ig III is encoded by an invariant exon (IIIa), which is spliced to either exon IIIb or IIIc, 
both of which splice to the exon that encodes the transmembrane (TM) region. C) FGFR 
signals through four pathways, the MAPK pathway (red), the PI3K/AKT pathway (purple) 
the JAK/STAT pathway (orange) and PLCγ pathway (green). Both MAPK and AKT signalling 
require the presence of an FGFR specific adaptor protein: FRS2. Proteins in black boxes are 
inhibitors of the FGFR signalling pathways (Adapted from Dickson et al, 2000). 
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JAK/STAT and the PLCγ pathways (Fig. 1.3C). The predominant signalling pathway 
activated downstream of FGFRs in development is MAPK signalling (Corson et al, 
2003), which promotes cell proliferation. 
FRS2, a major adaptor that links FGFRs to the ERK and PI3K/AKT pathways, binds to 
the active kinase domain of the receptor and becomes phosphorylated on specific 
tyrosine residues (Kouhara et al, 1997; Ong et al, 2001). GRB2, another adaptor 
protein, is then recruited and can transduce the signal to ERK and PI3K/AKT 
pathways. Activation of the AKT pathway results in anti-apoptotic signalling, as 
well as cell growth and proliferation cues (Gotoh, 2008), whereas MAPK activates 
transcription factors involved in control of the cell cycle. Indeed, it has been shown 
that cyclin D1 and D2, master regulators of the cell cycle, are downregulated when 
FGFR signalling via MAPK is inhibited (Koziczak et al, 2004).  
Independently of adaptor proteins, the active receptor can bind to and 
phosphorylate PLCγ (Mohammadi et al, 1991) which leads to the activation of PKC, 
via DAG, and therefore reinforce the MAPK pathway. 
The JAK/STAT pathway is also independent of adaptor proteins and leads to the 
translocation of STAT to the nucleus, which in turn directs the transcription of 
target genes associated with proliferation, differentiation and apoptosis (Darnell, 
1997).  
FGFR signalling can differ between receptors in nature and strength of the signal 
produced (i.e. the pathway activated). For instance, it was found that FGFR4 
produced a weaker signal than either FGFR1 or FGFR2, particularly with respect to 
responses involving PLCγ and FRS2, whereas FGFR3 produces signals similar to 
FGFR1 (Raffioni et al, 1999). Internalisation and degradation of the receptor 
constitute an important aspect of FGFR regulation and are mediated by key FGF 
negative regulators such as CBL (responsible for FGFR and FRS2 ubiquitination) 
(Wong et al, 2002), SPRY (which interrupts the GRB2/FRS2 complex and prevents 
Ras phosphorylation) and SEF (inhibits FGFR and FRS2 phosphorylation, prevents 
phosphorylated ERK from migrating to the nucleus)  (Fig 1.3C). 
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1.2.3. FGFs in the mammary gland  
Normal development of the mammary gland relies on highly orchestrated 
interactions between epithelial and mesenchymal cells that start during 
embryogenesis and continue during puberty where the glands undergo growth 
and differentiation. It has been studied most closely in the mouse (Fig. 1.4), 
nevertheless the basic processes and signalling mechanisms hold true for human 
development (Hynes and Watson, 2010).  
Bulb-like structures on the tips of the epithelial ducts, called terminal end buds 
(TEBs), proliferate and penetrate into the fat pad as the ducts elongate (Fig. 1.4). 
TEBs diverge and secondary branches appear, until the entire fat pad is filled with 
a network of branched ducts. This simple epithelial tree within the mammary fat 
pad remains quiescent until the onset of puberty, when ovarian steroid hormone 
production commences. During repeated oestrous cycles, the ductal network 
increases in complexity and side-branches grow under the control of 
progesterone. In response to prolactin, alveolar structures bud off the ductal 
system during pregnancy, and these differentiate into milk-producing sacs. Steroid 
hormones, growth hormone and prolactin are the master regulators of mammary 
growth and pregnancy-induced differentiation, whereas epidermal growth factor 
(EGF) and FGFs have more specific and specialised roles (Hynes and Watson, 2010). 
Alternative splicing of FGFRs in the third IgG loop yields different isoforms of the 
receptors that bind different FGFs (Fig. 1.3B) and are expressed in epithelial or 
mesenchymal compartments, respectively. FGF10 and its main receptor FGFR2-IIIb 
have important roles during embryonic mammary gland development. Starting at 
embryonic day 10.5 in mice, FGF10 acts on FGFR2-IIIb in the ectoderm to initiate 
induction and positioning of the future mammary glands. The ligand and the 
receptor are both essential for induction of placode pairs (Mailleux et al, 2002; 
Veltmaat et al, 2006). 
During ductal growth, multiple FGFs (FGF1, FGF2, FGF4, FGF7, and FGF10) as well 
as FGFR1 and FGFR2 are expressed (Schwertfeger, 2009). It has been shown that 
the epithelial specific FGFR2-IIIb isoform is responsible for ductal outgrowth, and 
TEBs usually express high levels of FGFR2 (Parsa et al, 2008). Indeed, it was 
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demonstrated that FGFR2-null glands penetrate the fat pad more slowly and show 
fewer branch points compared with wild-type controls (Lu et al, 2008). Finally, 
some FGFs are expressed during pregnancy and lactation (Coleman-Krnacik and 
Rosen, 1994), their role remains unclear however.   
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Figure 1.4: Morphological stages in the embryonic development of the mouse mammary 
gland and FGF signalling 
Around embryonic day 10 (E10) of mouse development the milk line (orange) is defined by 
a slight thickening and stratification of the ectoderm (grey) as shown here in this series of 
cross sections through the trunk. On E11.5 the milk line breaks up into individual placodes 
(orange) and the underlying mammary mesenchyme (blue) starts to condense. Over the 
following days the placodes sink deeper into the dermis and the mammary mesenchyme 
becomes organised in concentric layers around the mammary bud (orange). Starting on 
E15.5, the mammary epithelium (orange) starts to proliferate at the tip and the primary 
sprout pushes through the mammary mesenchyme towards the fat pad (green). On E18.5 
the elongating duct has grown into the fat pad and has branched into a small ductal 
system. The cells of the mammary mesenchyme have formed the nipple, which is made of 
specialised epidermal cells (purple)(Robinson, 2007). 
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1.2.4. FGFR2 and cancer 
Germ line and somatic FGFR mutations are known to play a role in a range of 
diseases, most notably skeletal disorders and cancers; they are predominantly 
activating mutations resulting in sustained signalling promoting survival, 
proliferation and angiogenesis, therefore indicating that FGFR2 can act as an 
oncogene (Grose and Dickson, 2005). However, FGFR2 can be ambivalent, and 
there are certain types of cancers, like bladder or skin, in which FGFR2 has been 
associated with a tumour suppressive phenotype (Gartside et al, 2009). Generally, 
activating mutations in FGFR2 are found most frequently in endometrial cancer 
(Byron et al, 2008) and are rare in breast cancer (Greenman et al, 2007). Mouse 
models of mammary carcinogenesis have long established the FGF signalling 
pathway as a major contributor to tumourigenesis (Grose and Dickson, 2005), and 
a mouse mammary tumour virus (MMTV) insertional mutagenesis screen for genes 
involved in breast cancer identified FGFR2 and  FGF10, one of its ligands, as 
potential oncogenes in the breast (Theodorou et al, 2007).  
Although FGFR2 amplification has been reported in several publications 
(Heiskanen et al, 2001), a genome-wide copy number variation screen found 
FGFR2 to be ampliﬁed in only 2 out of 161 primary breast cancer samples (1.2%) 
(Kadota et al, 2009). This result was confirmed in other similar screens looking at a 
large group of unselected breast cancer samples (Adelaide et al, 2007), and 
sometimes amplification or losses of FGFR2 were not observed at all (Andre et al, 
2009). When looking at specific types of cancers like triple negative disease, 
amplification was more common, reaching 4% of cases and was not found in other 
subtypes. A concomitant increase in FGFR2 mRNA levels was also observed in 
those samples, suggesting a potential role for FGFR2 in triple-negative breast 
cancer (Turner et al, 2010). FGFR2 expression was also significantly higher in 
familial breast cancer patients with germ line mutations in BRCA1 and BRCA2 
(Bane et al, 2009).  Functional studies in cell lines have implicated FGFR2 as playing 
a role in tumourigenesis, with an alternative splicing in the C-terminal domain of 
FGFR2 giving rise to a more transforming isoform (Tannheimer et al, 2000). The 
presence of this transforming isoform in patients is, however, quite rare.  
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Additionally, high FGFR2 expression has been associated with poor prognosis and 
lower (disease-free) survival rates (Sun et al, 2012). The exact molecular 
mechanism linking FGFR2 and breast cancer is however not clear and remains to 
be determined. Finally, FGFR2 was also identified as a new risk locus for ER 
positive breast cancer in two independent GWAS studies (Easton et al, 2007; 
Hunter et al, 2007), and this novel mechanism is the focus of this study.  
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1.3. Single nucleotide polymorphisms 
Deleterious somatic and germinal mutations are rare but play a determinant role 
in the emergence of cancer and other Mendelian disorders. Common and frequent 
genetic variations (polymorphisms) on the other hand may also play a role in 
cancer susceptibility but are more complex to identify. 
The most common type of genetic polymorphisms are single nucleotide 
polymorphisms (SNPs), accounting for 90% of human DNA variations (Collins et al, 
1998). In one of the first comprehensive reviews on the subject, Brookes describes 
SNPs as “single base pair positions in genomic DNA at which different sequence 
alternatives (alleles) exist in normal individuals in some population(s), wherein the 
least frequent allele has an abundance of 1% or greater” (Brookes, 1999). 
Subsequently, the human genome project identified more than 1.42 million SNPs, 
which corresponds, on average, to one SNP every 1,300 bp (Taillon-Miller et al, 
1998; Lander et al, 2001; Sachidanandam et al, 2001). However, SNPs are not 
distributed uniformly over the entire human genome and their distribution sheds 
light on the unique properties and history of each genomic region.  
Some SNPs have a well defined impact on phenotypes, as they are located in the 
coding region of genes, and create a non-synonymous substitution that leads to 
amino-acid change or, in the 3’-UTR region of messenger RNA, affects the binding 
of micro RNAs (Abelson et al, 2005). However, the rate of nucleotide difference is, 
understandably, four-fold lower within coding exons compared to non-coding 
regions and only half of those changes result in non-synonymous codon-change (Li 
and Sadler, 1991; Nickerson et al, 1998). The importance of SNPs located in non 
coding regions is now recognised but their functions remain elusive. 
The Functional Single Nucleotide Polymorphism (F-SNP) database was created in 
2007 to integrate information about the functional effects of SNPs (Lee and 
Shatkay, 2008). The aim was to predict the effect of SNPs at the splicing, 
transcriptional, translational and post-translational level using bioinformatic tools. 
Their results show that an estimated 20% of SNPs disrupt genomic regions known 
to be functional, including splice sites and transcriptional regulatory regions. 
Recently, the first publications of the ENCODE consortium (Consortium et al, 2012; 
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Sanyal et al, 2012; Thurman et al, 2012) have shed more light on the impact of 
functional information within the non coding regions of the genome and the 
importance of variation in regulating gene function.  
1.3.1. Functional SNPs in cancer  
The characterisation of human SNPs and their role in phenotypes remains a 
challenge and the study of rare genetic variants is only becoming possible in recent 
years with advances in data mining and new genetic technologies.  Although it is 
now possible to sequence the entire human genome, this information alone is not 
sufficient to understand the biological implication of most sequence variations. 
SNPs have been used mostly by research groups as genomic markers to identify 
regions that are associated with disease. Within a single chromosome, a conserved 
combination of SNPs can be concentrated at a specific region, usually implying a 
region of medical or research interest. For instance, an extreme example is the 
human leucocyte antigen (HLA) region on chromosome 6, in which a high SNP 
density is observed (5 to 10% of nucleotide diversity), reflecting the fact that a 
diverse combination of HLA alleles has been maintained for many thousands of 
years by natural selection, since they emerged long before the divergence of Homo 
sapiens from its common ancestor (Hughes et al, 2005). 
Similarly to somatic mutations, SNPs located in coding regions are known to play a 
role in cancer progression or response to treatment. In the FGFR family for 
example, a functional FGFR4 polymorphism (Gly388Arg) located in the 
transmembrane domain of the receptor was first found associated with colorectal 
cancer (Spinola et al, 2005) and more recently, was used as a predictive marker for 
outcome of treatment with an mTOR inhibitor in pancreatic neuroendocrine 
tumours (Serra et al, 2012).  
Methods to study non-exonic SNP functions rely on the study of expression level of 
genes and prediction of binding sites for transcription factors. To date, only a few 
regulatory SNPs have been characterised at the genetic and phenotypic level. 
Members of the pathway of the tumour suppressor p53, which is involved in at 
least half of human cancers, provide one such example. MDM2 is a direct negative 
regulator of p53 and SNP309, located in the MDM2 promoter, was found to 
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increase the binding affinity of the transcription factor Sp1 which leads to 
overexpression of MDM2 and, subsequently, to an attenuation of the p53 
pathway. Patients with hereditary (Li Fraumeni) and sporadic cancers (soft tissue 
sarcoma) that are homozygous for the G allele of SNP309 show an accelerated 
progression of the disease (Bond et al, 2004; Bond et al, 2006).  
The methods usually applied in the study of non-intronic SNPs involve indirect 
assessment of transcription factor binding by electrophoretic mobility shift assay 
(EMSA), chromatin immunoprecipitation (ChIP) and reporter assay. Recently, 
whole genome screens are emerging, analysing the total number of binding sites 
of certain transcription factors and their relation with known polymorphisms 
(Spivakov et al, 2012). But these whole genome approaches are more appropriate 
to identify general patterns in transcription factor dynamics than to shed light on 
individual functional SNP. New approaches are therefore needed in order to study 
the impact of such polymorphisms on cell behaviour.  
1.3.2. The  FGFR2 haplotype 
Breast cancer was one of the first diseases to be studied using the new power of 
GWAS and many new susceptibility genes were subsequently identified. In 2007, 
two studies identified a region of the second intron of the FGFR2 gene as the most 
significant locus associated with increased risk for sporadic postmenopausal ER 
positive breast cancer in patients of European descent (Easton et al, 2007; Hunter 
et al, 2007). This haplotype lies within a 25 kb linkage disequilibrium block almost 
entirely within intron 2 of FGFR2 (Fig. 1.5A). This particular region was found to be 
conserved among mammals, showed Histone 3 acetylation marks and DNaseI 
hypersensitivity clusters, all of which are often found near active regulatory 
elements (Fig. 1.5B). The carriers of the risk allele of the most significantly 
associated SNP, rs2981582, showed a risk of breast cancer 1.26 times greater than 
non-carriers (Fig. 1.5C). The haplotype was not in linkage disequilibrium with other 
SNPs elsewhere in the coding region of the gene and its intronic location 
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Figure 1.5: The FGFR2 locus 
A) Map of FGFR2 showing the linkage disequilibrium block in the large second intron. The 
gene is 126 kb long and in reverse 3’-5’ orientation on chromosome 10 (Easton et al, 
2007). B) Genomic landscape around FGFR2 haplotype region containing rs2981578 (red 
box), showing mammalian sequence conservation, H3 histone acetylation marks, DNaseI 
hypersensitivity regions on the UCSC genome Browser (GRCh37/hg19). C) Estimated risk 
increase in developing breast cancer associated with the different alleles of rs2981578 
(Easton et al, 2007; Hunter et al, 2007). 
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indicated that its association with breast cancer most likely was mediated through 
regulation of FGFR2 expression.  
rs2981578, a putative functional SNP found within this haplotype, mapped to 
binding sites for the transcription factors Oct1/Runx2 (Meyer et al, 2008). Using 
ChIP, it was found that the disease-associated allele (G) created a new binding site 
for the Runx2 transcription factor. The disease associated allele (G) is also the 
ancestral allele and is found in the vast majority of individuals of African origin and 
to a lesser extent in other populations (Fig. 1.6). Luciferase assays, using a cloned 
region of intron 2, revealed that the presence of several Runx2 and an Oct1 
binding sites in close proximity caused an increase in luciferase expression, thus 
suggesting a molecular explanation for the risk phenotype. Indeed, the 
Runx2/Oct1 complex has also been identified on the promoter of β-casein, a 
mammary gland specific gene. Paul Shore’s group used ChIP, RNA interference and 
promoter mutagenesis to show that the complex acted as an enhancer of β-casein 
expression (Inman et al, 2005). Moreover, the increased risk conferred by the 
minor FGFR2 allele associated most strongly with ERα positive breast tumours, 
suggesting a potential interaction between the two pathways (Easton et al, 2007; 
Hunter et al, 2007; Udler et al, 2009). The other risk allele looked at in this study 
was rs7895676, which displayed a reduced binding capacity to C/EBPβ (Meyer et 
al, 2008). In addition, a meta-analysis found that FGFR2 rs2981582 was 
significantly associated with the risk in BRCA2 mutation carriers predominantly 
(Antoniou et al, 2008). Indeed, the vast majority of BRCA1 breast cancer tumours 
are oestrogen receptor negative whereas BRCA2 tumours have an ERα status 
distribution similar to that of unselected breast cancers, of which the majority are 
ER positive. However BRCA1 patients can sometimes present with an ER positive 
cancer and the same association was found in this particular group (Mulligan et al, 
2011) indicating a strong link between the oestrogen receptor and the FGFR2 risk 
alleles, via a mechanism that remains to be elucidated. 
Several other successive GWAS have confirmed the association of the FGFR2 risk 
alleles with breast cancer. Different populations were tested: Jewish and Israeli 
(Raskin et al, 2008), Tunisians (Shan et al, 2012), Hispanic (Slattery et al, 2011),
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rs2981578 G A 
ALL 0.623 0.377 
AFR 0.921 0.079 
AMR 0.547 0.453 
ASN 0.535 0.465 
EUR 0.532 0.468 
 
 
Figure 1.6: 1000 Genomes population data for rs2981578 allele frequencies 
Allele frequencies for rs2981578 in the populations of the 1000 Genomes project. G is the 
ancestral allele and the risk allele for breast cancer (green), A is not associated with risk 
(yellow). Super population codes that regroup data from several populations: AFR: African, 
AMR: Ad Mixed American, ASN: East Asian, EUR: European. When the code ALL is used this 
means that all individuals from that data set are being considered (1000 Genomes Project, 
2008-2012; Genomes Project, 2010)  
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African American (Udler et al, 2009; Zheng et al, 2009; Barnholtz-Sloan et al, 2010; 
Barnholtz-Sloan et al, 2011), Chinese (Long et al, 2010; Chan et al, 2012), Korean 
(Han et al, 2011), and all showed association with breast cancer and FGFR2 
haplotype. 
In one study, only a trend towards association was found in African American 
women (Hutter et al, 2011). Additionally, male breast cancer was also found to be 
associated with the FGFR2 haplotype (Orr et al, 2011), although the same 
association did not reach significance in another study (Orr et al, 2012). This result 
also strengthens the hypothesis of a cross-talk between FGFR2 and ERα as male 
breast cancers are almost entirely ER positive.  
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1.4. Zinc finger nucleases: targeted genome editing 
Existing methods for targeted gene modification in vitro require several rounds of 
homologous recombination and drug selection to isolate rare desired events - a 
laborious and time consuming process that has limited the access to certain cell 
models.  Zinc-finger nucleases (ZFNs) have become powerful tools for gene 
manipulation and offer a potential solution to this problem. 
ZFNs are engineered to introduce a double-strand break (DSB) at any user-defined 
genomic locus. The double-strand break is resolved by the cell’s own DNA repair 
machinery, while introducing modifications of the original sequence. This new 
technology is very promising thanks to its high specificity and the many potential 
applications that have arisen in recent years. 
1.4.1. FokI restriction enzyme 
ZFNs are synthetic modular molecules made from the fusion of zinc-finger DNA-
binding domains to the catalytic domain of the endonuclease FokI (Fig. 1.7A) 
(Smith et al, 2000; Bibikova et al, 2001; Mani et al, 2005). Natural FokI is a two-
domain protein (heterodimer) that binds a specific 5 bp DNA sequence and cuts at 
a distance away on the two strands. Chandrasegaran and colleagues were the first 
to show that the Type IIS restriction endonuclease FokI is a two-domain protein, 
with separable DNA recognition and cleavage functions. Change of the original 
cleavage target site was achieved by replacing the natural DNA-binding domain of 
FokI with one with different recognition binding site specificity (Kim et al, 1996). In 
ZFNs, the site of DNA cleavage is therefore determined by the recognition 
specificity of modular zinc fingers subunits. 
Doyon et al identified critical residues involved in dimerisation, and used these 
residues to engineer ZFNs that have superior cleavage activity, while preventing 
homodimerisation (Fig. 1.7B) (Doyon et al, 2011). Two ZFNs are required, since the 
ZFN endonuclease activity is dependent upon dimerisation of heterogeneous FokI 
subunits. The prevention of homodimer formation in the new generation ZFNs has 
contributed greatly to reduced toxicity (Miller et al, 2007). 
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Figure 1.7: Spatial organisation of Zinc Finger Nucleases at the target site 
A) Each ZFN consists of two functional domains: the zinc finger protein (ZFP), a DNA-
binding domain comprised of a chain of four zinc finger domains, each recognising an 
unique sequence of DNA (left and right ZFP), and DNA cleavage domain formed of the two 
endonuclease domains of FokI, working as a highly-specific pair of 'genomic scissors'. B) 
New FokI protein design with obligate heterodimers (L+ and R-, right), as opposed to 
potential homodimers (Lwt and Rwt, left), in order to eliminate off-target activity by 
homodimer species (Miller et al, 2007). 
  
A 
B 
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1.4.1. Zinc Finger proteins 
The Cys2His2 zinc finger is a module of about 28-30 amino acids that is commonly 
found in transcription factors (Razin et al, 2012). ZFNs consist of an α-helix, two β-
sheets, and a single zinc atom. Each finger recognises a particular triplet of DNA 
bases through contacts in the DNA major groove, many of which occur naturally. 
They can however be rearranged easily by changing the identities of the residues 
that alter the DNA recognition specificity of the finger to recognise all the potential 
DNA triplets. This ability to modify the DNA binding specificity of these molecules 
allows targeting of virtually any desired site in the genome. 
1.4.2. Genome editing 
ZFN-induced double strand breaks can stimulate two different DNA repair 
pathways: homologous recombination (HR) (Moynahan and Jasin, 2010) or non-
homologous end joining (NHEJ) (Lieber, 2010). The latter is very inaccurate and, 
unlike homologous recombination, does not rely on sister chromatid homology. 
The homologous recombination pathway has evolved to deal with stalled DNA 
replication forks and double-strand breaks (endogenous and exogenous) and also 
contributes to genetic recombination (Moynahan and Jasin, 2010). However, in the 
absence of DNA damage, these recombination events have a very low efficiency. 
ZFNs enhance this efficiency by creating a double-strand break in a specific locus, 
therefore directing the DNA repair machinery to this site (Urnov et al, 2005).  A 
repair template (plasmid DNA that contains the targeted genetic change) can be 
used for genome editing, replacing the sister chromatid, leading to targeted 
sequence replacement. Indeed, the highly homologous repair matrix is transfected 
in the cell at a high concentration, shifting the balance towards modification rather 
than normal repair. The repair template can introduce deletions, substitutions or 
insertions at the target site, along with selector genes that may be used for 
screening. Several kinds of DNA template have been tested with variable efficacy.  
A recent study using ZFNs for gene knockout showed that the modification 
frequency of the Glutamine Synthetase (GS) gene reached 25% in CHO cells (Liu et 
al, 2010), which is much greater than the average 1% rate normally achieved with 
classic homologous recombination techniques. Indeed, in mammalian cells the 
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targeted DNA predominantly integrates in a random fashion rather than through 
homologous recombination, and it was estimated that for every one gene 
targeting event, there will be 10 to 20,000 random integrations (Sedivy and Sharp, 
1989; Porteus and Baltimore, 2003).   
The possibility of creating double strand breaks with high efficiency and at specific 
sites in the genome forms the basis for a wide range of applications for therapies 
and research. This technology has first been used in models like Drosophila 
melanogaster (Bibikova et al, 2002), Arabidopsis thaliana (Lloyd et al, 2005), 
zebrafish (Doyon et al, 2008) and rats (Geurts et al, 2009). For instance, ZFNs have 
been used successfully to create knockout mammalian cell lines (Liu et al, 2010), 
but this method can also be applied to rodent embryonic stem cells (Geurts et al, 
2009) and constitutes a novel and rapid method to create new knockin or 
knockout mice. As an alternative to the use of stem cells, direct embryo injection 
of ZFN-encoding mRNA has been used in the fruit fly and zebrafish to generate 
heritable knockout mutations at specific loci (Carroll, 2008). Multiple pairs of ZFNs 
can also be used to remove large segments of genomic sequence (Lee et al, 2009). 
Moreover, clinical applications of ZFN-gene therapy open new possibilities: 
dysfunctional genes (with a known, limited mutation) could be repaired directly in 
patients using a ZFN-based method. ZFNs can be used to disable dominant 
mutations in heterozygous individuals by producing double strand breaks in a 
mutant allele which will, in the absence of an homologous template, be repaired 
by non-homologous end-joining (NHEJ). The error-prone repair will result in 
deletion or insertion of base-pairs, producing a shifting in the reading frame and 
preventing the production of the mutated protein. The private company Sangamo 
Bioscience is currently testing (ongoing Phase 1/2 clinical trial) a ZFN mediated 
genome-editing of T-cells for the treatment of HIV/AIDS by targeting the receptor 
CCR5 (Holt et al, 2010; Ledford, 2011).  CCR5 is a co-receptor for HIV entry into T-
cells and, if CCR5 is not expressed on their surface, HIV infects them with lower 
efficiency. Naturally occurring mutations of CCR5 have been identified in 
individuals resistant to infection with the most common strain of HIV (Liu et al, 
1996). The mutation CCR5delta32 leads to the expression of a truncated, and non-
functional CCR5 protein, with no other observable deleterious effect (Perez et al, 
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2008; Holt et al, 2010; Moehle et al, 2007; Urnov et al, 2005). Their ultimate aim is 
to edit the immune cells of the infected patient, and then re-implant them in that 
same patient. Another therapeutic approach is to target episomal viral DNA. For 
instance, promising results have been obtained in the treatment of Hepatitis B, 
where the ZFN targeted cleavage is directed toward HPV DNA (Cradick et al, 2010). 
1.4.3. Conclusion 
Although the first ZFN was reported more than 10 years ago, the number of 
publications in this field has increased remarkably in the past few years and 
improved ZFNs are now more commonly available to researchers.  
The capability of interfering with and manipulating gene sequences is one of the 
most reliable ways of learning about the importance of that sequence, especially 
when looking at non coding DNA sequences. In the study of risk-alleles associated 
with diseases, ZFNs show therefore great potential for basic research.   
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1.5. Aims and Objectives 
The second intron of FGFR2 contains SNPs that are associated with an increased 
risk of developing breast cancer. Notably rs2981578 has been identified as a 
putative functional SNP, modulating the binding of transcription factors. 
The aim of this project was to study the effect of rs2981578 on FGFR2 expression. 
The first objective was to create new cell line models that differ in this particular 
SNP status. The in vitro system created consisted of multiple isogenic mammary 
epithelial cell lines that represented the different allelic versions of rs2981578. 
The second objective was to use these cells in functional studies to identify the 
mechanism by which the FGFR2 SNP variant confers an elevated risk for the 
development of breast cancer. 
The third objective was to assess the level of allele specific expression of FGFR2 in 
a cohort of breast cancer patients with ER positive tumours.  
The final, distinct but related objective was to use the FGFR ZFNs to allow insertion 
of a replacement cDNA into the endogenous FGFR2 locus in order to induce 
specific FGFR2 mutations and assess the effect of such mutant proteins, expressed 
at physiological levels, on both receptor and cell behaviour. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2. Materials and Methods 
 
2.1. Cells, culture reagents and tissues 
2.1.1. General principles 
Cell culture was carried out in a laminar flow hood, which provided a sterile 
environment. Non-sterile tissue culture reagents were filter-sterilised, using 0.22 
µm syringe-driven or vacuum-driven filters (Millipore), and stored in sterile 
containers at 4°C. All cells were grown in an humidified atmosphere, maintained at 
37°C and 5% CO2. The cells were passaged weekly in T75 flasks (Corning) and all 
the experiments were performed with sub-confluent cells. 
Most of the reagents used for cell culture were provided by the BCI central service. 
These included 1X PBS, FBS, 10X Trypsin-EDTA, DMEM, Hams-F12 and L-Glutamine 
(all from PAA Laboratories). 
2.1.2. Breast cancer cell lines 
The immortalised, non-transformed, epithelial breast cell line MCF10A (Soule et al, 
1990), the breast adenocarcinoma MCF7 (Soule et al, 1973) and the breast ductal 
carcinoma T47D (Keydar et al, 1979) were used predominantly throughout this 
study.  MCF7 and T47D cells were cultured in DMEM supplemented with L-
Glutamine and 10% foetal bovine serum (FBS). MCF10A cells required 
DMEM:Ham’s F12 1:1 volume, 10 µg/ml Insulin from bovine pancreas, 500 ng/ml 
Hydrocortisone, 100 ng/ml cholera enterotoxin and 5% horse serum (all from 
Sigma).  20 ng/ml of human EGF (Sigma) was added to the MCF10A media 
following filtration. The MCF10A cell line series composed of MCF10A.neoT, 
MCF10At1k.c12, MCF10.CA1a, MCF10A.CA1h and MCF10ADCIS.com was also used 
(Santner et al, 2001; Kadota et al, 2010). Most grew in the same medium as the 
original MCF10A cell line except for MCF10A.CA1a and MCF10ADCIS.com, which 
required DMEM:Ham’s F12 1:1 volume and 5% horse serum. Additionally, Cal51, 
MDA-MB-453, MDA-MB-231, MDA-MB-468, ZR-75-1, β4-1089, BT474, BT20, 
H3396, SUM159, AU561 and SKBR3 lines were cultured only briefly for genomic 
DNA purification (Appendix 12). 
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2.1.3. Fibroblast cell lines 
NIH 3T3 fibroblasts were cultured in DMEM and 10% FBS, to use as feeder cells. 
They were treated with 10 µg/ml of mitomycin C (Sigma) to induce cell cycle 
arrest. Treated NIH 3T3 cells were seeded in 96 well plates at a concentration of 
3,200 cells/well (equivalent to 10,000 cells/cm2). 
2.1.4. Storage and recovery of liquid nitrogen stocks 
Mammalian cells were preserved effectively by the presence of a cryoprotectant, 
dimethylsulphoxide (DMSO), which reduces cellular damage that ice crystals might 
cause. Cells requiring storage were harvested in log phase growth. Following 
trypsination, cells were washed in complete medium and resuspended in FBS 
containing 10% DMSO at 1 to 2x106 cells per ml. One ml of cell suspension was 
transferred to a cryogenic tube and placed at -80°C in an insulated container for up 
to two weeks before being transferred to liquid nitrogen (-196°C) for long term 
storage.  
Cryopreserved cells are fragile and require quick thawing and immediate retrieval 
into complete medium. Vials were therefore placed in a water bath at 37°C to 
thaw rapidly, and the cell suspension was mixed with 15 ml of complete warm 
medium and transferred to a T75 culture flask. The medium was changed 24h 
later, in order to remove any trace of DMSO.  
2.1.5. Breast tissue samples 
Frozen tissue from ER positive breast tumours was obtained from the Breast 
Cancer Campaign Tissue Bank (Barts Cancer Institute, BCI), in collaboration with 
Prof Louise Jones, breast cancer pathologist at BCI, under ethical approval (Ethics 
REC reference: 10/H0308/49). 
2.2. In vitro experiments 
2.2.1. Proliferation assays 
Cell viability and proliferation can be assessed using different approaches, either 
by detecting proteins only present in proliferating cells (MTS assay and Ki67 
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staining) or by analysing the different proportion of cells in each phase of the cell 
cycle based on their DNA content (Flow cytometry with Propidium Iodine staining).  
2.2.1.1. MTS assay 
Proliferation of cells over a 72 h time period was measured using the CellTiter 96 
Aqueous One Solution Cell Proliferation assay (Promega). The assay is a 
colorimetric method for determining the number of viable cells in culture by 
incubating then in a solution of a tetrazolium compound, 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, and an electron 
coupling reagent, phenazine methosulphate. Together they react with 
dehydrogenase enzymes found in metabolically active cells and convert the MTS 
into formazan. The amount of formazan product, as measured by the amount of 
absorbance at 490 nm, is directly proportional to the number of living cells in 
culture. 
The cells were seeded on a 96 well plate at a concentration of 2,500 cells/well, in 
triplicate for each time point (24 h, 48 h and 72 h). 
At the end of each time point, the medium was removed and replaced with 100 µl 
of fresh medium and 20 µl of CellTiter Solution (controls wells did not contain any 
cells). The plate was incubated at 37°C for 2 h. Absorbance in the different wells 
was measured at 490 nm on a LT-4000 Microplate reader (Labtech). The wells 
without cells were used as blanks for normalisation.   
2.2.1.2. Ki67 staining 
The cells were plated on glass cover slips at a density of 20,000 cells/well in a 24 
well plate. The next day, cells were fixed in 4% paraformaldehyde (PFA, Sigma) at 
room temperature for 10 min and washed three times in PBS for 5 min. The cells 
were permeabilised in 0.1% Saponin (Sigma) for 10 min, followed by three PBS 
washes. Non-specific antibody binding was blocked by incubation for 1 h in 5% 
bovine serum albumin (BSA) in PBS and prior to incubation with anti-Ki67 antibody 
(FITC Mouse, 1:100 dilution, BD Transduction). The cells were washed several 
times in PBS with one last wash in distilled water before mounting on a glass slide 
with mounting media (ProlongTM Gold DAPI antifade reagent, Invitrogen). DAPI 
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(4',6-diamidino-2-phenylindole), contained in the mounting medium, allowed 
fluorescent labelling of cell nuclei.  
Images were taken on a confocal laser-scanning microscope LSM 510 (Zeiss). 
Quantification was performed by counting the percentage of Ki67 positive cells per 
field of view using 40x magnification (10 pictures were used for each cell clone).  
2.2.1.3. Cell cycle analysis 
After reaching 65% to 80% confluency, the cells were harvested by trypsination, 
pelleted and resuspended in 1 ml of cold 70% ethanol with vortexing. The cells 
were fixed at 4°C for 30 min (but could be stored for up to a week) before being 
processed for staining with propidium iodide (PI, Sigma). After two washes in PBS, 
the cells were resuspended in 350 µl of staining solution containing 50 µg/ml of PI 
and 100 µg/ml of RNase (Sigma) diluted in PBS. The tubes were protected from 
light and incubated at room temperature (RT) for 30 min.   
The amount of DNA staining was then assessed by flow cytometry on a 
FACSCalibur machine (BD Biosciences). Raw data were analysed using FlowJoTM 
software, using the Watson (Pragmatic) algorithm. Two-way Anova statistical test 
was used to determine significance (GraphPad Prism, version 5.03).  
2.2.2. ERα pathway inhibition 
Cells were seeded in 6 well plates at a density of 3x105 cells per well in normal 
medium. The cells were treated with 1 µM Tamoxifen (Sigma) or with ethanol 
(vehicle control) for 48 hours and total RNA was purified using an RNeasy Kit 
(Qiagen) according to manufacturer’s recommendations. Complementary DNA was 
generated from 500 ng of RNA and quantitative real time PCR performed using 
SYBR Green (Invitrogen) and the StepOnePlus Real-time PCR system (Applied 
Biosystems). 
2.2.3. FGF7 and FGF10 stimulation 
Cells were seeded in 6 well plates at a density of 3x105 cells per well in normal 
medium. The next day, the medium was replaced by starvation medium (DMEM + 
0.1% BSA) and the cells were starved overnight. The starved cells were then 
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stimulated for a period of time ranging from 5 min to 1 hour with several different 
concentrations of ligand (100, 50, 10, 1 ng/ml of FGF7 or FGF10) and 300 ng/ml of 
Heparin. At the end of the time course, the cells were lysed in 2X NuPage Sample 
buffer (Invitrogen) supplemented with 10mM DTT and a western blot was 
performed using anti phospho-ERK antibody (#9101S, Cell Signalling). Equal 
loading was verified using Ponceau staining (Sigma) on the membrane prior to 
antibody incubation.  
2.2.4. Selection pressure experiment 
MCF7 cells (2x106 cells) were transfected in triplicate with mRNA encoding the ZFN 
pairs, along with the MCF7 repair template, as described in section 2.5.2. At 
passage 1 post-nucleofection, and every third passage thereafter, the cells from 
each triplicate transfection were divided into 3 different T75 flasks:    
1-maintenance 
2-genomic DNA extraction 
3-Liquid nitrogen stock 
The genomic DNA was used for Taqman SNP genotyping assay to determine 
relative presence of the major and minor allele of rs2981578 SNP over a period of 
20 passages.   
2.2.5. Single cell dilution and colony picking 
Following ZFN transfection, cell screening was performed on a clonal population of 
cells that were obtained by single cell dilution cloning or colony picking.  
2.2.5.1. MCF10A cells 
MCF10A cells were isolated using serial dilutions of a cell suspension (Fig. 2.1). 10 
to 20 plates were prepared and incubated at 37°C for 7 to 10 days. The single 
colonies found in some wells were then trypsinised and transferred to a new 96 
well plate. Alternatively, a very low concentration of MCF10A cells (4 cells/ml) was 
used. 100 µl of cell suspension was seeded in each well of a 96 well plate.  These 
cells were co-cultured with inactivated NIH 3T3 feeder fibroblasts, previously 
treated with mitomycin C. After the MCF10A cell colonies reached 50 to 100 cells, 
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Figure 2.1: Schematic set up of serial dilution cloning in a 96 well plate 
Well A1 of a 96 well plate was seeded with 9x104 cells, then serial 1:1 dilutions were 
performed vertically from A1 to H1 (red arrow). Finally, using a multi-channel pipette, the 
second serial dilutions were performed horizontally across all the remaining wells in rows 
2 to 12 (blue arrows).   
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they were detached by trypsination and transferred to a new 96 well plate in order 
to remove any non-cycling feeder cells. 
2.2.5.1. MCF7 cells 
MCF7 cells were seeded at a concentration of 200 cells/plate in 150 mm diameter 
culture plates and cultured for a minimum of 7 days. Once the colonies reached 
approximately 100 cells in size, the medium was removed and the cells washed 
with sterile PBS. Using a 200 µl tip and/or cloning rings, individual colonies were 
picked and transferred to a 96 well plate containing fresh medium. 
Alternatively, following GFP enrichment (see section 2.5.2), MCF7 cells were 
diluted to a concentration of 4 cells/ml or single cells were directly FACS-sorted 
into a 96 well plate. 100 µl of this cell suspension was then seeded into each well 
of a 96 well plate, with NIH 3T3 feeder cells previously treated with mitomycin C.  
2.2.6. Migration assay using Organotypic cultures 
Conventional cell culture models involve the culture of cells on two-dimensional 
(2D) substrates. Breast cancer cells can adapt to this synthetic environment, 
become flattened and behave in an adherent fashion.  Different methods have 
been developed, however, to study epithelial cell behaviour in a more 
physiological context, and in the presence of mesenchymal cells. The organotypic 
culture model adopted consisted of growing epithelial cells on top of a 
collagen/matrigel substrate embedded with fibroblasts to provide a 
chemoattractant signal to encourage cell migration and invasion (Fig 2.2). MCF7 
cells do not demonstrate invasive behaviour (unpublished data) in this assay, so it 
was therefore modified to study migration. After 6 days of culture, the cells form a 
layer covering the whole surface of the gel. This cell layer was subject to punch 
biopsy wounding, leaving a hole in the middle of the gel. The capacity of the cells 
to close the wound was then assessed over a period of 14 days.    
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2.2.6.1. Wound assay 
The migratory capacity of modified MCF7 clones was analysed by organotypic 
culture wound healing assay (Fig. 2.2). This was modified from previously 
published protocols (Nystrom et al, 2005; Chioni et al, 2010).  
3.48 mg/ml collagen type I (Millipore) and Matrigel (BD) were mixed in a ratio of 
70:30 (80% of final gel volume), 10× Hank’s buffer (10% final gel volume) was 
added to the mix, and pH was adjusted to 7.4 with 2 M NaOH. Human foreskin 
fibroblasts (HFF2) were resuspended in FBS (10% final gel volume) at a 
concentration of 5×105/ml and added to the mix. The final mixture was applied to 
a 24-well plate (1 ml/well) and incubated at 37°C in 8% CO2 for 4 h, after which the 
gels were equilibrated by immersion in medium for 16 h, whereupon the medium 
was replaced by 500 µl culture medium containing 1x106 cells of MCF7 derived 
clones. 250 µl collagen mix (7 vol collagen type I, 1 vol each of 10× Hank’s buffer, 
FBS, and culture medium neutralised with 2 M NaOH) was added dropwise onto 
400 mm2 Nylon membranes (100-µm pore; Tetko). Membranes were incubated at 
37°C for 30 min and then fixed for 1 h at 4°C with 1% glutaraldehyde (Sigma-
Aldrich)/PBS. After fixation, the membranes were washed 4 times for 5 min in PBS 
and incubated overnight in culture medium at 4°C. The coated membranes were 
placed on 25 mm2 sterile stainless steel grids in 6-well plates. Gels were lifted from 
the 24-well plate and laid on top of the coated membranes. An appropriate 
amount of culture medium was added to each well until it reached the lower part 
of the gel, so that the cultures were maintained at the air-liquid interface. Medium 
was changed every 2 days. After 6 days of culture, the thin layer of cancer cells 
proliferating on the top of the organotypic gel was wounded using a circular Biopsy 
punch (Stiefel, 5 mm) and all the cells of the wound were removed. The 
organotypic cultures were maintained for different periods of time (0, 9 and 14 
days post-wounding). The gels were fixed in 10% neutral buffered Formalin 
(CellPath) for 16 h at 4°C. After fixation, gels were washed thoroughly in PBS, 
bisected, and dehydrated through a graded ethanol series before wax embedding. 
The sizes of the wounds (in triplicate) at the end of the experiment were assessed 
using light microscopy and compared to the initial wound size (day 0).  
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Figure 2.2: Wound assay: Organotypic culture to study cell migration 
The cancer cells were seeded (pink) on top of a matrigel and collagen matrix (yellow) 
containing stromal cells (fibroblasts). The gels were raised to the air-liquid interface, on a 
metal grid (grey) and fed with normal growth medium from underneath. To study cell 
migration, the cell layer was wounded and the closure of the wound monitored, at several 
time points.   
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2.3. DNA  
2.3.1. Genomic DNA extraction 
Nucleic acids such as DNA have the capacity to bind to solid substrates (silica 
membrane) at specific pH and high salt concentration. This property forms the 
basis of most of the current methods to extract and purify DNA, in which the cell 
lysates are passed through a colomn with a silica membrane, washed with ethanol, 
and eluted in a low salt solution. Another method routinely used to purify DNA is 
based on the interaction of DNA with a mixed solution of phenol and chloroform. 
Upon addition of equal amounts of phenol and chloroform to a cell lysate, a 
biphasic mixture is formed and, after centrifugation, results in an upper aqueous 
phase (containing the DNA) and a lower organic phase, with proteins present at 
the interphase. The nucleic acids contained in the upper phase are then 
precipitated using ethanol. This method achieves a high DNA purity but is more 
time consuming than the silica column based technique.  
2.3.1.1. Cell lines 
Total DNA from breast cancer cells was extracted using the GenEluteTM 
mammalian genomic DNA miniprep kit (Sigma), according to the manufacturer’s 
instructions. Cultured cells (2x106 to 4x106 cells) were detached with Trypsin, and 
pelleted by centrifugation at 300x g for 5 min.  The pellet was resuspended in 200 
µl resuspension solution and digested in 180 µl Lysis buffer C supplemented with 
20 µl proteinase K (20 mg/ml) and incubated at 70°C for 10 min. 200 µl 100% 
ethanol was added to the lysate and transferred to the pre-equilibrated binding 
column. Wide bore pipette tips were used to reduce DNA shearing. The columns 
were centrifuged at 6,500x g for 1 min, washed twice with wash solution 
containing 100% ethanol and eluted in 200 µl of elution solution.  
2.3.1.2. Tissues 
Total DNA from breast tissues was extracted using the GenEluteTM mammalian 
genomic DNA miniprep kit (Sigma Aldrich) as above but using Lysis buffer T instead 
and digested for up to 4 hours at 55°C.  
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 The gDNA concentration was measured using a Nano Drop spectrophotometer 
(ND-1000).  
2.3.1. DNA purification 
2.3.1.1. QIAquick kit 
PCR products or ChIP samples were purified using a QIAquick PCR purification kit 
(Qiagen), according to the manufacturer’s instructions. Five volumes of PB buffer 
were added to one volume of PCR product. The pH was adjusted using 3M sodium 
acetate in order to keep the pH indicator yellow and the mix was transferred to a 
QIAquick spin column. The DNA was bound to the column by centrifugation at 
16,000 x g for 1 min followed by a wash with 750 μl buffer PE and a centrifugation 
at 16,000 x g for 1 min. DNA was eluted by applying 50 μl EB buffer (10 mM Tris-Cl, 
pH 8.5) to the column and centrifugation for 1 min.  
2.3.1.2. Phenol/chloroform method 
DNA was mixed with phenol/chloroform isoamyl alcohol (25:24:1) at a 1:1 v/v 
ratio. The solution was vortexed thoroughly and spun at 16,000x g for 3 min. The 
upper phase was transferred into a fresh tube, with the addition of an equal 
volume of 3M sodium acetate and 2.5 volumes of 100% Ethanol. The mixture was 
incubated 1h on dry ice or overnight at -20°C and the DNA was pelleted by 
centrifugation at 16,000x g, 4°C for 20 min. The DNA pellet was washed once with 
70% ethanol, air-dried and resuspended in an appropriate volume of sterile 
distilled water.   
2.3.1.3. Gel electrophoresis 
DNA fragments were separated on 0.8% w/v or 1.5% w/v agarose gels made with 
UltraPureTM agarose (Invitrogen) in 1X TAE with 1X Gel Red (10,000X, Biotum). 
Loading buffer was added to samples prior to loading (6X, Fermentas). Bands were 
visualised under UV light and photographed using an AutoChemi System (UVP 
Biolmaging System).  
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2.3.1.4. Gel extraction 
DNA was extracted from agarose gels using the QIAquick Gel Extraction Kit 
(Qiagen) according to manufacturer’s instructions. The desired band was excised 
using a scalpel and dissolved in 3 volumes of buffer QG for 10 min at 50°C. 1 gel 
volume of isopropanol was added and the mix was transferred to a QIAquick spin 
column. The DNA was bound to the column by centrifugation at 16,000 x g for 1 
min followed by a wash with 750 μl buffer PE and a centrifugation at 16,000 x g for 
1 min. DNA was eluted by applying 30 μl of elution buffer to the column and 
centrifugation for 1 min.  
 
2.3.2. Cloning  
All restriction enzymes and enzyme buffers used in this study, unless stated 
otherwise, were obtained from New England Biolabs.  
2.3.2.1. DNA repair templates 
a. Double-stranded DNA repair template 
The DNA sequence that was used as a repair template after the ZFN-mediated cut 
required a 1 kb homology arm each side of the rs2981578 SNP. The 2kb fragment 
was obtained by PCR using genomic DNA from MCF7 and MCF10A cell lines with 
hFGFR2_11496-11515_for and hFGFR2_13647-13628_rev primers (Primer table, 
section 2.8). The following PCR conditions were used: 
Megamix (Microzone)   47 µl 
Primers mix (100mM)    0.5µl   
gDNA     2.5 µl 
 
94°C  2 min 
94°C  30 s 
60°C  30 s                   30 cycles 
72°C  2 min 
72°C  7min 
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 The purified PCR product was cloned in pJET1.2/blunt vector (Fermentas) as 
follows: 
2X reaction buffer   10 µl 
PCR product    2 µl 
Water     up to 17 µl 
DNA blunting enzyme   1 µl 
 
The mixture was incubated at 70°C for 5 min and chilled on ice. The following was 
added to the blunting reaction: 
pJET1.2/blunt cloning vector (50 ng/µl)   1 µl 
T4 DNA ligase (5 units/µl)     1 µl 
The ligation reaction was incubated at RT for 5 min and used for bacterial 
transformation of E. coli, DH5α strain (Bioline, α-select, Gold Efficiency).  
b. Single stranded DNA repair template 
A second type of repair template, containing the risk allele (bold and underlined) 
was used to edit the MCF7-derived clones using the FGFR2 ZFN pair. The 137 base 
repair template (below) was synthesized by Integrated DNA technologies (IDT) and 
transfected (2 µg) into cells, similarly to the double-stranded DNA repair template 
(section 2.5.2).  
5’-CAGCCCTTCTGAGATCTAAAGCTTCCCTCTGAATGCTGCTTTGGAGGATTGTGAGAGG 
TAGTGACTCTTCAAAGTTTGTTTGTTTTCTTGAAGCTTTTACCTCTATGCAAATATGCGGTT
TGGAGCAGGGAAGAAA-3’ 
 
2.3.3. Bacterial transformation 
DNA (5 µl ligation mixture or 1-10 ng plasmid DNA) was added to 50 µl chemically 
competent bacteria (Bioline, α-select, Gold Efficiency), incubated on ice for 15 min, 
heat shocked for 30 s at 42°C and placed on ice for 2 min. The bacteria were 
resuspended in 500 µl antibiotic-free warm Luria Broth (LB) and incubated at 37°C 
with shaking at 225 rpm for 1h. 100 μL to 200 µl cells were plated onto LB agar 
plates containing the appropriate selection antibiotic (100 µg/ml) and incubated 
overnight at 37°C. 
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2.3.4. Preparation of plasmid DNA 
Small scale plasmid DNA preparations were carried out using a QIAprep Spin 
Miniprep kit (Qiagen) according to the manufacturer’s instructions. A 2 ml 
overnight culture was pelleted by centrifugation and the pellet was resuspended in 
250 μl cell resuspension solution (P1). 250 μl cell lysis solution (P2) was added and 
mixed by inversion; 350 μl neutralisation solution (N3) was added and mixed by 
inversion. The mix was centrifuged at 16,000 x g for 10 min and the clear lysate 
was transferred into a spin column and spun at 16,000 x g for 1 min. The column 
was washed by adding 750 μl wash solution (PE), spun at 16,000 x g for 1 min, 
followed by a 2 min spin at maximum speed to dry the column. DNA was eluted by 
adding 50 μl nuclease-free water or EB buffer to the column and stored at -20°C. 
 
Large scale plasmid DNA preparations were carried out using the QIAfilter plasmid 
purification kit (Qiagen) according to manufacturer’s instructions. A 200 ml 
overnight culture was pelleted by centrifugation (15 min at 6,000x g) and the 
pellet was resuspended in 10 ml buffer P1. 10 ml buffer P2 was added, mixed by 
inversion and incubated at RT for 5 min. 10 ml chilled buffer P3 was added and 
mixed by inversion before the lysate was poured into a QIAfilter cartridge and 
incubated for 10 min at RT. The clear lysate was transferred into a QIAGEN-tip 
(pre-equilibriated with 10 ml buffer QBT) and entered the resin by gravity flow. 
The QIAGEN-tip was washed twice with 30 ml buffer QC. DNA was eluted with 15 
ml buffer QF and precipitated with 10.5 ml isopropanol. The solution was 
centrifuged 30 min at 15,000x g and the DNA pellet washed with 5 ml 70% ethanol 
and centrifuged  10 min at 15,000x g. DNA pellet was air-dried under the hood and 
eluted in 1 ml sterile distilled water and stored at -20°C. DNA concentrations were 
measured on a Nanodrop spectrophotometer. 
2.3.1. Surveyor assay 
The Surveyor assay provides a way of visualising mutations in DNA after PCR, 
endonuclease digestion and resolution on an agarose gel. Cel-I nuclease, a 
mismatch-specific endonuclease derived from celery, can recognise and cleave all 
types of mismatches arising from the presence of single nucleotide polymorphisms  
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Figure 2.3: Surveyor nuclease assay for detection of ZFN activity 
PCR on ZFN-edited cells generates a mixture of wild-type and mutated PCR products (left). 
Melting and re-annealing of the PCR strands creates a mixture of homoduplex and 
heteroduplex DNA where mismatches are present (circled) and are substrates for the 
Surveyor nuclease (Cel-I). Electrophoresis gel: lane 1-Cells transfected with a GFP plasmid 
(Neg); lane 2- cells transfected with plasmids encoding ZFNs (DNA); lane 3- cells 
transfected with ZFNs mRNAs (RNA). Arrows point to bands of the expected sizes based on 
the size of the PCR product and the site of ZFN target site cleavage (gel from FGFR2 ZFN 
certificate of Analysis, Appendix 5).  
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(SNPs) or from small insertions or deletions (Fig. 2.3). Purified gDNA from cells 
transfected with zinc finger nuclease (ZFN) mRNA or pmaxGFP vector (Lonza) was 
amplified using ZFN specific primers (25µM) (Primer table, section 2.8) with the 
following reaction conditions: 
Initial denaturation 95°C  3 min  
Denaturation  95°C  30 s                
Annealing  57°C  30 s  30 cycles 
Extension  72°C  30 s 
Final extension 72°C  7 min 
 
After PCR, the product was denatured and re-annealed to create mismatch 
duplexes using the following thermal cycler conditions: 
95°C  10 min 
85°C  Cool at 2°C/second  
25°C  Cool at 0.1°C/second 
4°C until next step 
 
The Cel-I endonuclease from the SurveyorTM mutation detection kit 
(Transgenomic) was then used to cleave DNA at any mismatch bubble. 1 µl 
Surveyor endonuclease and 1 µl Surveyor enhancer were added to 10 µl re-
annealed PCR products and the sample was then incubated at 42°C for 45 minutes. 
The product was resolved on a 2.5% high resolution agarose (Sigma) gel stained 
with 1X Gel Red (Biotum). 
2.3.2. Genotyping  
Sanger sequencing, a method which incorporates fluorescent dideoxynucleotides 
(ddNTPs) into newly synthetised DNA during in vitro DNA replication, was used to 
assess the SNP status of different breast cell lines.   
2.3.2.1. Sequencing of plasmid DNA 
For assessing the SNP status of rs2981578 in different breast cell lines, a 500 bp 
insert generated by PCR using SNP_For and SNP_Rev primers (Primer table, section 
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2.8) was cloned in pJET1.2/blunt vector using the CloneJET PCR cloning kit, 
transformed into chemically competent E.coli (DH5α strain) and at least 6 colonies 
were sequenced (Genome Centre, BCI) using the same primers, following 
preparation of plasmid DNA. Sequencing files were analysed using BioEdit 
Sequence Alignment editor (version 7.0.5.3) and CLC Sequence viewer 6 software.   
2.3.2.2. Cycle sequencing of PCR product 
Cycle sequencing was performed to genotype several FGFR2 SNPs.  The region 
containing the SNPs was first amplified by PCR using a proof reading DNA 
polymerase, Hot Start Taq DNA polymerase (Qiagen), in the following reaction 
mixture: 
PCR buffer 10X w or w/o Coral load (Qiagen)  2 ul 
dNTPs (2mM) dilution 1:5     2 ul 
Primer 1 (10 µM)      1 ul 
Primer 2 (10 µM)      1 ul 
Hot start Taq polymerase     0.1ul 
DNA template       1 ul 
Water        13 ul 
The PCR programme conditions were as followed: 
94°C  5 min 
94°C  30 s 
58°C  30 s           35 cycles 
72°C  30s  
72°C  10 min 
The samples were cleaned using Exonuclease 1 (Exo) (20,000 units/ml, New 
England Biolabs) and Shrimp Alkaline phosphatase (SAP) (1 unit/µl, USB).  
Exo  1 µl    
SAP  20 µl 
Water  179 µl 
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4 µl of the above mix was added to each 5 µl PCR sample, and incubated for 15 
min at 37°C, followed by 15 min at 80°C in order to inactivate the enzymes.  
BigDye (Applied Biosystems) sequencing was performed using one of the original 
primers used for PCR or an internal primer, when specified.  
BigDye v3.1   0.25 µl 
5X Buffer   1.875 µl    
Water    6.375 µl 
Primer (3.2 µM)  0.5 µl 
Cleaned PCR sample  1 µl 
The following conditions were used: 
96°C  1 min 
96°C  30 s                 25 cycles 
50°C  15 s                 
60°C  4 min  
The post-PCR reaction mixture was sent to the Barts Genome Centre for capillary 
electrophoresis and the resulting sequencing trace was returned to us for analysis.  
Sequencing files were analysed using BioEdit Sequence Alignment editor (version 
7.0.5.3) and CLC Sequence viewer 6 software.  
2.3.2.1. Allelic discrimination using Taqman assays 
SNP genotyping using Taqman probes allow the direct genotyping of biallelic SNPs 
directly from gDNA without the need for cloning the SNP locus prior to the 
genotyping step. It can discriminate homozygous from heterozygous samples by 
the use of two fluorescent probes. The genotypes of rs2981578, rs1047100 and 
rs755793 (Primer table, section 2.8) were determined by Taqman SNP genotyping 
assay (Applied Biosystems) in a panel of breast cancer cell lines and breast tissue 
samples (Fig. 3.1A and Table 5.1). Each sample was used in duplicate in the 
following reaction mix: 
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Taqman SNP genotyping assay 40X  0.25 µl 
Taqman genotyping master mix 2X  5 µl 
Water      3.75 µl 
 
AD files were used to visualise the genotyping results (Genotyper software, version 
1.0.1, Applied Biosystems), whereas specific allele amplification data could be read 
with RQ files, using SDS software, version 2.3 (Applied Biosystems). 
2.3.3. Site-directed mutagenesis (SDM) 
Site-directed mutagenesis is a technique used to make point mutations on a 
circular double stranded plasmid DNA, witch ultimately allows the substitution, 
deletion or insertion of single or multiple amino acids in a recombinant protein 
(Fig. 2.4, step 1). It requires of pair of complementary primers that contain the 
mutation to be introduced in the wild-type plasmid sequence (step 2). After a PCR 
amplification of the mutated plasmid, the product is digested by the endonuclease 
Dpn I, that can recognise and digest the methylated, wild-type DNA and leave the 
newly synthesized DNA untouched (step 3). The final product is then cloned into 
competent bacteria to be recircularised and amplified (step 4). 
Site directed mutagenesis was performed using an adaptation of the QuikChange 
protocol (Fig. 2.4) (Stratagene). KOD DNA polymerase (Novagen) was used to 
amplify 50 ng DNA template (2kb of FGFR2 intron 2 containing the SNP and cloned 
in pJET1.2/blunt vector) using mutagenesis primers created using the 
QuikChangeTM Primer Design Programme (Agilent Technologies). 
DMSO      1 µl 
10X Buffer #2     5 µl 
MgCl2 (25 mM)    3 µl 
dNTPs (2 mM each)    5 µl 
Forward primer (5 µM)   4 µl 
Reverse primer (5 µM)   4 µl 
Template DNA     50 ng 
KOD DNA polymerase    0.4 µl 
Water      up to 50 µl 
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Figure 2.4 : Overview of the different steps involved in Site-directed Mutagenesis (SDM) 
Site-directed mutagenesis is a multistep molecular biology technique used to specifically 
mutate a DNA plasmid using mutagenesis primers and bacterial cloning. Source : Quick 
Change Site-directed mutagenesis kit, Stratagene.  
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94°C  15s 
60°C  30 s             18 cycles 
72°C  1 m 40 s 
 
The amplification was followed by 2 to 3 hours of DpnI digestion to remove any 
methylated parental DNA, and the remaining DNA was transformed in competent 
DH5α E. coli cells, prior to preparation of plasmid DNA from overnight cultures.  
2.4. RNA 
2.4.1. RNA isolation  
The same principles as gDNA extraction and purification apply for RNA. 
2.4.1.1. Cell lines 
Total RNA was isolated using an RNeasy Kit (Invitrogen) according to 
manufacturer’s recommendations for cells cultured as monolayer. RTL buffer (350 
µl/well of a 6 well plate) was added to the washed cell monolayers and the cells 
detached from the flask using a cell scraper. The cell lysate was homogenised by 
several passes through a 0.8 mm diameter sterile needle and 350 µl of 70% 
ethanol was added before transfering the lysate to the columns. The column was 
centrifuged for 30 s at 8,000x g, 350 µl RW1 buffer was added before being spun 
again. DNase treatment (Qiagen) was performed by incubating the membrane 
with a mixture of 50 µl DNase and 350 µl RDD buffer for 15 min at RT. The column 
was washed twice with RPE buffer and the RNA was eluted in 50 µl RNase-free 
distilled water. RNA concentration was determined by the absorbance 
measurements at 260/280 nm using a Nanodrop spectrophotometer. 
2.4.1.2. Breast tissues 
Total RNA from breast cancer tissues, previously snap frozen in liquid nitrogen, 
was purified with Trifast reagent (PeqLab). The tissue sample (80 to 100 mg) was 
immersed in 1.5 ml of Trifast and homogenised using a tissue homogeniser (Ultra-
Turrax), before being incubated for 5 min at RT. 300 µl chloroform (Fisher 
Scientific) was added and the tube shaken vigorously, before 3 min incubation at 
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RT. The different phases were separated by 5 min centrifugation at 12,000x g. The 
upper aqueous phase containing the RNA was transferred to a fresh tube and RNA 
was precipitated by addition of 750 µl isopropanol (Fisher Scientific). The samples 
were kept on ice for 15 min and centrifuged at 4°C, 12,000x g for 10 min. The RNA 
pellets were washed twice with 75% ethanol, mixed by vortexing and spun at 
12,000x g for 10 min (4°C). The excess liquid was removed and the pellets were air-
dried and resuspended in 200 µl RNase-free water. The samples were then stored 
at -80°C. 
2.4.2. cDNA synthesis 
Complementary DNA was generated by reverse transcription from RNA isolated 
from tissues or cell lines.  Random hexamer primers were used to prime the 
reverse transcription reaction and ensure the efficient amplification of all mRNAs 
in the samples and avoid the bias toward the 3’ end of message, seen when using 
oligo dT primers (Bookout and Mangelsdorf, 2003). 0.5 µl of random hexamers (50 
ng/µl) were mixed with 400 ng (or up to 1 µg) total RNA, plus 1 µl dNTP Mix 
(10mM each) in a total volume of 12 µl (topped up with distilled water). The 
mixture was heated to 65°C for 5 min and then quickly chilled on ice. The contents 
of the tube were collected by brief centrifugation, then 4 µl of 5X First-Strand 
buffer and 2 µl DTT (0.1M) were added.  
After incubation at RT for 2 min, 1 µl SuperscriptTM II Reverse transcriptase enzyme 
(200 units, Invitrogen) was added. The final mixture was incubated at 25°C for 10 
min to allow primer binding, then at 42°C for 50 min during which period the 
reverse transcription occurred. A final 15 min at 70°C was required to inactivate 
the enzyme. cDNA samples were used immediately for RT-PCR or Taqman assay 
whenever possible, or stored at -20°C. 
 
2.4.3. Real time polymerase chain reaction 
All real time PCR reactions were carried out in triplicate in a 20 µl reaction volume 
containing 0.06 µl of each primer (100 µM stock), 1 µl cDNA, 10 µl SYBR green 
(Qiagen) and 8.88 µl RNase-free distilled water.  
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Serial dilutions (1, 0.75, 0.5, 0.25, 0.1, 0.01, 0.001) of one of the control samples 
were used to establish a standard curve for each of the new primer sets used in 
the real time PCR reaction. GAPDH and/or HPRT primers were used as internal 
controls. 
PCR amplification was performed using a StepOne® (Applied Biosystems) Real-
Time PCR system under the following thermocycling profile: 
Reaction conditions:  
95°C  15 min  
95°C  30 s 
60°C  30 s         40 cycles 
72°C  30 s 
Melting curve   
95°C  60 s 
60°C  30 s 
95°C  60 s 
The results were analysed using the Comparative ΔΔCT method and presented as 
the mean of three independent experiments (Livak and Schmittgen, 2001).  
2.4.4. miRNA isolation and amplification by q-RT-PCR 
Micro RNAs (miRNA) are small, single stranded, non-coding RNA molecules that 
play a role in transcriptional and post-transcriptional regulation of gene 
expression. Their main function is the downregulation of gene expression, either 
by repressing mRNA translation or by targeting the mRNA for degradation. They 
originate from pre and pri-mRNA which are processed into miRNA by Drosha and 
the miRNA-RISC Complex (Chen and Rajewsky, 2007). 
A mirVana isolation kit (Applied Biosystems) was used to amplify the total miRNA 
population expressed in MCF10A and MCF7 cells. 2x106 cells were trypsinised, 
washed in PBS and pelleted. The pellet was lysed on ice by addition of 600 µl 
lysis/binding solution and vortexed to mix. 1:10 v/v miRNA homogenate additive 
was added and incubated on ice for 10 min. 600 µl Acid-Phenol/Chloroform 
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solution was then added and the solution vortexed for 1 min. The aqueous and 
organic phases were separated by 5 min centrifugation at 10,000x g. The upper 
(aqueous) phase was transferred into a fresh tube and 1.25 volumes of 100% 
ethanol at RT were added. The solution was pipetted into a filter cartridge, spun 
for 15 s and washed with 700 µl wash solution 1. The wash was repeated with 500 
µl wash solution 2/3 and the RNA was eluted by applying 100 µl pre-heated (90°C) 
elution buffer. The total miRNA solution was kept at -20°C. The miRNA was reverse 
transcribed using specific primers for miR-221 and miR-19a (Taqman microRNA 
assays, Applied Biosystems) and the Taqman MicroRNA Reverse transcription kit 
(Applied Biosystems) according to the following reaction: 
 
dNTPs (100 mM)     0.15 µl 
Reverse transcriptase enzyme (50 units/µl)  1 µl 
10X Reverse transcription buffer   1.5 µl 
RNase inhibitor (20 units/µl)    0.19 µl 
RNase-free water     4.16 µl 
The master mix was transferred to PCR tubes,  5 µl total miRNA (150 ng/µl) and 3 
µl 5X stem loop miR primers (miR-221 or miR-19a) were added. The reaction was 
incubated on ice for 5 min and transferred to a thermocycler: 
 
16°C  30 min 
42°C  30 min 
85°C  5 min 
 
The reverse transcription reaction was used in quadruple for RT-PCR: 
2X Taqman master mix  10 µl 
Taqman primer+ probes  1 µl 
RNase-free water   8 µl 
miR cDNA    1 µl 
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The following programme was used: 
95°C  10 min 
95°C  30 s        40 cycles 
60°C  1 min 
4°C  hold 
2.4.5. Custom-made FGFR2 zinc finger nucleases 
The CompoZrTM custom made FGFR2 ZFNs were purchased from Sigma-Aldrich. 
Vials of ZFNs mRNA sufficient for 10 transfections were provided. Additional mRNA 
was generated from ZFN plasmids (Sigma). Briefly, the two plasmids were 
transformed in E. coli (using Kanamycin selection) and purified. 20 µg of each ZFN 
plasmid was digested with 10 µl of XbaI to linearise the plasmid template 
(Appendix 4). The linearised DNA was purified by phenol chloroform extraction 
and used for mRNA run-off transcription using MessageMax T7 mRNA 
transcription kit (Epicentre). 
2.4.5.1. mRNA synthesis 
Messenger RNA can be synthesised in vitro by run-off transcription from an 
expression vector containing a T7 promoter and nascent molecules can be 
stabilised by addition of a 5’ cap and 3’ poly A tail (Appendix 4). 
The following reagents were combined in a 1.5 ml eppendorf tube for each ZFN 
plasmid: 
RNase-free water   5 µl 
Prepared plasmid template.  1 µl 
10X transcription buffer  2 µl 
Cap/NTP premix   8 µl 
DTT (100 mM)    2 µl 
MessageMax T7 Enzyme solution 2 µl 
 
The mixture was incubated at 37°C for 30 min, before the addition of 1 µl of DNase 
and another incubation at 37°C for 15 min.  
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2.4.5.1. PolyA tailing 
An mRNA PolyA tailing reaction was set up using an A-Plus Poly(A) Polymerase 
tailing kit (Epicentre) as follows: 
RNase-free water     55.5 µl 
10X A-plus reaction buffer    10 µl 
ATP (10 mM)      10 µl 
ScriptGard RNase inhibitor    2.5 µl 
In vitro transcription reaction (freshly prepared) 20 µl 
A-Plus Poly(A) polymerase    2 µl 
The mixture was incubated at 37°C for 30 min.  
The final mRNA transcripts were purified with MEGAClear kit (Ambion) according 
to the manufacturer’s instructions. To the poly(A) tailing reaction, 350 µl binding 
solution concentrate and 100 µl 100% ethanol was added. The solutions were then 
transferred to filter cartridges and centrifuged for 1 min at 15,000x g. The 
cartridges were washed with 500 µl wash solution and spun at 15,000x g for 1 min.  
The RNA was eluted twice in two separate tubes by adding 50 µl elution solution 
and incubating the cartridge at 65°C for 10 min. The two eluates were pooled 
together under the hood, on ice, in aliquots of 2 µg each, ready to be used in 
transfection. The vials were stored at -80°C. 
2.4.6. RNA quality control for Breast tissue samples  
The quality of RNA purified from snap frozen breast tissue samples was assessed 
using an RNA 6000 Nano Kit (Agilent Technologies). The assay was performed by 
the Barts Genome Centre. The results are displayed as RNA concentrations, 
ribosomal ratio between the intensity of the signal from ribosomal RNA subunits 
18S and 28S and the RNA Integrity Number (RIN). The RIN software algorithm 
allows for the classification of eukaryotic total RNA, based on a numbering system 
from 1 to 10, 10 being the most intact. Samples below 2 were excluded from 
analysis.   
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2.5. DNA and RNA transfection 
Nucleic acids can be transfected into mammalian cells using different techniques 
which are based on two distinct principles. The first is lipid-based transfection, in 
which the nucleic acid is enclosed in a micelle formed by lipids, that can fuse with 
the lipid bilayer of eukaryotic cells and therefore incorporate the nucleic acid in 
the cytoplasm. The second technique, electroporation (nucleofection), is more 
toxic to the cells but allows higher transfection efficiency. The nucleic acids are 
present in solution with the cells and get incorporated in the cytoplasm by the 
action of an electric current, applied for a very brief moment.  
2.5.1. Lipid based transfection 
a. Lipofectamine 
Cells were seeded at 5x105 or 1x106 cells per well in a 6 well plate and cultured for 
24 hours to reach 80% to 90% confluency. Lipid-based transfection was performed 
using 3 µl of Lipofectamine 2000 (Invitrogen) diluted in 250 µl Opti-MEM + 
Glutamax (Invitrogen). Transfection was performed as per manufacturer’s 
instructions. Briefly, MCF10A and MCF7 cells were transfected with 2 µg either ZFN 
mRNAs or ZFN plasmid DNAs along with 2 µg repair template (major or minor 
allele as appropriate). Cells transfected with 2 µg pmaxGFP (Lonza) served as a 
transfection control. The cells were incubated at 37°C and, 4 hours later, 2 ml 
complete medium was added. Transfected cells were cultured for 7 days to allow 
the degradation of the ZFN mRNA and repair template and then used for the 
establishment of clonal populations of cells. 
b. Interferin 
Cells were seeded at 3x105 cells per well for MCF10A cells and 1.5x105 cells per 
well for MCF7 cells in a 6 well plate and cultured for 24 hours to reach 50% 
confluency. Lipid-based transfection was performed using 4 µl of Interferin 
(Polyplus) diluted in 100 µl Opti-MEM. Transfection was performed as per 
manufacturer’s instructions. Briefly, MCF10A and MCF7 cells were transfected 
with 20 µM of siRNA against Oct1 and Runx2. The cells were incubated at 37°C in 
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1ml complete medium. Total mRNAs and proteins were isolated 48h post-
transfection. 
2.5.2. Nucleofection 
a. ZFN 
The ZFN pairs were transfected into breast cancer cell lines using the Amaxa 
System (Lonza). Nucleofection was performed using the Cell line NucleofectorTM kit 
(Lonza) according to the following conditions: 
Cell line Kit Programme 
MCF10A L T-020 
MCF7 V P-020 
T47D V X-005 
 
2x106 cells were pelleted and resuspended in 100 µl transfection solution (with 
complement), 2 µg plasmid DNA and 2 µg ZFN mRNA. The cell suspension was then 
transferred into an electroporating cuvette and placed in the nuceofection 
machine. Immediately after the chosen programme was executed, 500 µl warm 
complete medium was added to the cuvette and the cell suspension was 
transferred to a 10 cm culture dish, with 10 ml warm complete medium. The 
medium was changed 24 h post-Nucleofection, and every other day thereafter.  
If GFP enrichment was required, this was performed 48 hours post transfection, 
which constitutes the peak expression window for the pmaxGFP construct (Lonza). 
The cells were sorted by Dr Guglielmo Rosignoli or Mr William Day (FACS facility 
manager and assistant) using the ARIA II cell sorter (Becton Dickinson). Different 
cell populations were gated to exclude debris, doublets and GFP negative cells. The 
top 10% to 50% of GFP expressing cells were then collected in a separate culture 
dish (Appendix 13).  
b. Antagomirs 
Antagomirs are small synthetic RNA molecules capable of inhibiting the action of 
miRNA. Their inhibition is very specific toward a single miRNA as the antagomirs 
are synthesized to be complementary to them. They harbour mutations that 
reduce their degradation by the cell machinery. The antagomirs (antagomir-
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miR221, antagomir-miR222) were transfected into the MCF10A cell line using the 
Amaxa System (Lonza). Nucleofection was performed using the Cell line 
NucleofectorTM kit (Lonza) according to the following conditions: 
Cell line Kit Programme 
MCF10A L T-020 
 
2x106 cells were pelleted and resuspended in 100 µl transfection solution (with 
complement) and 100nM antagormir and electroporated using the Amaxa system. 
The medium was changed 24 h post-Nucleofection, and every other day 
thereafter.  
 
2.6. Chromatin Immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) can be used to determine whether, in vivo, 
a given protein binds to specific regions of DNA within the genome. The cells are 
fixed using paraformaldehyde, which locks any proteins bound to the DNA in place. 
The genomic DNA is then purified and sheared into small fragments (200-600 bp) 
which are used for immunoprecipitation with an antibody against the protein of 
interest. After only one type of protein/DNA complex has been retrieved, the 
cross-linking is reversed and the resulting DNA can be analysed by quantitative 
PCR. 
Runx2 ChIP 
ChIP for RUNX2 was carried out on target cells using the Magna ChIPTM A/G kit 
(Millipore) according to manufacturer’s instruction. Cells were plated in a 150 mm 
culture dish and medium was changed every other day until they reached 90% 
confluence (1x107 cells in total). The cells were then cross-linked at RT in 1% 
formaldehyde (Sigma) for 10 min. The reaction was quenched by adding 2 ml 10X 
glycine at RT for 5 min. The cells were washed twice in cold PBS containing 1X 
protease Inhibitor cocktail II, scraped and collected by centrifugation at 800x g for 
5 min (all centrifugation steps were carried out at 4°C). The pellet was lysed on ice 
for 15 min in Cell lysis buffer containing 1X protease Inhibitor cocktail II. The debris 
was pelleted by centrifugation and the supernatant was resuspended in 500 µl 
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Nuclear Lysis buffer. The DNA contained in the lysate was sheared using a 
Bioruptor (Diagenode) according to the programme [30 s shearing, 30 s stop] 
repeated 6 or 10 times, as determined by optimisation of the protocol. At this 
stage the samples were stored at -80°C to be used within 1 month.  
50 µl each sample was diluted in 450 µl Dilution buffer, containing protease 
Inhibitor cocktail II (5 µl was kept as ‘input DNA’) and 20 µl protein A/G magnetic 
beads, as well as the immunoprecipitating antibody. 4 µg anti-Runx2 antibody (sc-
12488X, Santa Cruz), 1 µg anti-RNA polymerase antibody (05-623, Upstate) and 1 
µg IgG control (556648, BD Pharmingen) were used and incubated overnight, at 
4°C with rotation. The magnetic beads were then washed in a series of cold buffers 
and the cross-linking was reversed by addition of ChIP elution buffer containing 
Proteinase K, incubating with agitation at 60°C for 2 h. The DNA was purified using 
spin columns provided in the kit or using QIAquick columns (Qiagen).  
A standard PCR was performed for the control samples (IgG ctr, input DNA and 
DNA-pol samples). Real time quantitative PCR was used to assess the fold 
enrichment of Runx2 binding at the rs2981578 locus (Primer table, section 2.8). A 
master mix was prepared as described previously and 2 µl sample (IgG or Runx2) 
was added, in triplicate. The programme consisted of 10 min of initial denaturation 
at 94°C, and 50 cycles of 20 s denaturation at 94°C, 1 min annealing and extension 
at 60°C. The Ct values obtained were used to evaluate the fold enrichment of 
Runx2 binding compared to the IgG control by calculating the ΔCt (see section 
2.4.3).  
FOXA1 chromatin immunoprecipitation 
FOXA1 ChIP was carried out using an in-house protocol from Prof Ponder’s lab 
(CRUK, Cambridge Research Institute) using 5 µg of anti-FOXA1 antibody (Ab5089, 
Abcam). Cells were plated in a 150 mm culture dish. After 24h, test cells were 
deprived of oestrogen for 3 days by replacing the media by phenol-red free DMEM 
(Sigma) supplemented with 5% of charcoal-stripped FBS (Gibco). The starvation 
medium was changed every day for three days. The starved cells were then 
stimulated with 100nM of β-oestradiol (Sigma) for 1 hour. The control plates were 
grown either in full medium or starved without oestrogen stimulation. All the cells 
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were then cross-linked at 37 C in 1% formaldehyde (Sigma) for 10 min. The 
reaction was quenched by adding 1.5 ml of 1M glycine at RT for 5 min. The cells 
were washed twice in cold PBS containing 1X protease Inhibitors (Roche), scraped 
and collected by centrifugation at 10,000x g for 3 min (all centrifugation steps 
were carried out at 4°C). The pellets were frozen on dry ice and stored at -80°C to 
be used for up to 1 month. 
The day before immunoprecipitation, 50 µl of protein G magnetic beads 
(Invitrogen) were washed and blocked in 1ml PBS + 5mg/ml BSA. They were then 
resuspended and 300 µl of PBS/BSA and 5 µg of FOXA1 antibody was added. The 
beads were incubated overnight on a rotator, at 4 C. 
The cell pellets were resuspended in three consecutive lysis buffers to expose the 
genomic DNA and sheared using a Bioruptor for 15 min (30 s sonication, 30 s rest, 
repeated 15 times). The debris was pelleted by centrifugation and the supernatant 
was added to the pre-incubated beads and incubated overnight on a rotator, at 
4 C. 30 µl of input samples were removed prior to the incubation with the beads 
and stored at 4 C.  
The magnetic beads were then washed several times in RIPA buffer (Upstate, 
Milipore) and the cross-linking of samples and inputs was reversed by incubation 
at 65°C overnight (or a minimum of 6 hours). The DNA was eluted in 70 µl of pre-
warmed elution buffer (50 C) using a PCR purification kit (Qiagen).  
Real time quantitative PCR was used to assess the fold enrichment of FOXA1 
binding at the rs2981578 locus. Primers binding the Greb1 promoter were used as 
positive control and primers recognising an intronic site of Cyclin D1 with no 
FOXA1 binding site were used as negative control (Primer table, section 2.8). A 
master mix was prepared as described previously and 2 µl of sample or input (1:14 
dilution) were added, in triplicate. The programme consisted of 15 min of initial 
denaturation at 95°C, and 40 cycles of 30 s denaturation at 95°C, 30 s annealing at 
60 C and 30 s extension at 72°C. The Ct values obtained were used to evaluate the 
total amount of DNA in samples and inputs. The enrichment was normalised first 
to the input and then to the negative control.  
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2.7. Western blot analysis 
2.7.1. Protein quantification 
Cells plated in 6 well plates were washed with PBS and lysed in 100 µl 1X RIPA 
buffer, supplemented with phosphatase inhibitors cocktail II and protease 
inhibitors (both Calbiochem) at a 1:100 dilution.  The plate was incubated for 30 
min at 4°C with agitation. The cells were then scraped off the wells, transferred to 
1.5 ml eppendorf tubes on ice and centrifuged at 10,000x g for 20 min (4°C). The 
supernatant was transferred to a fresh tube for protein quantification by DC 
protein assay (BioRad). Standards containing known concentrations (2000, 1600, 
1200, 800, 400, 200, 100 and 0 µg/ml) of BSA were used in duplicate to establish a 
standard curve. Standards or samples (5 µl) were added to a 96 well plate, 
followed by 25 µl reagent A’ and 200 µl reagent B. Reagent A’ was prepared by 
mixing 20 µl reagent S and 1 ml reagent A. The plate was incubated at RT for 10 to 
15 min until the colour had developed and the optical density (OD) was measured 
by spectrophotometry at 595 nm. The sample concentration was extrapolated 
from the standard curve obtained by plotting the OD against the known protein 
concentrations. The samples were then diluted 1:1 in NuPAGE LDS Sample buffer 
4X (Invitrogen; supplemented with 100 mM DTT) and stored at -20°C until needed. 
When cell number was similar across the plate, protein quantification was not 
required and the cells were lysed directly using NuPAGE LDS Sample buffer 2X 
(supplemented with 100mM DTT) for 5 min at RT. The cells were scraped off the 
plate, and sonicated briefly. The samples were stored at -20°C until needed.  
2.7.2. SDS-PAGE 
Total proteins were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Identical volumes of protein samples (or 25 μg 
protein/lane when proteins were quantified) were loaded in 4-12% gradient 
NuPAGE gels, in NuPAGE MES running buffer (both Invitrogen) and run at 110 V, 
for 90 min.  Proteins were transferred onto nitrocellulose membranes (Schleicher 
& Schuell) by electro-blotting for 3h (4 °C) at 30 V in Tris/glycine buffer with 20% 
methanol and transfer was confirmed with Ponceau Red staining of the 
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membranes. After de-staining in distilled water, membranes were incubated in 
blocking buffer (5% powdered milk, Marvel in  1X TBS) for 30 min at RT. 
Membranes were then incubated with primary antibody for 1h to overnight (RT or 
4°C), washed 4 times in 1X TBST (TBS containing 0.1% Tween-20) for 5 min, and 
incubated with secondary antibody for 1h at RT. After additional washes the 
antibody was detected using ECL Chemiluminescence reagent mix (GE Healthcare) 
and specific bands were visualised on X-ray film (Kodak).  
2.7.3. Antibodies 
All antibodies were diluted in 1x TBS containing 3% v/v BSA. Anti-ERα (sc-543 
HC20), anti-FGFR2 (Bek sc-122), anti-HSC70 (sc-7298) and anti-Runx2 (sc-10758) 
antibodies were purchased from Santa Cruz Biotechnology. Anti-Oct1 (ab51363) 
and anti-FOXA1 (ab5089) were from Abcam, anti-tubulin α (T5168) was from 
Sigma, anti-P-ERK (#9101S) was from Cell Signaling and anti-GAPDH (MAB374) was 
from Milipore. All polyclonal secondary antibodies coupled with horseradish 
peroxidase were used at a 1:1,000 dilution and were purchased from Dako.    
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2.8. Table of Primers 
Primer name Sequence Application 
SDM 
  a1021g CCTCTATGCAAATATGCGGTTTGGAGCAGGGAAGA major to minor allele change 
a1021g_antisense TCTTCCCTGCTCCAAACCGCATATTTGCATAGAGG major to minor allele change 
g1021a CCTCTATGCAAATATGCAGTTTGGAGCAGGGAAGA minor to major allele change 
g1021a_antisense TCTTCCCTGCTCCAAACTGCATATTTGCATAGAGG minor to major allele change 
ZFN_binding_F ATCTAAAGCTTTCCTCTGAATGCTGCTCTCGAGGATTGTGAGAGG 3 ZFN binding site mutations  
ZFN_binding_R CCTCTCACAATCCTCGAGAGCAGCATTCAGAGGAAAGCTTTAGAT 3 ZFN binding site mutations 
c929t CCTTCTGAGATCTAAAGCTTTCCTCTGAATGCTGC 1 ZFN binding site mutation 
c929t_antisense GCAGCATTCAGAGGAAAGCTTTAGATCTCAGAAGG 1 ZFN binding site mutation 
t945c_g947c TTCCCTCTGAATGCTGCTCTCGAGGATTGTGAGAGGTAG 1 ZFN binding site mutation 
t945c_g947c_antisense CTACCTCTCACAATCCTCGAGAGCAGCATTCAGAGGGAA 1 ZFN binding site mutation 
c31a_t33a TGGTCAGCTGGGGTCGTTTAAACTGCCTGGTCG new PmeI site  
c31a_t33a_antisense CGACCAGGCAGTTTAAACGACCCCAGCTGACCA new PmeI site  
a433c_g434a_t436a GGATGACACCGATGGTGCGGACAAATTTGTCAGTGAGAACAGTAAC new PmeI site  
a433c_g434a_t436a_antisense GTTACTGTTCTCACTGACAA ATTTGTCCGCACCATCGGTGTCATCC new PmeI site  
c24a_a26t GCTTGGCCTTGGGGCAACAGAACTAGTCTAGCACAAAT new SpeI site 
c24a_a26t_antisense ATTTGTGCTAGACTAGTTCTGTTGCCCCAAGGCCAAGC new SpeI site 
t1609a ATAAAGCATTTTTTTCACTGCATACTAGTTGTGGTTTGTCCAAACTC new SpeI site 
t1609a_antisense GAGTTTGGACAAACCACAACTAGTATGCAGTGAAAAAAATGCTTTAT new SpeI site 
 
Primer name Sequence Application 
PCR 
  FGFR2IIIa F AAGGTTTACAGCGATGCCCA FGFR2 isoforms 
FGFR2IIIb R AGAGCCAGCACTTCTGCATT FGFR2 isoforms 
FGFR2IIIc F GTGTTAACACCACGGACAAA FGFR2 isoforms 
FGFR2IIIc R TGGCAGAACTGTCAACCATG FGFR2 isoforms 
ZFN_forward GCAGAGTTTCTTGCCAGGTC Surveyor assay 
ZFN_reverse ACATTCCACGTTAAGAGCCG Surveyor assay 
SNP_forward TTGAGGCTCACCAAGTTCAG sequencing of rs2981578 
SNP_reverse CTGTCCCAGAAAGCCTACAT sequencing of rs2981579 
hFGFR2_11496-11515_for  ACTGGGACTATGAAGCTGCT cloning of repair template 2kb 
hFGFR2_13647-13628_rev  CACCACAGAATTCCCTTGAG cloning of repair template 2kb 
markerSNP_forward GATGGTGCGGAAGATTTTGT Marker SNP sequencing  
markerSNP_reverse CCCGTATTTACTGCCGTTCT Marker SNP sequencing  
WWC2_27_F      AAATGCTACAGCAGAAGACTTCAC Off-target sequencing 
WWC2_362_R    CGAGTCTGTTAGCTCTGCTTCTT Off-target sequencing 
LFNG_72_F     GTGGGCTGGCTCTGAAGAT Off-target sequencing 
LFNG_417_R    CACACTCCCTGCACAGCTC Off-target sequencing 
DPP6_133_F AGGATACGGGAGGATGTGCT Off-target sequencing 
DPP6_460_R GCGAGACGCTGTATCAAAAA Off-target sequencing 
IGSF9B_59_F    CAGGGGATTAGAGCTGAGGA Off-target sequencing 
IGSF9B_436_R   AGGCATGATGGATACAGAGC Off-target sequencing 
TSPAN11_45_F   AGTCTCTCTAGGCGCAGCTC Off-target sequencing 
TSPAN11_376_R   CACAAGTGCAGAAAGGCAGA Off-target sequencing 
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top1_68_F    AGGACAGGACACCACTTGCT Off-target sequencing 
top1_435_R    TAGTCTCTTGGGCAGGGCTA Off-target sequencing 
top2_70_F    GACAGGTTCCAGCAGATTCC Off-target sequencing 
top2_431_R    TGTGATTGTGGTGGCAAGTT Off-target sequencing 
 
Primer name Sequence Application 
real time RT-PCR 
  hGAPDH_forward CAATGACCCCTTCATTGACC qRT-PCR 
hGAPDH_reverse TTGATTTTGGAGGGATCTCG qRT-PCR 
HPRT_forward CCTGCTGGATTACATCAAAGCACTG qRT-PCR 
HPRT_reverse GTCAAGGGCATATCCTACAACAA qRT-PCR 
ERalpha_forward GCACCCTGAAGTCTCTGGAA qRT-PCR 
ERalpha_reverse TGGCTAAAGTGGTGCATGAT qRT-PCR 
cMyb_forward GAAGGTCGAACAGGAAGGTTATCT qRT-PCR 
cMyb_reverse GTAACGCTACAGGGTATGGAACA qRT-PCR 
pS2_forward GAGAACAAGGTGATCTGCGC qRT-PCR 
pS2_reverse TGGTATTAGGATAGAAGCACC qRT-PCR 
runx2-forward AAGGACTTGGTGCAGAGTTC qRT-PCR 
runx2_reverse TTACTGTCATGGCGGGTAAC qRT-PCR 
oct1_forward CCGTCAGAAACCAGTAAACC qRT-PCR 
oct1_reverse CCGTCAGAAACCAGTAAACC qRT-PCR 
FGFR2IIIa_for AAGGTTTACAGCGATGCCCA qRT-PCR 
FGFR2IIIa_rev CTGCTGAAGTCTGGCTTCTT qRT-PCR 
FGFR2IIIb_for AAGGTTTACAGCGATGCCCA qRT-PCR 
FGFR2IIIb_rev AGAGCCAGCACTTCTGCATT qRT-PCR 
FGFR2IIIc_for GTGTTAACACCACGGACAAA qRT-PCR 
FGFR2IIIc_rev TGGCAGAACTGTCAACCATG qRT-PCR 
 
Primer name Sequence Application 
Taqman assay 
  
rs1047100 TGATGGACCCGTATTCATTCTCCAC[C/T]ACACAGGTATAATTTCCCTTGTCAG 
allelic 
discrimination 
rs755793 GTTTTTCAGCCACCGCATGGTTGGC[A/G]TTGGGTTCCCCCCGGCTGGGCAGCG 
allelic 
discrimination 
rs2981578 TTAACCTTTCTTCCCTGCTCCAAAC[C/T]GCATATTTGCATAGAGGTAAAAGCT 
allelic 
discrimination 
hsa-miR-221 AGCUACAUUGUCUGCUGGGUUUC quantification 
hsa-miR-19a UGUGCAAAUCUAUGCAAAACUGA quantification 
 
Primer name Sequence Application 
Chromatin 
Immunoprecipitation (ChIP) 
  FGFR2_rs2981578_for AGGTAGTGACTCTTCAAAGTTTGTTTGT ChIP-PCR 
FGFR2_rs2981578_rev CGCCATCACAGTTAACCTTTCTTC ChIP-PCR 
Greb1_For GAAGGGCAGAGCTGATAACG ChIP-PCR 
Greb1_Rev GACCCAGTTGCCACACTTTT ChIP-PCR 
Kbm359-CCND1F TGCCACACACCAGTGACTTT ChIP-PCR 
Kbm360-CCND1R ACAGCCAGAAGCTCCAAAAA ChIP-PCR 
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2.9. Table of Constructs 
Vector name Common name Antibiotic resistance Size (kb) 
pJET2.1/MCF10A MCF10A repair template Ampicillin 5.1 
pJET2.1/MCF7 MCF7 repair template Ampicillin 5.1 
pJET2.1/FGFR2b-GFP FGFR2b -GFP Ampicillin 8.2 
pJET2.1/FGFR2b-GFP/neo FGFR2b-GFP/neo Ampicillin 9 
PGKneotpAlox2 Neomycin selection casette (Addgene) Ampicillin 5.6 
pCAG-cre Cre recombinase (Addgene) Ampicillin 5.8 
pmaxGFP Transfection control (Lonza) Kanamycin 3.5 
PZFN1 ZFN1 targeting reverse strand Kanamycin 4.2 
PZFN2 ZFN2 targeting forward strand Kanamycin 4.2 
pCRII-TOPO TOPO cloning vector Ampicillin and Kanamycin 4 
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CHAPTER 3 
 
ZFN-MEDIATED GENOME EDITING  
IN BREAST CANCER CELL LINES 
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3. ZFN-mediated genome editing in breast cancer cell lines 
3.1. Introduction 
In complex diseases such as breast cancer, as opposed to diseases that show 
Mendelian inheritance, the familial aggregation usually appears to be caused by a 
number of genes or genetic elements, interacting with various environmental 
factors (Motulsky, 2006). Genome wide association studies have identified some of 
these risk loci, particularly by identifying numerous SNPs associated with 
susceptibility to disease, altered response to drug treatment and other phenotypic 
variations. However the connection between most of those variants and the 
underlying mechanism of carcinogenesis remains unknown. Comprehensive 
functional validation studies at the biological level are needed to better 
understand the significance of these risk alleles.  
3.1.1. Non-coding polymorphisms 
Data from published GWAS demonstrate that 88% of disease associated SNPs 
occur in non-protein coding DNA, with 45% and 43% occurring in introns and 
intergenic regions respectively (Hindorff et al, 2009). Another study established 
that up to 71% of GWAS SNPs have a potential causative SNP overlapping a DNase 
I hypersensitive site, and 31% of loci have a candidate SNP that overlaps a binding 
site occupied by a transcription factor (Bernstein et al, 2012). The non-coding 
regions also include promoters and 3’ untranslated regions (3’UTR) that may play a 
crucial role in modulating the expression of a neighbouring gene (or genes). Most 
of the SNPs that are localised to such regions are therefore expected to give rise to 
a phenotype. The high number of non-coding polymorphisms correlates with the 
non-homogeneous distribution of SNPs across the genome, with non-coding 
regions being less subject to natural selection than coding regions (Zhao et al, 
2006), but also emphasises the increasing awareness of the importance of non-
coding DNA in regulating genes. In addition to regulatory element binding sites, 
non-coding DNA sequences play other functions involved in transcriptional and 
translational regulation that can also potentially be affected by SNPs, such as the 
transcription of non-protein coding RNA (transfer RNA, ribosomal RNA, micro-RNA) 
(Jin et al, 2011; Ritz et al, 2012).  
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SNPs located in non-coding regions are more difficult to identify as, by definition, 
protein structure and/or function is unchanged. Current methods of investigating 
such SNPs consist of indirect in vitro assays such as chromatin 
immunoprecipitation (ChIP) and Electrophoretic Mobility Shift Assay (EMSA), that 
can detect the binding of proteins to a given DNA sequence. Additionally, 
chromatin conformation capture is used to demonstrate the physical interaction 
between a transcription factor binding site and a gene promoter.  The putative 
regulatory sequences can also be cloned upstream of reporter genes, such as 
Luciferase, to assess whether the impact on the level of gene expression is SNP 
dependent. However, in vitro proof of binding does not necessarily mean that a 
significant phenotype will ensue. 
3.1.1. Site-specific genome editing 
The early stages of cancer development are accompanied by subtle phenotypic 
changes that can be difficult to model using in vitro cancer cell lines. This is 
because oncogenic phenotypes might be modulated by biological variation 
between the cells lines themselves (either caused by a prolonged culture period or 
inter-individual variation), concealing any SNP-specific phenotype. It is therefore 
essential to set up models of isogenic cell lines where the putative disease causing 
genetic polymorphism is the sole modified variable.  
The objective of this study was to generate a panel of control and disease-
associated breast cancer cell lines by editing the allele of rs2981578 to assess the 
importance of that SNP in the development of breast cancer, and decipher the 
apparent association with ER positive disease.   
Genome editing techniques relying on homologous recombination have been used 
extensively to create knock out and knock in of genes in animal models (and 
plants) and cell lines to study the role of genes and/or regulatory sequences. 
Random transgene integrations, used extensively in microorganisms and plants in 
biotechnology, have the principal drawback of unpredictable gene expression due 
to multiple transgene copy integration and lack of control over integration sites 
(Dellaire and Chartrand, 1998; Conner and Jacobs, 1999).  Site-specific 
recombination, however, is much safer but has a low efficiency. Classical targeting 
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approaches employ the co-integration of an antibiotic resistance cassette with the 
transgene to allow for positive selection of transfected clones. Such selection 
cassettes may be flanked by recombination sites (such as LoxP sites) that can be 
excised by recombinases (e.g. Cre) to facilitate excision of the cassette, to prevent 
interference with the transgene (Birling et al, 2009). The remaining LoxP site at the 
site of integration consist of a 34 bp sequence that could be a disadvantage when 
studying a region of the genome that is rich in regulatory sequence such as 
transcription factor binding sites and methylation sites. A key advantage of 
targeted genome editing using zinc finger nucleases (ZFN) is that it leaves the 
neighbouring DNA intact and is therefore a more suitable approach for the study 
of regulatory DNA. Recently, many studies have used engineered ZFNs to drive 
efficient genome editing in different cell types such as rat zygotes (Geurts et al, 
2009), human embryonic stem cells (Chang and Bouhassira, 2012), human cancer 
cells (Gutschner et al, 2012) and human T cells (Geurts et al, 2009). Some studies 
use ZFN technology for gene therapy by inserting a transgene into a safe harbour 
gene locus, as in the study by Chang and colleagues for correction of α-thalassemia 
(Chang and Bouhassira, 2012). Others have attempted to modulate the response 
to certain anti-cancer drugs by deleting polymorphisms in the pro-apoptotic gene 
BIM, which affect the response to tyrosine kinase inhibition (Ng et al, 2012).  
In this study, ZFN technology was used as a proof of concept to show it is possible 
to engineer and study functional intronic SNPs. Because of the known association 
between FGFR2 SNPs and breast cancer, we determined to use rs2981578 as a 
model system to examine the feasibility of this approach.  
3.2. Results 
3.2.1. rs2981578 SNP status in a panel of breast Cancer cell lines 
rs2981578 has three possible genotypes in diploid cells: (A;A), (A;G) and (G;G), 
where the G allele is the disease associated allele that confers an increased risk of 
developing ER positive breast cancer. Cloning of the rs2981578 locus and 
sequencing was first carried out to determine the SNP genotype of the candidate
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Figure 3.1: Candidate breast cancer cell lines characteristics 
A) Comparison of rs2981578 SNP status, ERα status and FGFR2 copy number variation 
(when available) in a panel of breast cancer cell lines. Dataset from Cancer Cell Line 
Enclyclopedia database: DNA Copy Number Affymetrix SNP 6.0 arrays. B) Comparison of 
FGFR2 copy number value in a panel of ERα positive (pink) and ERα negative (white) 
breast cancer cell lines. CNV value of 3 is equivalent to duplication whereas a value of 1 
represents the loss of one copy of a chromosome portion. CNV data were visualised using 
the IGV2.2 software, data obtained from http://www.broadinstitute.org/ccle (September 
2012). C) RT-PCR for the different FGFR2 isoforms in MCF10A and MCF7 cell lines. The 
western blot is a representative image of three independent experiments (35 cycles, 
GAPDH serves as a control for RNA integrity). 
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breast cancer cell lines use for ZFN-mediated editing. Cell lines were classified 
depending on their ERα status, since this is the only tumour characteristic that was 
found to be associated with FGFR2 dependent risk, and their respective FGFR2 
copy number, which is crucial information for genome editing of multiple alleles 
(Fig. 3.1A and B). Interestingly, the results indicated that all the cell lines 
investigated were homozygous, except the SKBR3 cell lines (Fig. 3.1A). The 
proportion of cell lines with the non-disease associated allele (four out of eleven 
A;A) was slightly lower relatively to the disease-associated allele (six out of eleven 
G;G). Genome editing using ZFN mainly allows the editing of one copy of the target 
allele at a time, but in some cases can lead to biallelic editing (12.2% vs. 2.4%) 
(Urnov et al, 2005); it is therefore probable that two rounds of ZFN specific editing 
would be necessary in order to change the SNP status of one diploid cell line into 
the other alternative homologous genotype.  
Additionally, one might hypothesise that the putative phenotype of rs2981578 
could be more visible in the early stage of breast cancer development, rather than 
at a more advanced stage, where other new mutations in oncogenes might mask 
any phenotypes related to the SNP; therefore candidate cell lines that possessed a 
relatively normal karyotype, with only two copies of chromosome 10, were 
favoured. Copy number variation data from the Cancer Cell Line Encyclopaedia 
(Affymetrix SNP6.0 Array, CCLE, Broad Institute) were used to determine whether 
the candidate cell lines showed FGFR2 deletion or duplication (Fig. 3.1B). MCF10A 
cells, which were homozygous for the disease associated allele, were initially 
chosen as working models for this study, as they fit this profile and are a well 
characterised spontaneously immortalised breast epithelial cell line used in many 
studies (Wang et al, 2012; Scribner et al, 2012; Ward et al, 2012). The only 
drawback regarding the use of MCF10A cells as model was the fact that they did 
not express ERα (Neve et al, 2006). The MCF7 cell line, which is ERα positive and 
homozygous for the major allele of rs2981578, was another possible candidate, 
despite showing a small FGFR2 amplification (Log2 (Copy Number/2)=0.113, Fig. 
3.1A and B). Both MCF7 and MCF10A cells expressed FGFR2 isoform b 
predominantly but transcripts of the c isoform also were detected by RT-PCR (Fig. 
3.1C). 
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3.2.1. Oestrogen receptor expression in the MCF10A cell line 
MCF10A, a non-tumourigenic, spontaneously immortalised epithelial breast cell 
line (Soule et al, 1990), constitutes an attractive model for the study of cancer 
initiation, as the cells have not yet accumulated many genetic alterations, 
compared to the weakly metastatic MCF7 cell line (Neve et al, 2006). Indeed, their 
karyotypes are very different, with many abnormalities with high-level 
amplification in the MCF7 cells (Appendix 1).  All the GWAS have consistently 
demonstrated that the correlation between FGFR2 intronic SNPs and breast cancer 
risk was statistically more significant in ERα expressing tumours as compared to ER 
negative ones (Easton et al, 2007; Hunter et al, 2007; Antoniou et al, 2008). 
However, the MCF10A cell line, the favoured model cell line, is ERα negative (Neve 
et al, 2006).  
Possible acquisition of ERα expression was investigated in a series of cell lines, of 
increasing tumourigenicity,  that were derived from the original MCF10A cells after 
a series of mouse xenografts and induced RAS mutations (Fig. 3.2A) (Santner et al, 
2001). Original MCF10 cells were obtained from benign breast tissue from a 
woman with fibrocystic disease (Soule et al, 1990). The series then was initiated 
with the mortal MCF10M and MCF10MS cells (mortal cells grown in serum-free 
and serum-containing media, respectively), that gave rise to the spontaneously 
immortalised but otherwise normal MCF10F and MCF10A lines (free-floating 
versus attached cells), the transformed MCF10AneoT cells, transfected with T24 
Ha-Ras, and premalignant MCF10AT1/k.c12 cells. Additionally, fully malignant 
MCF10CA1 (a and h) lines were developed to complete the spectrum of 
progression from normal breast epithelial cells to breast cancer cells capable of 
metastasis. MCF10A DCIS.com is a human cell line that forms ductal carcinoma in 
situ (DCIS) when xenografted into immunodeficient mice, and was derived from 
premalignant MCF10AT cells (Miller et al, 2000). Western blot analysis for ERα in 
the different cell lines revealed that only a very small amount of ERα protein was 
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Figure 3.2: Oestrogen receptor, miR-221 and miR-222 expression in the MCF10A cell line 
series 
A) The MCF10A cell line series. MCF10 panel of cell lines, derived from a single patient, 
representing sequential stages of progression (immortalised, pre-malignant and 
malignant) as shown by their ability to form xenograft lesions in immunodeficient mice 
(mouse icon)(Kadota et al, 2010). B) ERα expression in the MCF10A cell line series as 
assessed by western blot analysis. MCF7 is an ER positive cell line used for positive control. 
HCT116 is a colon cell line, used as negative control for ERα expression. C) Taqman assay 
showing miR-221 expression (normalised to miRNA-19a expression) in MCF7 and MCF10A 
cells, one biological experiment, three technical repeats, error bar represents SEM. 
Transient knock down of both miR-221 and miR-222 and the effect on ERα protein level in 
MCF10A cells. D) Relative mRNA expression of ERα and cMyb (an ER response gene) in the 
MCF10A cell series and MDA-MB-468 cells, another ER negative cell line used as control, 
relative to GAPDH expression. The experiment was done in triplicate, error bars represent 
SEM. 
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detected in MCF10A cells and all the other related cell lines, as compared to high 
levels observed in MCF7 cells, which are classified as ERα positive (Fig. 3.2B).   
Interestingly, it was shown that the 221-222 microRNA cluster can target ERα 
mRNA and might therefore be responsible for a fraction of the ERα negative breast 
carcinomas or breast cancer cell lines (Zhao et al, 2008). Zhao et al reported that, 
although not detectable at the protein level, ERα mRNA was transcribed in 
MCF10A cells, indicating a post-transcriptional repression of ERα by miR-221 and 
miR-222. They used antagomirs, miRNAs that target endogenous miRNAs, to 
inhibit miR-221 and miR-222 and therefore release the ERα inhibition.The same 
approach was considered, to re-establish ERα protein expression in MCF10A and 
thus potentially create an inducible system where ERα positive and ERα negative 
MCF10A modified cells could be used in parallel for functional studies. The 
expression level of miR-221 was assessed by quantitative RT-PCR using specific 
Taqman probes in MCF10A and MCF7 cells. The Taqman assay used was specific 
for miR-221 only, however as miR-221 and miR-222 are part of the same cluster on 
the X chromosome and are located on the same pri-miRNA, they are co-expressed 
at similar levels (Yu et al, 2006). The results indicated that although MCF7 cells lack 
miR-221 expression, it was expressed at high levels in MCF10A cells and might 
therefore be responsible for the downregulation of ERα. However, all three 
attempts to knock down miR-221 and miR-222 with specific antagomirs failed to 
demonstrate any significant increase in ERα protein expression (Fig. 3.2C).  
In an attempt to replicate the findings of the Zhao study, quantitative RT-PCR was 
performed to compare ERα transcript levels in the MCF10A cell series and the ER-
positive cell line, MCF7.  However, RT-PCR results showed very low levels of ERα 
mRNA in all the members of the MCF10A series (Fig. 3.2D). Similarly, low cMyb 
mRNA levels, a positively ERα-regulated gene (Gudas et al, 1995), were detected. 
The low level of ERα transcription is contradictory to published data (Zhao et al, 
2008), which indicates that the MCF10A cells at our disposal must somehow differ 
from those used in the Zhao study. Short tandem repeats (STR) profiling of all the 
cell lines used by the Tumour Biology department was carried out and confirmed
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Figure 3.3: Runx2, Oct1 and FGFR2 expression 
A) Western blot showing Oct1 and Runx2 protein levels in three breast cancer cell lines, α-
tubulin was used as loading control. B) Transient knock down of Runx2 (shown in 
duplicate) using a pool of 4 different targeting siRNAs (or non-targeting control) was 
performed and FGFR2 protein levels were determined by Western blot in MCF10A and 
MCF7 cells. The two top bands are full length receptor and the lower bands represent 
truncated forms of FGFR2 (∼60 kDa). GAPDH was used as loading control. Densitometry of 
FGFR2 expression relative to GAPDH, is shown below the graph and represents a total of 4 
independent experiments. Error bars show SEM.   
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Figure 3.4: Runx2 knock down in MCF7 and MCF10A cells 
A) Knock down of Runx2 in MCF7 and MCF10A cells, using a pool of four siRNAs, was 
assessed by quantitative RT-PCR. Paired T test was performed on triplicate experiments. B) 
Immunocytochemistry staining of FGFR2 and Runx2 in MCF7 and MCF10A cells 48 hours 
following a transient Runx2 knock down using siRNA. Scale (yellow bar) equals 50 µm. 
Measurement of the average green pixel intensity per cell (in 10 fields of view) was used 
for quantification purposes. 
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the identity of the MCF10A cells used in this study, indicating that we had been 
using the correctly designated line (Appendix 2).     
This approach was therefore halted and the use of an ERα positive cell line, or one 
where the overexpression of ERα had been engineered was considered instead.  
3.2.1. Runx2, Oct1 and FGFR2 expression 
Meyer et al. (2008) hypothesised that Runx2 is capable of binding the disease 
associated allele of rs2981578 only (G;G), and acts as an enhancer of FGFR2 
transcription. Western blot analysis and immunocytochemistry were used to 
assess the basal expression level of transcription factors Runx2 and Oct1 in two 
breast cancer cell lines (Fig. 3.3A and Fig. 3.4B). MCF10A cells did not express high 
levels of Runx2 as seen by Western blot and immunocytochemistry, possibly 
consistent with reports in the literature suggesting higher Runx2 expression occurs 
in more metastatic samples, compared to normal tissues (Shore, 2005). Moreover, 
Western blotting for Oct1 only picked up a smear instead of a single band in 
MCF10A cells, compared to the other cell lines. A Transient knock down of Runx2, 
using a pool of 4 siRNA, was performed in MCF10A and MCF7 cells. Technical 
issues with a different Runx2 antibody lot made the protein detection by Western 
blot quite difficult (Fig. 3.3A and B) in MCF7 cells and no band was detected in the 
MCF10A blot (data not shown). Other techniques, such as real-time PCR and 
immunocytochemistry, were used to detect Runx2 knock down (Fig. 3.4A and B). A 
clear reduction in total FGFR2 protein and mRNA levels were however observed in 
MCF7 cells, but not in MCF10A cells (Fig. 3.3B and Fig. 3.4C). MCF7 cells are 
homozygous for the major allele of FGFR2, not associated with breast cancer risk, 
and therefore should not possess any Runx2 binding site at the rs2981578 locus. 
The decrease in FGFR2 protein level observed in Figure 3.3B thus should not be 
caused by the absence of the Oct1/Runx2 complex at this site. Considering that 
Runx2 is a key transcription factor involved in many cellular mechanisms, we 
decided it was unlikely that this line of investigation would be informative 
regarding the effect on FGFR2 intronic SNPs independently from any other Runx2 
target genes. Other approaches such as Chromatin Immunoprecipitation (ChIP) 
were therefore used to analyse the importance of Runx2 binding
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Figure 3.5: FGFR2 donor template with modified ZFN binding sites 
A) The wild-type ZFN target sequence is displayed next to the mutated sequence that 
impairs ZFN binding. Also shown is the region around rs2981578 (shown in red at position 
1033), showing ZFN sites (green) and mutations (red). The mutated target site forms a 
new XhoI site (underlined), used for screening purposes. B) Restriction map of 
pJET1.2/blunt plasmid containing the 2kb insert from FGFR2 intron two. A new XhoI site 
was created by site directed mutagenesis. C) DNA from several colonies obtained after 
SDM was digested with XhoI and resolved by electrophoresis.  The mutated inserts have a 
different digestion profile than the wt, displaying a new band of 1 kb. Control lanes 
correspond to digestions with no plasmid DNA, uncut lane does not contain XhoI enzyme. 
Two alternative SDM primers (that either contained the three changes or only one at a 
time) were used. 
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in the mechanisms associated with the increased breast cancer risk. 
3.2.1. Design of repair template for genome editing 
Genome editing using the custom-made FGFR2 ZFN requires a repair (or donor) 
template in the form of a plasmid with 1kb homology arms flanking the target SNP 
(a minimum of 750 bp of homology was required). The creation of in vitro models 
composed of isogenic cell lines that only differ in rs2981578 SNP status requires 
the absence of foreign DNA at the site of integration, excluding therefore the use 
of an antibiotic selection marker in the DNA repair template. However, an 
additional change to the ZFN binding site was recommended to reduce ZFN 
targeting of the repair template and to allow for more efficient additional editing 
rounds. Such cutting of the exogenous template would happen considerably more 
often considering the great abundance of the template present in the cell after 
transfection and consequently would reduce the chance of obtaining an allelic 
change. Three bases on the ZFN target site of the repair template were modified 
using site directed mutagenesis (SDM), creating a new XhoI site as a result, which 
was used for post-SDM screening (Fig. 3.5A). Two alternative SDM primers (that 
either contained the three changes or only one at a time) were used (Primer table, 
section 2.8). The multiple changes approach was successful as three plasmids (one 
from MCF10A cells and two from MCF7 cells) contained the new XhoI site as 
shown by restriction enzyme digestion (Fig. 3.5C).  
Plasmid number 5 in MCF10A cells and number 2 in MCF7 cells were used to 
create the repair templates. An additional round of SDM was used to edit the 
rs2981578 locus, either replacing the major allele in MCF7 (A;A) or the minor allele 
in MCF10A (G;G). In the absence of restriction sites, the SNP change on the repair 
template was assessed by sequencing. An additional repair template for MCF7 
cells was created that contained the change in SNP status only, without the 
modified ZFN binding site, to be tested for genome editing alongside the original 
template.   
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Figure 3.6: Workflow of the ZFN-mediated genome editing process in the MCF7 cells 
A) MCF7 cells were transfected using Amaxa nucleofection with FGFR2 ZFN mRNAs, repair 
templates containing the rs2981578 risk allele and a pmaxGFP plasmid. At the FGFR2 SNP 
locus, the ZFN pairs, previously translated by the cells’ own translation machinery, was 
able to induce DNA double stranded break (DSB) and direct the cell DNA damage repair 
sytem to this specific locus. The DNA damage was repaired by homologous recombination 
using the exogenous repair template, present in excess after transfection. An 
heterozygous population of MCF7 cells were therefore obtained. GFP enrichement by 
FACS was performed and clonal populations were screened using a SNP genotyping 
Taqman assay specific for rs2981578.  B) Homologous recombination is initiated by 
resection of DSB to provide 3' single-stranded DNA (ssDNA) overhangs. Strand invasion by 
the 3' ssDNA overhangs into the repair template (red) is followed by DNA synthesis at the 
invading end. The second DSB end can be captured to form an intermediate with two 
Holliday junctions (HJs, green arrow heads). The final structure is resolved by DNA 
synthesis and ligation (modified from Sung et al, 2006). 
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3.2.1. ZFN editing in breast cancer cell lines 
The CompoZrTM custom made FGFR2 ZFNs, purchased from Sigma-Aldrich, were 
designed following a screening of the region surrounding the rs2981578 locus, to 
validate the optimum cutting site. The algorithm used by Sigma, constantly 
updated by Sangamo, has been designed to yield obligate-heterodimer pairs of 
ZFNs with high binding affinity to their specific target site. Several ZFN pairs were 
designed and the best performing ones were then assembled and validated 
biologically in HCT116 cells, a human colon carcinoma cell line (cell line of choice 
used by Sigma/Sangamo during the ZFN quality control process) (Park et al, 1987). 
Custom forward and reverse primers were provided for sequencing (Appendix 3 
and 5).  
The workflow of the ZFN-mediated genome editing process is summarised in 
Figure 3.6A.  ZFNs are synthetic modular molecules made from the fusion of zinc-
finger DNA-binding domains to the catalytic domain of the endonuclease FokI 
(Urnov et al, 2005). ZFNs create a double stranded break at the FGFR2 SNP locus, 
thereby directing the DNA repair machinery to this site. For genome editing, the 
sister chromatid that would, in the normal context of homologous recombination 
(Fig. 3.6B), be used as a template for DNA damage repair, is bypassed in favour of a 
synthetic repair template (Fig. 3.5) that contains the alternative allele and is 
present in vast molar excess. The efficiency of this targeted recombination is far 
higher than normal homologous recombination. However, in the absence of a 
selectable marker, clonal cell populations are used for screening, using an allele 
specific Taqman SNP genotyping assay.  
Several approaches to transfect ZFNs into a cell were tested, for transfection either 
in the form of mRNA or as an expression vector. The most efficient approach for 
the transfection of the FGFR2 ZFNs was electroporation of the nucleic acids as 
mRNA. However, the amount of cell death using that method was higher than 
expected and could only be used with the MCF7 cells. The high percentage of cell 
death in MCF10A cells (data not shown) impaired their transfection efficiency. 
Therefore the less toxic method of lipid-based transfection, using Lipofectamine 
2000 with serum-free medium supplemented with Glutamax, was favoured.  
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3.2.2. Assessment of DNA cleavage by Surveyor assay 
To assess the cutting ability of the ZFN pairs, 2 µg of ZFN mRNAs were transfected 
in each cell line.  Transfection efficiency, using pmaxGFP (Lonza), was estimated to 
be between 30% and 50% in MCF10A cells (data not shown) and 60 to 70% in 
MCF7 cells (Fig. 3.7A).  ZFN cutting efficiency was assessed using the SurveyorTM 
assay (Transgenomic) (Fig. 2.3). Cells transfected with either ZFN mRNA or 
pmaxGFP were harvested for genomic DNA preparation 24 hours after 
transfection. In the absence of repair template, double-stranded breaks are not 
resolved by homologous recombination but by the non-homologous end joining 
pathway instead,  which leads to small errors such as indels (insertions and/or 
deletions)  (Lieber, 2008). The Surveyor mutation detection assay is based on the 
Cel-I endonuclease, derived from celery, that specifically cleaves small mismatches 
caused by SNPs, small insertions or deletions and can therefore be used to detect 
those potential errors and to estimate the frequency of double stranded breaks in 
control transfected cells relative to those transfected with the custom ZFN pair 
(Fig. 2.3). A 333 bp fragment containing the ZFN target site was amplified by PCR. 
The products were denatured and re-annealed, allowing the formation of 
homoduplexes and heteroduplexes between the DNA molecules that had been cut 
and repaired and those which were not cut. The percentage of cleaved products 
compared to the intact DNA was visualised after digestion with Cel-I (Fig. 3.7B). A 
new band, reflecting ZFN-mediated cleavage is present in the ZFN transfected lane 
and absent in the GFP control lane. The ratio of band intensity should, in theory, 
represent the ZFN cutting efficiency but this is difficult to quantify with such faint 
secondary bands. The presence of such bands was an indication that cleavage had 
occurred and constituted validation for the ZFN mRNA. An estimate of the ZFN 
cutting efficiency is important to determine the number of clones required for 
screening; however it was assumed, from the Surveyor assay data, that the 
efficiency was rather low and that screening of around 100 clones was the best 
strategy for this study.  
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Figure 3.7: Transfection efficiency and Surveyor assay 
A) Transfection of pmaxGFP shows a transfection efficiency of about 50% of the cells as 
assessed by the number of GFP positive cells under a UV microscope. ZFN mRNA 
transfection without the DNA repair template was performed to be used for the Surveyor 
assay to control the cutting efficiency of the ZFN pair. Scale bar represent 200 µm. B) 
MCF7 and MCF10A cells were used for Surveyor assay. The samples were resolved on 10% 
non-denaturing polyacrylamide gels. A new band (black arrow head) was present in the 
ZFN mRNA samples compared to the GFP control, reflecting the modification induced by 
the ZFN cutting of genomic DNA.  
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3.2.3. Single cell cloning and screening 
a. MCF10A cell line 
The slow growing MCF10A cells performed very poorly in initiating colonies from a 
single cell in culture. Feeder cells (NIH 3T3 fibroblasts previously treated with 
mitomycin C) were therefore used to support the growth of the clonal populations. 
MCF10A cells are strongly adherent cells that often display plasma membrane 
lamellipodia and filopodia, and were therefore more difficult to detach from their 
substrate, making the colony picking method, used for MCF7 cells, poorly suited to 
this cell line. 
As an initial attempt, 48 MCF10A single cell colonies (in duplicate) were screened 
using SNP genotyping Taqman assay for rs2981578. The number of cells present in 
each well was highly variable, as not all colonies grew at the same rate. The 
Taqman assay was therefore performed with different DNA concentrations. 
Interestingly, the samples with the highest DNA concentrations did not give a 
strong signal (Fig. 3.8B). On average, a DNA concentration around 10 ng/μl was 
optimal for the assay conditions. 
Overall, the majority of the colonies, from the first screening attempt, were 
homozygous for the disease associated SNP allele (G), with the exception of three 
samples that contained the modified allele (A) (Fig. 3.8C, blue circles). Among 
these three, two originated from the same colony in duplicate. The third modified 
colony was not selected as each of its duplicates gave a different result, potentially 
indicating a problem of contamination with gDNA from some other wells.  
Additionally, the only modified clone obtained failed to grow further in culture, 
displaying quiescent cell features. The addition of NIH 3T3 fibroblasts, treated with 
mitomycin C, triggered an increase in proliferation, which stopped shortly after the 
fibroblasts died.  After no visible change in proliferation within 3 weeks, the 
culture was terminated. In a new attempt to modify the SNP status of MCF10A 
cells, the ZFN transfection and screening was repeated. This time the cells were 
transfected with either a minor or a major DNA repair template in order to obtain 
a control cell line with only the ZFN binding site change.  The second attempt of
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Figure 3.8: ZFN-mediated genome editing of MCF10A cell line 
A) Allelic discrimination is achieved by the selective annealing of TaqMan probes. Only a 
matching probe is degraded by the DNA polymerase (yellow) exonuclease activity, 
releasing the fluorophore and allowing emission of fluorescence, as shown in the left hand 
sideof the figure. B) DNA concentration against Total Signal Strength. The samples with a 
concentration above 25ng/µl failed to yield genotyping results. C) Allelic discrimination for 
rs2981578 presented as a plot of fluorescence signal strength for allele (A) against allele 
(G). The two graphs represent the two attempts using MCF10A cells transfected with ZFN 
and major allele repair template. Three heterozygous clones (including two duplicates), 
containing one or two allele A were obtained at the first attempt (blue circles), unlike the 
second time, where all clones screened were wild-type (G;G). Non template control (NTC) 
was used to determine the basal level of background fluorescence.  
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modifying the SNP status of the MCF10A cells failed, as demonstrated by the allelic 
discrimination plot (Fig. 3.8C (right)) where all of the 68 clones screened displayed 
the wild-type allele.  
b. MCF7 cell line 
Two alternative approaches were adopted for single cell cloning of MCF7 cells. The 
first one consisted of creating serial dilutions from a concentrated cell suspension 
until reaching a concentration of one cell per well in a 96 well plate (Fig. 2.1). This 
strategy yielded only a small number of single cell colonies per plate (between 1 to 
4 single-cell colonies). The MCF7 cells also struggled to grow at very low cell 
density but formed, relatively readily, loosely attached, self-contained colonies 
within a week in a large culture plate. The colonies were visible by eye, thus 
making direct colony picking, or the use of cloning rings, an attractive solution.  
After ZFN delivery, and addition of a transiently expressed GFP expressing plasmid, 
the cells were subject to GFP enrichment by FACS, followed by single colony 
picking: 93 colonies were then screened using Taqman assay for rs2981578 (Fig. 
3.9A). The result showed three heterozygous (A;G) MCF7 clones (3.2% efficiency), 
in the following location of the plate: A8 (Clone Het 1), C4 (Clone Het 2) and G11 
(Clone Het 3). Unmodified MCF7 clones, homozygous for the wild-type allele (A;A) 
were chosen as control clones: E4 (Clone Ctr 1), F4 (Clone Ctr 2) and E11 (Clone Ctr 
3). The names Ctr 1 to 3 and Het 1 to 3 are used to designate these MCF7 clones 
hereafter. The genotypes of the six clones were confirmed by direct sequencing 
and Taqman assay (Fig. 3.9B).  
c. Biallelic change in MCF7 heterozygous clone 
Another round of ZFN-mediated genome editing was carried out in the clone Het 2 
in order to obtain a MCF7 clone that carry the genotype (G;G)  for rs2981578. After 
screening 72 clones by Taqman genotyping assay, none of the clones carried the 
second allele modification. Recent studies suggested that short single-stranded 
oligodeoxynucleotides (ssODNs), instead of double stranded donor templates,  
could be used as an alternative DSB repair template for ZFN-driven genome editing 
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Figure 3.9: Sequencing of rs2981578 in ZFN-edited MCF7 clones  
A) Allelic discrimination for rs2981578 presented as a plot of fluorescence signal strength 
for allele (A) against allele (G). Heterozygous clones are circled in red. Non template 
control (NTC) was used to determine the basal level of background fluorescence. B) Cycle 
sequencing performed from PCR products of the three heterozygous and three wild-type 
clones. The wild-type genotype of MCF7 (A;A) was identical to the non-modified controls, 
whereas the heterozygous clone sequencing traces displayed two overlapping peaks for 
nucleotide A and G. 
  
A 
B 
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Figure 3.10: Biallelic change in MCF7 clone (Het 2) 
Sequence of the single stranded oligodeoxynucleotide containing the rs2981578 risk allele 
used a repair template for ZFN-mediated genome editing. A) GFP expression in Het 2 cells 
48 hours post transfection, showing a 90% transfection efficiency, scale bar =50 microns. 
B) Taqman assay showing the genotyping of the 17 clones screened for biallelic change. 
The GFP-positive cells were FACS sorted 48 hours post-transfection. T47D, MDA-MB-134 
and ZR75-1 genomic DNA were used as controls for the different rs2981578 genotypes. 
Allele 1(VIC) correspond to the G allele, and Allele 2 (FAM) correspond to the A allele. NTC 
is the non-template control.   
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(Soldner et al, 2011). A 137 base ssODN was synthesised to be used as a repair 
template for genome editing using the ZFNs. The ssODN, the ZFN pair (mRNA) and 
a GFP vector (pmaxGFP) were electroporated in Het 2 cells using Nucleofection. 
The GFP expression 48 hours post transfection was used as an indicator for 
transfection efficiency (Fig. 3.10A) and used for single cell sorting using flow 
cytometry. 288 single cells were distributed in 96 wells plates containing NIH 3T3 
fibroblasts (treated with mitomycin C). After 10 days, only 17 clones had 
proliferated sufficiently to be used for SNP genotyping screening. T47D (A,A), 
MDA-MB-134 (G,A) and ZR75-1 (G,G) were used as controls for each SNP 
genotype. The results showed that none of the clones were successfully modified 
to homozygosity (Fig. 3.10B). The number of viable clones obtained was 
insufficient to obtain a modified clone. 
3.3. Discussion 
GWAS have identified a haplotype in linkage disequilibrium in the large second 
intron of FGFR2 associated with risk of developing ER positive breast cancer. 
Meyer et al (2008) observed that FGFR2 expression was significantly higher in 
patients with the disease-associated alleles of the intronic haplotype and identified 
rs2981578 as the putative functional polymorphism. The objective of this study 
was to generate a panel of isogenic breast cancer cell lines differing only in the 
genotype of the disease-associated allele of rs2981578, to further investigate the 
potential mechanism by which this allele affect breast cancer susceptibility.  
None of the four ER positive cell lines screened were heterozygous for rs2981578 
and only one, ZR-75-1, possessed the breast cancer risk allele. The study of risk 
variants that only confer a small risk increase requires the need for diploid cell 
lines with few oncogenic mutations. The MCF10A cell line constituted an ideal 
candidate, except for its lack of ERα expression, and was chosen for genome 
editing in order to engineer its genotype to the non-disease associated allele. The 
MCF7 cell line, an ER positive cell line bearing the opposite genotype, was also 
chosen. The problem caused by the lack of ERα expression in MCF10A cells 
appeared reversible in the light of a study on the role of miRNAs in cancer 
progression (Zhao et al, 2008). Indeed, miR221 and miR222 are co-expressed 
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miRNAs associated with the ER negative, aggressive basal-like breast cancer 
subtype and have been found to mediate metastasis through the regulation of 
epithelial to mesenchymal transition (EMT) (Stinson et al, 2011). Zhao et al (2008) 
observed that miR221 and miR222 were overexpressed in some ER negative breast 
cancers, but not in most ER positive cases, consistent with our real time PCR 
results comparing miR221 expression in MCF10A and MCF7 cells (Fig. 3.2C). They 
then demonstrated that the expression of miR221 and miR222 synthetic mimetics 
in MCF7 and T47D cells (both ER positive) was capable of blocking ERα expression 
and that, conversely, the inhibition of these miRNAs in MCF10A cells restored ERα 
protein expression.  The results showed that the MCF10A cell line did not express 
ERα mRNA and therefore the knock down of miR221 and miR222 was not 
successful in re-establishing ERα in those cells (Fig. 3.2D). The data strongly 
support the idea that the oestrogen receptor alpha is not transcribed in MCF10A 
cells because this transcript is also absent in all MCF10A derived cell lines (Fig. 
3.2D), which is further supported by a published study showing very low levels of 
ERα mRNA in the MCF10A cell line series (Fu et al, 2010).  
Meyer and colleagues reported that a new binding site for Runx2, an important 
transcription factor implicated in osteoblast differentiation, is created by the 
presence of the disease-associated allele of rs2981578 (Meyer et al, 2008). It was 
hypothesised that Runx2 was acting as an enhancer of FGFR2 expression, in 
association with the transcription factors Oct1 and C/EBPβ. In preliminary studies, 
we aimed to assess the expression of those proteins in the candidate cell lines. 
Runx2 was expressed in MCF7 cells but not detected in MCF10A cells by Western 
blot, consistent with the progressive increase in Runx2 expression in more 
metastatic cells compared to normal cells (Shore, 2005). Small amounts were, 
however, detected using real time RT-PCR and immunocytochemistry. Runx2 
knock down using siRNA in MCF7 cells led to a decrease in FGFR2 protein levels, as 
previously reported (Zhu et al, 2009) but no such decrease was observed in 
MCF10A cells. MCF7 cells are homozygous for the non-disease associated allele of 
FGFR2 and should therefore not possess any Runx2 binding site at the rs2981578 
locus. The decrease in FGFR2 protein level observed (Fig. 3.3B) should, 
consequently, not be caused by the absence of the Oct1/Runx2 complex at this 
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site. Considering that Runx2 is a key transcription factor involved in many cellular 
mechanisms, it is unlikely that total Runx2 knock down would be informative 
regarding the effect on FGFR2 intronic SNPs. The endogenous low levels of Runx2 
might be responsible for the lack of change in FGFR2 expression in MCF10A cells, 
making the knock down inconsequential. 
The DNA repair templates were designed using genomic DNA isolated from 
MCF10A and MCF7 cells: one kb of DNA sequence each side of rs2981578 and the 
SNP status was modified, along with three bases located in the ZFN binding site. 
The ZFN and the appropriate DNA template were then tested in MCF10A and 
MCF7 cells.  
The FGFR2 ZFN cutting efficiency was lower than previously anticipated, reaching 
only 3% in both cell lines and only producing monoallelic changes. In a study 
reporting the use of ZFNs, the efficiency of the ZFN pair used for correction of 
point mutations at the endogenous locus of the interleukin-2 receptor-γ (IL2RG) 
gene in K562 cells reached 20% in the absence of any selection marker (Urnov et 
al, 2005). Importantly, 8% of the single cell derived clones obtained showed 
biallelic modifications. Comparable gene correction frequency was also observed, 
in the same study, at this locus in human CD4+ T cells. The low efficiency 
encountered with the FGFR2 ZFNs might be caused by the spatial constraint of the 
ZFN cutting site (100 bp away from rs2981578) in the SNP region as opposed to 
other gene areas that are less GC rich (54.62% in the SNP region compared to the 
average 46.98% in the second FGFR2 intron). Another explanation may be the low 
levels of homologous recombination in the MCF10A and MCF7 cell lines (as 
assessed by Surveyor assay). Moreover, the ZFN mRNA synthesis process was 
about 50% less efficient than reported by Sigma, making the total volume of ZFN 
mRNA transfected higher than recommended, possibly impairing the transfection 
efficiency.  
Transient cell hypothermia has been shown to further increase ZFN-driven double 
strand break frequency in transformed and primary cells by two to five fold (Doyon 
et al, 2010) but did not improve the efficiency of the FGFR2 ZFN pair. The low cell 
proliferation rate of MCF10A cells added another level of difficulty in terms of 
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single cell clone formation for screening and use of this cell line was stopped. It is 
important to note that a recent study, that reported using ZFNs for changes of 
point mutations associated with early onset of Parkinson’s disease, had very low 
editing efficiency (4 out of 480, and 1 out of 240 clones screened had the desired 
nucleotide change) and overcame this problem by co-transfecting a GFP plasmid 
transiently, to enable GFP-positive FACS sorting of single cells (Soldner et al, 2011). 
Using this additional step of GFP-positive cell enrichment by FACS was successful, 
and the SNP rs2981578 was eventually modified in the ER positive MCF7 cell line 
only (Fig. 3.1A), resulting in a set of six clones: three controls and three 
heterozygous clones (Fig. 3.9). 
The combination of high-fidelity DNA recognition by the ZFN pairs and homology-
directed repair of ZFN-induced double-strand breaks has allowed this technology 
to be used for the comprehensive functional study of risk polymorphisms. The 
results presented here establish a proof of concept for the permanent 
modification of intronic SNPs in cell line models, but also highlight the inherent 
difficulties of using low efficient ZFNs for single nucleotide modification without 
the use of a selection marker.  
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4. MCF7 clone characterisation 
4.1. Introduction 
Mutations and polymorphisms in various genes and their regulatory elements are 
implicated in tumour initiation, progression and drug resistance (Cimoli et al, 2004; 
Sur et al, 2009). The understanding of the consequences of such genetic changes 
relies on the availability of genetic and cancer models. Site specific genome editing 
that does not leave any scar on the DNA, and therefore no genomic alteration, was 
achieved using ZFN and homologous recombination, resulting in a panel of control 
and disease-related breast cancer cell lines. The panel is composed of three MCF7-
derived clones heterozygous for rs2981578, and three MCF7-derived wild-type 
controls that lack the disease associated allele of the SNP. The homozygous clones 
containing two copies of the risk allele could not be established after ZFN editing 
was repeated (one attempt with the normal repair template and another with the 
ssODN template). Additionally, several attemps to produce the same array of 
clones in MCF10A cells failed due to the difficulty of maintaining single cell cultures 
with this cell line.   
rs28981578 is a polymorphism contained in the FGFR2 intronic haplotype that has 
been associated with increased risk of ER positive breast cancer. However, one 
copy of the risk allele confers a 1.2 increase in risk for breast cancer development, 
and this figure goes up to 1.64 for individuals that carry two copies of the allele 
(Fig. 1.5) (Easton et al, 2007). It was hypothesised that the risk was mediated via 
an upregulation of FGFR2, which acts as an oncogene in breast cancer. FGFR2 
signalling, principally through the MAP kinase pathway, is implicated in many 
cellular mechanisms including proliferation, migration, and survival (Turner and 
Grose, 2010). In order to detect the impact of the single nucleotide change that 
was engineered in MCF7 cells, heterozygous MCF7 clones were compared to their 
control counterparts in a series of in vitro assays. The mechanism of action of 
rs2981578 in mediating the breast cancer risk was also investigated using 
Chromatin immunoprecipitation followed by SNP genotyping Taqman assay in 
order to evaluate the degree of allele specific binding (ASB) in the heterozygous 
clones. Overall, this chapter is dedicated to characterising the MCF7 clones 
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obtained and assessing their capacity to become a model for the study of the 
intronic FGFR2 SNP in breast cancer. 
4.1. Results 
4.1.1. Assessment of the off-target effect of FGFR2 ZFNs 
A potential limitation of ZFN-mediated genome editing is the induction of DNA 
strand breaks at sequences other than the intended target site. To examine off-
target effects in the heterozygous clones, DNA binding affinity for other, less 
specific, genomic target sites was examined using the ‘ZFN-site’ database (Cradick 
et al, 2011) to allow the identification of the most probable off-target cleavage 
sites. Genotyping of the top seven off-target sites was performed to reveal any 
potential modification or deletion, caused by non-homologous end joining (NHEJ). 
The results from the software algorithm revealed no other perfect match other 
than FGFR2 (Fig. 4.1A). All the other potential non-specific binding regions only 
allow for a five nucleotide long spacer region, compared to six nucleotides at the 
original FGFR2 site, making the binding and subsequent cutting very unlikely. The 
top two hits were located in an intergenic region of the genome, and the following 
four hits were localised in non-coding regions (introns or promoters). The only site 
detected in a coding region was located in the membrane scaffolding protein 
Tetraspanin 11 (TSPAN11). Typically, off-target effects after a ZFN-mediated cut 
are repaired by NHEJ and can be visualised as 8 or 9 base pair deletions 
(Hockemeyer et al, 2009).  Sequencing of these regions was sometimes difficult 
due to the high GC content (LFNG and the second intergenic hit for instance), but 
no such deletions were detected in any of the loci investigated, except for IGSF9B 
in Ctr 3 clone, the sequencing trace of which was not of sufficient quality to yield 
reliable base pair calling (Fig. 4.1B) (Appendix 7 and 8). Overall, this indicated that 
the FGFR2 ZFN pairs were highly specific and did not appear to cause any off- 
target modification of the genome apart from the rs2981578 allele change. 
Additionally, unbiased screening, such as genome-wide integration site analysis 
(using integrase-defective lentiviral vectors) might be necessary to address this 
question (Gabriel et al, 2011). Furthermore, one of the hallmarks of cancer cells is
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Figure 4.1: Potential off-targets of the FGFR2 ZFN pair 
A) Result from the ZFN site website (http://ccg.vital-it.ch/tagger/targetsearch.html). When 
a nucleotide mismatch is found at a given position between query and hit, the 
mismatched position is highlighted and underlined; the original nucleotide being displayed 
underneath (red).The spacer sequence size is represented by Ns (green).  Results also 
show the number of mismatches between queries and mismatch site, and the genomic 
locus of the off-target. B) Sequencing results of the off-target ZFN binding site for each 
clone. The tick symbol means that the sequence was identical to database, proving that 
the ZFN did not cut that locus. N.A. means that some sequencing reaction failed to give a 
sequencing trace. See Appendix 8 for the entire sequencing data.  
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genome instability (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011) 
along with an increased rate of mutations as compared to normal cells. It is 
therefore expected that the cell lines cannot stay true isogenic cell lines for an 
extended period of time and that, as passage number increases, the risk of 
accumulating additional point mutations increases as well. 
4.1.1. Proliferation, cell cycle analysis and migration 
In order to detect the impact of the single nucleotide change, the heterozygous 
clones (Het 1, Het 2 and Het 3) were compared to their control counterparts (Ctr 1, 
Ctr 2 and Ctr 3) in a series of in vitro assays.  
The MCF7 cells are a weakly metastatic breast cancer cell line usually growing in 
clusters and not very motile, retaining contact inhibition. At confluence, they 
present a cobblestone morphology, typical of epithelial cell lines. The appearance 
of the sublines varied moderately between each other (Fig. 4.2A) but did not 
correlate with the rs2981578 genotypes. Het 1, Ctr 1 and Ctr 3 displayed more 
membrane elongations, resembling filopodia, observed at the edges of cell 
clusters, compared to the other clones. It has often been reported that MCF7 cells, 
like many cell lines (Wenger et al, 2004) have a tendency to deviate from their 
initial phenotypes as the number of passages in culture increases, and this 
discrepancy in phenotypic appearance may also have been caused by the stressful 
single cell cloning process.   
The six clones were first subjected to cell cycle analysis using PI staining followed 
by flow cytometry. The heterozygous clones displayed a normal cell cycle profile, 
similar to the wild-type controls (Fig. 4.2B). Although their proliferation rate 
appeared reduced compared to MCF7 cells which had not been subject to 
transfection or single cell cloning (data not shown), directly after single cell 
cloning, MTS assay (Fig. 4.2C) and anti-Ki67 staining (Fig. 4.2D) did not reveal any 
significant differences between the clones themselves.  
Additionally, migration was investigated using the organotypic model combined 
with a wound assay. The MCF7 cells do not normally invade during an organotypic
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Figure 4.2: Characterisation of the heterozygous MCF7 clones, as compared to 
homozygous controls 
A) MCF7-derived clones grown as a monolayer at passage 4 (x100). The ZFN-modified 
clones were derived from the MCF7 cell line, an adherent luminal epithelial cell line 
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isolated from pleural effusions from a woman with invasive breast carcinoma. The MCF7 
cell line has a classic epithelial appearance in culture, usually growing as clusters retaining 
contact inhibition. Bar: 50 microns. B) Cell cycle analysis by PI staining and flow cytometry. 
DNA fluorescence signal showed a normal cell cycle DNA content profile for the ctr and 
the het clones. Two-way Anova statistical test was performed but did not reach 
significance with a p value of 0.1293. C) MTS assay comparing the cell number of the 
control clones and the heterozygous clones over 72 hours. Each bar represents an average 
of three independent experiments by indicating the mean of absorbance measured at 492 
nm and the SEM. D) Proliferation was assessed using Ki67 staining on fixed cells. 
Quantification was performed by counting the percentage of positive cells in 10 fields (on 
average 976 cells/10 fields) of view for each clone. Mean ± SEM of three independent 
experiments are presented. Bar: 50 microns. 
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 Figure 4.3: Migration assay using organotypic culture: Wound assay 
The wound healing process was examined in Ctr 3 and Het 2 MCF7-derived clones after 0, 
3, 6 and 9 days post wounding (with a punch biopsy). The MCF7 cells do not present any 
invasive phenotype in organotypic assay, and instead, proliferate on the top of the 
collagen/matrigel matrix. The cell layer sometimes detaches from the gel during the 
process of making slides. The different wound sizes at day 0 are therefore not comparable 
and no measurement of the wound closure can be undertaken. 
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assay (unpublished data), but instead, proliferate on top of the collagen/matrigel 
matrix and form, after a few days, a thick cell layer. This cell layer was wounded 
with a punch biopsy and the cells in the wound were removed (Fig. 2.2). The 
wound was then left to close for two weeks, allowing cells to migrate to the newly 
formed space. However, during the fixation of the organotypics and the 
embedding process at the end of the assay, thick cell layers occasionally detached 
(partially of entirely) from the matrix, making the measurement of the wound 
unrealiable. This assay was not best suited for the non-invading MCF7 cells, 
however, clear cell migration (cells moving as a single file at the edge of the 
wound) and wound closure could be seen in both Ctr 3 and Het 2 cells from day 6 
(Fig. 4.3). The migrating rates could unfortunately not be compared between the 
controls and the heterozygous cells.  
4.1.1. FGF and ERα signalling 
FGF signalling and oestrogen receptor alpha expression were investigated. As 
demonstrated in Chapter 3, MCF7 cells expressed FGFR2, predominantly the 
epithelial-associated isofom FGFR2-b. Real-time PCR showed that no statistically 
significant difference was found, in terms of isoform levels, between the control 
and the heterozygous clones (Fig. 4.4A).  
Two of the clones (Ctr 3 and Het 2) were chosen to be used in cell-based assays, on 
the basis of their most similar cell cycle profiles (Fig. 4.2B). The two cell lines were 
stimulated with 100 ng/ml of FGFR2-b specific ligands: FGF7 and FGF10, for 
increasing amounts of time and in the presence of heparin. The results showed 
that both FGF10 and FGF7 elicited robust ERK phosphorylation sustained after 60 
minutes of stimulation (Fig. 4.4B) in both Ctr 3 and Het 2 cells. In a second type of 
experiment, the sensitivity of the receptors toward decreasing amounts of ligands 
was assessed. Only key time points of zero, 30 minutes and one hour were chosen. 
Although phospho-erk relative intensity was decreased, even the smallest amount 
of ligand (1 ng/ml) was capable of eliciting a signal and leading to ERK 
phosphorylation, demonstrating no apparent change in receptor affinity for the 
ligands (Fig. 4.4C). Interestingly, basal erk phosphorylation seemed reduced in Het 
2 clones compared to the ctr 3 clones (Fig. 4.4B and C). In addition, the levels of  
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Figure 4.4: FGFR expression and signalling 
A) The MCF7 clones were subjected to real-time PCR to assess the level of expression of 
the three different FGFR2 isoforms. No statistical difference was observed between the 
controls and the heterozygous clones (2-way ANOVA). B) The MCF7 clones were 
stimulated with two FGFR2-b specific ligands (100 ng/ml) from 5 min to 1 hour. Two 
different exposures are showed. C) Erk phosphorylation after stimulation of the Ctr 3 and 
Het 2 cells with decreasing concentration of FGF7 or FGF10 ligands. The experiments were 
repeated independently three times and a representative blot is shown, as well as the 
densitometry analysis for all of the experiments.  
120 
    
 
 
Figure 4.5: Oestrogen receptor alpha level in the MCF7 clones and response to 
Tamoxifen treatment 
A) Western blot analysis of ERα expression level in the control versus the heterozygous 
clones. HSP70 was used as loading control. B) Quantitative RT-PCR of ERα level upon 
exposure to 1 µM Tamoxifen (TAM) relative to control (vehicle, EtOH) for 48h, and effect 
on the expression level of two ERα response genes: PS2 and cMyb. mRNA levels are shown 
here relative to GAPDH expression, and normalised over control. Mean ± SEM of three 
independent experiments are presented. Statistical analysis (2-way ANOVA) showed that 
the Tamoxifen treatment significantly changed the mRNA level of ERα, PS2 and cMyb 
(p<0.0001) but no significance was reached when comparing the control clones and the 
Het clones (ERα: p=0.6491, PS2: p=0.1098, cMyb: p=0.2304).  
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oestrogen receptor alpha were investigated as ER positivity constitutes the only 
significant tumour characteristic that was associated with the FGFR2 SNP 
haplotype.Western blot analysis did not show any significant differences between 
the oestrogen receptor alpha levels in the heterozygous versus the homozygous 
controls (Fig. 4.5A). The cells were treated with 1 µM Tamoxifen for 48 hours, 
which led to a significant increase in the level of ERα compared to the untreated 
controls. This increase has been reported in the literature as a response from a 
positive feedback loop (Carroll et al, 2003) but the exact mechanism remains 
unknown. Tamoxifen treatment, however, significantly reduced the level of ERα 
target genes such as PS2 and cMyb (p<0.0001) (Gudas et al, 1995; Kim et al, 2000). 
This reduction was equivalent in both control and heterozygous clones, as shown 
by the lack of any statistically significant difference between the two groups, as 
assessed by 2-way ANOVA test. 
From these first observations, the risk allele of rs2981578 does not seem to 
directly affect the expression level or the signalling of the FGFR2 gene nor the level 
of oestrogen receptor alpha expression. 
4.1.2. Transcription factor binding at the rs2981578 locus 
a. Runx2 transcription factor 
Runx2 was identified as the transcription factor mediating the increase in FGFR2 
expression in cell lines with the disease associate allele of rs2981578 (Meyer et al, 
2008). It was demonstrated in this study that exogenous Runx2 was able to bind 
the promoter of a Luciferase reporter gene on a site containing multiple repeats of 
the disease associated allele and its surrounding sequence. The disease associated 
allele at the Oct1/Runx2 site stimulated transcription 2 to 5 fold over the non-
disease associated allele, independently of orientation. The ChIP data were less 
conclusive and only showed a relative increase in Runx2 binding from 0.8 to 1.4 
(Meyer et al, 2008). 
The attempts to replicate the Runx2 ChIP data for the rs2981578 locus in the MCF7 
clones failed to show a significant enrichment of the binding of Runx2 to the 
rs2981578 locus (data not shown). Additionally, the ChIP experiements for Runx2 
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were carried out with a commercially available kit that used IgG controls only, for 
data normalisation. The apparent fold enrichment observed could have been an 
artefact caused by the use of IgG control for normalisation. Future experiments 
were carried out using internal positive and negative controls as well as the input 
DNA for normalisation of the real time PCR results. 
b. Identification of other potential trans-acting factors 
As Runx2 ChIP analysis failed to provide robust data, publicly available online ChIP-
seq (chromatin immunoprecipitation followed by high-throughput sequencing) 
data on whole-genome scale (ENCODE, 2012) were used to identify other potential 
transcription factors present at the rs2981578 locus. Whole genome data from 
MCF7 and HepG2 (hepatocellular carcinoma) cell lines revealed that the 
transcription factor E2F-1, involved in cell cycle control (Muller et al, 2001) and the 
pioneer factor FOXA1 (Cirillo et al, 2002) were bound to the DNA at this locus.  
E2F-1 is a transcription factor which acts predominantly as a regulator of the cell 
cycle by coordinating the expression of genes during early cell cycle progression 
(Takahashi et al, 2000). The E2F family works in tandem with the retinoblastoma 
tumour suppressor (RB1) to allow the entry of cells into the S phase of the cell 
cycle. It can also induce apoptosis in response to DNA damage. Because E2F-1 is 
such a key player in regulation of cell growth or cell death it has, not surprisingly, 
been implicated in human cancers such as lung (Park et al, 2012) and breast cancer 
(Xu et al, 2013).  
The second transcription factor, FOXA1, that was identified in the ENCODE 
database, constituted an ideal candidate for studying the link between FGFR2 
intronic SNPs and increased risk of ER-positive breast cancer. Indeed, FOXA1 is a 
pioneer factor responsible for opening the condensed chromatin for easy access 
by other transcription factors and has been shown to play an important role in 
maintaining euchromatic conditions and to be required for ERα binding (Carroll et 
al, 2005). The binding of FOXA1 to the rs2981578 SNP locus was confirmed in 
MCF7, T47D and ZR75-1 cell lines by ChIP-seq data analysis from a study on FOXA1 
and oestrogen receptor function in breast cancer (Hurtado et al, 2010) (Appendix 
6). Interestingly, Ross-Innes and colleagues (2012) have shown that ERα binding is 
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a dynamic process and that new ERα-binding sites were unique to seven patients 
with poor outcome as compared to eight patients with good outcome. When using 
the ChIP-seq data from that study, ERα was bound a few hundred base pairs away 
from the rs2981578 locus and only in samples associated with poor outcome 
(Appendix 6). The current hypothesis on the role of FOXA1 in breast cancer is that 
FOXA1 is capable of mediating a reprogramming of the ERα binding site (Ross-
Innes et al, 2012). Considering the strong association with ER positive breast 
cancer risk and the minor allele haplotype of FGFR2, further ChIP assays were 
performed to assess the binding of FOXA1 in the ZFN-modified MCF7 cells. 
As a pioneer factor, FOXA1 is capable of binding closed, condensed chromatin, 
which is transcriptionally inactive. The MCF7 clones (het 2 and ctr 3) were, 
therefore, either cultured in full medium or starved of oestrogen for 4 days and 
stimulated (or not) with 100nM of β-oestradiol (E2) for 1 hour, prior to chromatin 
isolation and ChIP analysis. A site within the fourth intron of CCND1 (Cyclin D1) and 
the Greb1 (growth regulation by oestrogen in breast cancer 1) promoter were 
used as negative and positive control, respectively, for FOXA1 binding (Ross-Innes 
et al, 2012). As expected, control cells showed enhanced binding of FOXA1 to the 
Greb1 promoter following oestrogen stimulation. Heterozygous cells showed 
relatively lower enrichment of FOXA1 binding. Despite an unexpected high level of 
FOXA1 binding to the Greb1 locus in heterozygous cells growing in full serum, the 
cells still showed a positive response of FOXA1 binding to the Greb1 promoter 
following oestrogen stimulation (Fig. 4.6A). Control cells showed significantly 
enhanced FOXA1 binding at rs2981578 relative to heterozygous clones in all 
culture conditions, but most achievably following ERα stimulation. Total FOXA1 
levels were equal in both control and heterozygous cell lines (Fig. 4.6B).  
a. Allele specific binding of FOXA1 
In order to assess if the reduced binding of FOXA1 at the rs2981578 locus was 
caused by the rs2981578 risk allele, allele specific binding (ASB) was investigated 
using FOXA1 ChIP material in a specific SNP genotyping Taqman assay for 
rs2981578. The results indicated that all the cell lines tested showed the correct 
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Figure 4.6: ChIP analysis of FOXA1 binding at rs2981578 locus in the SNP-edited MCF7 
clones  
A) FOXA1 ChIP-PCR results in heterozygous (grey) and control (white) clones, in full 
medium, upon β-oestradiol (E2) starvation or after 1h of E2 stimulation (100 nM). Greb 1 
was a positive control FOXA1 binding locus (primers located in Greb1 promoter region). 
The fold enrichment was normalised to a negative control (CCND1 primers, located in an 
intron) and to the Input DNA for each sample. Error bars represent SEM of three 
independent experiments. B) Expression of FOXA1 in the controls and heterozygous 
clones. HSC70 was used as loading control (western blot is representative of three 
independent experiments). 
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segregation in the different regions of the graph (in accordance with their 
genotype), except for the MCF7 clones ChIP material, which all appeared to be 
heterozygous (Fig. 4.7). This artefact was caused by the combination of ChIP and 
Taqman assays, as the Taqman assay alone, using genomic DNA, showed correct 
genotyping information (Fig. 3.8 and Fig. 3.9). It was therefore impossible to 
distinguish the control clones from the heterozygous clones and therefore no 
assumption could be made regarding any ASB. The PCR products resulting from the 
Taqman/ChIP assay were cloned into cloning vectors and sequenced. However the 
results obtained did not reflect the preferential binding of a particular allele, and 
only constituted an equal repartition of each of the two alleles. This indicated that 
the Taqman probes were sometimes cloned into the vector and not the actual 
ChIP PCR product. This approach of assessing allele specific binding was therefore 
abandoned and another strategy using patient tissue samples, discussed in 
Chapter 5, was adopted.    
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Figure 4.7: rs2981578 specific Taqman assay following FOXA1 ChIP  
In order to assess allele specific binding of FOXA1, the input FOXA1 ChIP DNA samples 
from T47D, MDA-MB-134 and ZR-75-1 cell lines were used as controls for the three 
possible genotypes of rs2981578.  ZF-75-1 (red), MDA-MB-134 (green) and T47D (blue) 
input samples segregated to the correct position of the graph (i.e. according to their 
respective amount of allele A and/or allele G). The ChIP samples of Ctr 3 and Het 2 MCF7 
clones (purple circles), used in fig. 4.6 (E2 stimulation), were also used for Taqman assay in 
order to determine if FOXA1 displayed allele-specific binding. However, the het and ctr 
samples all grouped to the same region of the graph (behaving like heterozygous samples, 
even in the case of control samples), indicating a technical problem with this specific 
assay. 
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4.1. Discussion 
Stable transgene expression is one of the most powerful genetic tools available 
when it is necessary to investigate the function of genes and the impact of genetic 
alterations such as oncogenic mutations. The generation of stable cell lines 
containing a randomly inserted transgene using recombinase-mediated cassette 
exchange or integrase-mediated site specific insertion (Sorrell and Kolb, 2005) is 
appropriate when studying a monogenic disease. However, expression levels 
between clones vary greatly due to chromosomal positions and copy number 
variations (Recillas-Targa, 2006), making the screening for identical clones 
laborious. In addition, random insertion may lead to genome alterations, such as 
gene inactivation, which may alter cellular phenotypes. The ability to use targeted, 
tailored changes, introduced into the genome using ZFN technology can overcome 
these limitations and can, potentially, allow the investigator to ask more precise 
biological questions. 
The functional significance of the presence of FGFR2 risk alleles is currently 
unknown. It was hypothesised that one SNP from the risk haplotype was functional 
and allowed the de novo binding of transcription factors that altered the FGFR2 
expression level (Meyer et al, 2008). A specific FGFR2 ZFN pair was used to 
introduce the risk allele in MCF7 cells and the modified clones obtained were used 
in a series of in vitro assays and compared to unmodified MCF7 control clones.  
The combination of zinc finger moieties used for target sequence specificity may 
not be completely specific; thus this might induce some cytotoxicity if off-target 
cleavages occur in essential areas of the genome. No off-target cleavage, and 
subsequent base pair deletions, was observed at seven possible off-target loci, in 
any of the controls or heterozygous MCF7-derived clones. The high specificity of 
the obligate heterodimers formed by the zinc fingers ZFNs, and their transient 
nature (mRNA rather than DNA) greatly reduces the possibility of off-target effects 
due to unspecific cleavage or stable integration to the genomic sequence. The 
spatial constraint of the 6 bp spacer sequence added an additional degree of 
specificity.  
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No marked or measurable changes (in cell cycle and proliferation markers) were 
detected between the two populations of MCF7 clones (Fig. 4.2B, C, D). 
Additionally, the lack of differences after FGF stimulation of Ctr 2 and Het 3 clones 
indicates that the receptor function and downstream signalling was not altered by 
the SNP modification, as expected given the intronic location of the SNP.  
Unlike the results published in the Meyer study, no substantial Runx2 binding was 
observed at the rs2981578 locus. Additionally, an attempt to use a positive control 
for Runx2 binding, in the β-casein promoter also failed (data not shown). This 
might be due to the Chromatin Immunoprecipitation technique used for Runx2, 
using a commercially available kit rather than the in-house method developed by 
the Carroll lab (CRUK, CRI) and used in the FOXA1 ChIP experiment. For instance, 
the beads used for immunoprecipitation were not pre-incubated overnight with 
the antibody, but were added to the cell lysate and antibody at the same time. 
Also, the absence of a negative control for normalisation (like CCND1 for FOXA 
ChIP) might explain the apparent fold increase in binding, but might only reflect 
the non-specific background binding of the antibody.  
The pioneer transcription factor FOXA1 was therefore a much better candidate to 
explain the function of rs2981578. First, FOXA1 is required for ERα/chromatin 
interactions (Carroll et al, 2005) and plays a crucial role in reprogramming ERα 
target sites during cancer progression (Ross-Innes et al, 2012). Using data from the 
Ross-Innes study we were able to confirm that a FOXA1 binding site was present in 
the second intron of FGFR2 in three breast cancer cell lines (ChIP seq data publicly 
available from Ross-Innes et al, 2012) (Appendix 6). FOXA1 ChIP showed a reduced 
binding of FOXA1 to the SNP locus in the heterozygous clone, whereas a very 
strong binding was observed in the control cell line (Fig. 4.6). FOXA1 is crucial in 
mediating the binding of ERα to its target genes, and whole genome ChIP-seq 
screening has demonstrated that FOXA1 plays a role in the reprogramming of ERα 
binding sites during breast cancer progression (Ross-Innes et al, 2012; Cowper-Sal 
lari et al, 2012). Interestingly, Ross-Innes and colleagues (2012) have shown that 
ERα binding is a dynamic process and that new ERα-binding sites were unique to 
seven patients with poor outcome as compared to eight patients with good 
outcome. When using the ChIP-seq data from that study, ERα was bound a few 
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hundred base pairs away from the rs2981578 locus and only in samples associated 
with poor outcome. The current hypothesis regarding the role of FOXA1 in breast 
cancer is that FOXA1 is capable of mediating a reprogramming of the ERα binding 
site (Ross-Innes et al, 2012). The role of each individual SNP forming the FGFR2 
haplotype, or their collective effect, on the dynamics of FOXA1 binding at the 
FGFR2 locus remains to be elucidated. However, we could not confirm that the 
binding was allele specific for either the risk or non-risk allele as the SNP 
genotyping assay did not work on the MCF7 cell following ChIP (Fig 4.7).   
The Meyer study (2008) hypothesised that increased FGFR2 expression, mediated 
by Runx2 binding at rs2981578 locus, was what underpinned the increased cancer 
risk. Howerver, no differencies in FGFR2 expression were detected between the 
SNP modified cell lines (Fig. 4.4A). Therefore, if FGFR2 is indeed acting as an 
oncogene, one might expect no differences in cell behaviour between the clones. 
This suggests that rs2981578 risk allele alone is not capable of giving any 
advantage in cell growth and mediating the increase in breast cancer risk. A new 
hypothesis must be formulated to include other FGFR2 risk variants (from the 
same haplotype) and what appear to be the key players: FGFR2, ERα and FOXA1.   
To this day, the only other ZFN-based approach used to correct two point 
mutations (with no additional footprint on the DNA), was carried out in patient-
derived induced plutipotent stem cells to correct mutations in a gene associated 
with early onset Parkinson disease (Soldner et al, 2011). These non-synonymous 
mutations were localised to the coding region of α-synuclein (A53T and E46K), and 
the modified cells were shown to have kept their pluripotent characteristics but 
were not used for functional studies. The consequences of these point mutations 
in term of cellular behaviour were therefore unknown. However, it is possible to 
anticipate that disrupting the coding regions of a gene might have serious 
consequences on the mutated proteins themselves and their partners. Altering any 
cis-acting regulatory elements, might also have an impact on the cell behaviour but 
only in a phenotypically very subtle manner. A recent study provides a good 
example of an unexpected negative result using ZFN. The authors used ZFN to 
abrogate MALAT1 expression (a non-coding RNA marker of lung cancer metastasis) 
in human tumour cells and found that this loss neither affected proliferation nor 
130 
    
cell cycle progression in human lung or liver cancer cells; furthermore it had no 
impact on nuclear architecture (Eissmann et al, 2012).  
The attention has now shifted from a single SNP, rs2981578, to a set of risk SNPs 
forming a haplotype to try to identify what is mediating the breast cancer risk in 
the FGFR2 second intron. Another SNP, rs35054928 (-/C), has emerged as new risk 
locus that might become important for elucidating this mechanism. The 
combination of different SNP genotypes was found more significantly associated 
with increased risk of breast cancer, compared to any individual SNP (personal 
communication, Dr Kerstin Meyer, CRUK Cambridge). Recently, a groundbreaking 
study by the Lupien group has shown that risk-associated SNPs of breast cancer 
are enriched for FOXA1 binding sites, which influence the function of this 
transcription factor (Cowper-Sal lari et al, 2012). Given more time, this project 
could now progress toward changing several SNPs at the same time and 
investigating the binding pattern of FOXA1 in these new cell line models. 
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ALTERNATIVE METHODS TO STUDY SNP RS2981578 
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5. Alternative methods to study SNP rs2981578 
5.1. Introduction 
The genomes of related species show a remarkable amount of conservation; 
however, this is not reflected by the great array of phenotypic diversity observed. 
It originally was hypothesised that this diversity was due to variation in gene 
expression rather than structural changes in the genes (King and Wilson, 1975). For 
instance, a study looking at mRNA expression differences in the brain of three 
humans showed that there was a similar level of differences between them as 
there is between humans and chimpanzees (Enard et al, 2002). Understanding the 
link between genotype and phenotype remains a challenge in evolutionary biology 
but also in the study of risk for complex diseases, such as breast cancer. Indeed, 
like mutations that affect the protein sequence, changes in gene expression can 
promote cancer development. For instance, subtle downregulation of the wild-
type tumour suppressor PTEN was enough to trigger cell proliferation and 
increased susceptibility to tumour development in a mouse model (Alimonti et al, 
2010). The detection and recognition of those regulatory sequences that affect 
gene expression levels are the new challenges of molecular biology, as 
demonstrated by the recent ENCODE Consortium effort (Bernstein et al, 2012): 
although the understanding of how non-synonymous mutations in coding regions 
affect tertiary and quaternary protein structures has increased, the effect of 
polymorphisms and indels in non-coding DNA remains unclear. A major reason for 
this is that they can have an impact at different levels (i.e. transcriptional, post-
transcriptional and epigenetic). The analysis of variation in gene expression is 
complicated by the potentially small differences associated with alterations in a 
single allele of a gene. 
5.1.1. Cause of allele specific expression 
The concentration of mRNA is controlled by two kinds of factors, cis and trans-
acting factors, named as such for their localisation in relation to the gene whose 
expression they are regulating. Trans-regulation is mediated via diffusible factors 
such as a protein or ribonucleic acid (i.e. transcription factors, microRNAs) and 
constitutes the major regulatory system (Schadt et al, 2003; Cheung et al, 2010) 
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whereas regulatory elements acting in cis regulate gene expression by directly 
altering the local genomic sequence (i.e. a mutation in the promoter or intronic 
sequence that alters a transcription factor binding site or impacts on methylation 
status) (Wray et al, 2003). Interestingly, cis regulatory elements are generally 
binding sites for factors acting in trans. Trans-regulation has the potential to 
influence the expression of a multitude of genes with a single factor and influences 
both alleles of a gene indiscriminately, whereas cis-acting regulatory variation can 
lead to differential allele specific expression (ASE), in which the expression of one 
allele differs from another in a diploid cell. It was established that 10 to 22% of 
human genes are differentially regulated in such a fashion (Zhang et al, 2009). 
Evidence for the medical importance of cis-acting polymorphisms has been 
provided by the discovery of disease susceptibility loci that are not associated with 
protein coding regions or splice sites (ENCODE, 2012).  
Cis-acting variation may explain 25% to 35% of inter-individual difference in gene 
expression and also influence mRNA processing, stability and isofom splicing 
(Pastinen and Hudson, 2004). Cis-acting elements may be located within enhancer 
and silencer elements that can be several tens or hundreds of kilo base pairs up or 
downstream from the transcribed sequence, or within the transcript itself in 
introns. Allelic imbalance can be caused by non-coding regulatory DNA 
polymorphisms but also by coding polymorphisms, in the case of nonsense-
mediated mRNA decay of transcript harbouring early stop codons (Francastel et al, 
1999). However, modulation of gene expression by epigenetic factors, including 
differential acetylation of histones or DNA methylation, parental imprinting 
(Ferguson-Smith et al, 2003) and random monoallelic expression (Ohlsson et al, 
1998), may all be mistaken with regulatory polymorphisms. 
5.1.2. Methods for measuring ASE 
Allele specific expression of a given gene results in a differential concentration of 
cytoplasmic mRNA, and can be measured in vitro or in vivo. 
In vitro approaches consist of the use of synthetic reporter constructs containing 
different portions of promoters (previously characterised, or known to contain 
candidate regulatory polymorphisms) to monitor the transcriptional activity of 
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several distinct reporter mRNA transcripts. However this strategy is only valid 
when employing a candidate approach and must take into account the fact that 
promoter regions are often poorly characterised and fail to represent the entire 
complexity of a given promoter in a given cell type, often omitting long range 
regulatory sequences. Additionally, these studies do not take into account the 
influence of trans-acting factors in the cell system used for transfection of the 
reporter construct (Volpi et al, 2000).  
In vivo approaches are a direct way of studying the expression of alleles in their 
normal environment, including genomic and chromatin context. During 
transcription, hetero-nuclear RNAs are synthesised from the two copies of the 
DNA template, each bearing the differences caused by any heterozygous intronic 
polymorphisms. This form of pre-mRNA only exists briefly before being fully 
processed into mRNA, in which introns are spliced out, erasing any trace of the 
heterozygous nature of the transcript. The presence of an informative 
polymorphism (or marker SNP) for each individual transcript is therefore required 
in order to trace back its allelic origin. Another problem is caused by the fragile and 
unstable nature of single stranded mRNA, thus measurements are commonly 
performed using amplified cDNA from tissues or cell lines of interest. Differences 
in expression as low as 1.2 fold can be detected between samples (Pastinen and 
Hudson, 2004). The main advantage of in vivo approaches is that they can be 
scaled up to include the whole genome. 
The method of polymerase loading assay (haploCHIP) can be used for studying the 
role of transcription in causing allele specific expression, and is based on isolating 
transcriptionaly active DNA fragments by immunoprecipitating the active RNA 
polymerase II enzyme (Charles Knight, 2005). Another approach combines whole 
genome screening using gene expression microarrays or RNA high throughput 
sequencing with genetic variation markers in order to identify new cis-acting 
polymorphisms that affect phenotypes, such sites of variation are named 
expression quantitative trait loci (eQTL). eQTL mapping studies have been applied 
in several model organisms and humans (Brem et al, 2002; Morley et al, 2004; 
Chesler et al, 2005). 
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The focus of this study was to assess allele specific modulation of FGFR2 
expression and therefore study the cis-acting regulation of FGFR2. Data from the 
Meyer et al (2008) study led these authors to hypothesise that the polymorphism 
rs2981578 creates a de novo cis-acting regulatory element in which binding of 
transcription factors on the risk allele led to increased FGFR2 expression. In this 
chapter, the role of rs2981578 was investigated with an alternative approach to 
the ZFN-modified cell line approach. A quantitative genotyping assay was used to 
measure relative allelic abundance in breast cancer samples heterozygous for the 
rs2981578 SNP. Imbalanced allelic expression was determined by the 
heterozygous allele ratio of mRNA (cDNA) compared to the ratio of genomic DNA 
(1:1). 
5.2.  Results 
5.2.1. Allele specific expression of FGFR2 
Using the relative expression levels of variant SNP alleles within the coding region 
of a gene in the same sample (instead of using total mRNA levels originating from 
the two different copies of a gene) is an effective approach for identifying cis-
acting regulatory SNPs (Milani et al, 2007). Since rs2981578 is intronic, and 
therefore spliced out of mature mRNA, the allelic origin of each mRNA molecule 
was tracked by looking at additional heterozygous SNPs in the coding region, 
named marker SNPs (Fig. 5.1A).   
Potential marker SNPs located in the coding region of FGFR2 were identified using 
the Ensembl Genome Browser website (Ensembl, 2010), by looking at the single 
nucleotide variants observed in the different FGFR2 transcripts. Among 327 total 
variations found in the coding sequence, 148 were synonymous variants and 179 
were non-synonymous. Two of those variants were shortlisted, since they showed 
minor allele frequencies greater than 10%. The essential characteristic of a marker 
SNP is its heterozygosity, thus minor allele frequency is an important factor 
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Figure 5.1: Allele specific binding (ASB) and Allele specific expression (ASE) 
A) This diagram illustrates the concept of allele specific binding (ASB) of cis-regulatory 
elements in the context of a heterozygous functional SNP and consequent allele specific 
expression (ASE). The allelic origin of each mRNA molecule (blue or grey) can be traced by 
the use of additional heterozygous marker SNPs located in the coding region of the gene. 
TF stands for transcription factor. B) Genotypes for rs2981578 and two marker SNPs, 
rs577593 and rs1047100, in a panel of breast cancer cell lines. 
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because the greater the minor allele frequency, the better the chance of 
identifying heterozygous samples within cell lines or patient tissue samples.  
rs1047100 is a synonymous SNP located in exon six of FGFR2 (GTA/GTG). The 
nucleotide variance is at position Chr10:123298158 (GRCh37) and both variants 
encode for valine. The minor allele (A) frequency varies between 8% to 22% in the 
different populations of the 1000 Genomes project (1000Genomes, 2011) (Fig. 
5.3). The second marker was the non-synonymous SNP rs755793 (ATG/ACG) in 
exon five, Chr10:123310871 (GRCh37). The ancestral codon, containing the 
thymine nucleotide, encodes for a methionine, which gets replaced by threonine, 
in the presence of the C allele.  The minor allele (C) frequency varies greatly 
between populations, with a 36% frequency in African populations and an absence 
in European populations (Fig. 5.3). SNP rs1047100 was therefore used 
predominantly in this study to determine the allelic origin of the FGFR2 mRNA 
molecules, because of the more homogeneous allele frequencies across 
populations and the fact that this change does not affect the amino acid sequence 
of the protein synthesised from the mRNA transcript. 
A panel of breast cancer cell lines was screened both for heterozygous functional 
SNP and marker SNP and analysed to detect allelic imbalance in FGFR2 gene 
expression. These cell lines were all derived from patients of white European 
ethnicity, with the exception of MDA-MB-468, derived from a black women (Neve 
et al, 2006). The results showed that none of the 13 cell lines screened were 
suitable for the study as none were heterozygous for both functional and marker 
SNPs (Fig. 5.1B). The allele frequencies of rs2981578 and rs577593 observed in the 
cell lines were in accordance with the European population frequencies, where C: 
53% and T: 47% for rs2981578 and G: 0% and A: 99.9% for rs577593 respectively. 
Concerning rs1047100, however, less than expected T alleles were found. The 
observed frequency was 3.8%, statistically significantly different from the 
population frequency of 22% (Binomial distribution, two tailed p=0.029), which 
indicate that obtaining such results from a panel of breast cell lines was highly 
unlikely (with a probability of 1.3%). The only cell line that showed heterozygosity 
for rs2981578 was SKBR3, an ERα negative cell line (Neve et al, 2006). 
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Data source 
Cell line: TT CCLE Neve et al, 2006 
MDA-MB-468 6.354 6.4021 
MCF7 6.574 5.942 
T47D 8.4 5.5236 
H3396 N/A N/A 
  
  Cell line: TC 
  SKBR3 7.2668 5.6499 
PMC42 N/A N/A 
  
  Cell line: CC 
  MDA-MB-453 5.100887 5.5976 
BT20 6.0416 6.3042 
MCF10A N/A 8.2614 
ZR-75-1 5.458313 6.0432 
HCC70 4.393347 6.6932 
 
Figure 5.2: FGFR2 expression levels in breast cancer cell lines according to their 
respective rs2981578 genotype (cell line based eQTL) 
The rs2981578 SNP was genotyped in 11 breast cancer cell lines (green are ER positive and 
red are ER negative). The expression data (log2 gene expression) were taken from 
Affymetrix expression microarray data publicly available using probe 2263_at (CCLE, 2012; 
Neve et al, 2006). SNP genotype data were then correlated with the expression level of 
FGFR2. A one-way ANOVA statistical test was carried out.   
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Additionaly, publicly available copy number variation (CNV) data were used to 
assess the level of FGFR2 expression in different breast cancer cell lines, according 
to their rs2981578 genotype (Fig. 5.2). The result suggested that FGFR2 expression 
was similar in all the cell lines for which CNV data was available. It is important to 
note that only 5 of the 11 cell lines were ERα positive (highlighted in green) and 
this approach could be informative if more ERα positive cell lines were included, as 
the rs2981578 locus appears to have no impact in an ERα negative setting.   
Given the established limitation of using cell lines (too few in numbers and not 
carrying the adequate genotypes) (Fig. 5.1 and 5.2), tissue from patients with ERα 
positive breast cancer was interrogated. Breast tissue samples were obtained from 
the Breast Tissue Bank at Barts in collaboration with Prof Louise Jones (ethics 
approved ref no. 05/Q0403/199) and selected purely on the basis of ERα positivity, 
regardless of treatment and ethnicity (Table 6.1). Total DNA and RNA from 72 ERα 
positive breast tumours and their surrounding tissues were used and each sample 
was genotyped for rs2981578 and the two marker SNPs (Table 5.1). The allele 
frequencies of rs2981578 and rs1047100 in the patients’ samples were 
representative of the overall population data from the 1000 Genomes project (Fig. 
5.3). Allele G of rs755793 was represented at a frequency higher than predicted 
from population data, indicating a potential bias towards an increased number of 
patients with African descent in the sample set. However, only 8.3% of the 
patients were of a Black background compared to 68% of a White background 
(Table 6.1). Additionally, patients qualified as Asian in the sample set (composed of 
Indians, Bangladeshi and Pakistani patients) represented 10% of the samples and 
are not representative of the East Asian population (ASN) of the Hap Map or the 
1000 genomes data bases, composed mostly of Chinese, Japanese and Vietnamese 
individuals. Little information is available as yet on SNP allele frequencies in Indian, 
Bangladeshi and Pakistani populations (SAN, south Asian super population code).  
Five samples (15, 36, 39, 59 and 62 in red), which were heterozygous for both 
functional and marker SNPs, were selected for ASE analysis, and 10 (green) were 
used as controls (homozygous for rs2981578 and heterozygous for rs1047100) 
(Table 5.1). 
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 Genotype 
  
Genotype 
Sample rs2981578 rs1047100 rs755793 
 
Sample rs2981578 rs1047100 rs755793 
1 GG CC AG 
 
37 GG CC AG 
2 AA CC AG 
 
38 AA CT AG 
3 GG CC AG 
 
39 AG CT AA 
4 GG ? AG 
 
40 GG CC AG 
5 AG CC AA 
 
41 AA CC AG 
6 GG CT AG 
 
42 AG CC AA 
7 GG CC AG 
 
43 AA CC AG 
8 GG CC AG 
 
44 GG CT AG 
9 AA CC AG 
 
45 AA CC AG 
10 AA CC AG 
 
46 ? CC AG 
11 GG CC AG 
 
47 ? CC AG 
12 GG CT AG 
 
48 AA CC AG 
13 AA TT AG 
 
49 AA CC AA 
14 GG CC AG 
 
50 GG CC AG 
15 AG CT AA 
 
51 AG CC AA 
16 ? CC AG 
 
52 GG CC AA 
17 GG CC AG 
 
53 AA CT AA 
18 AG CC AA 
 
54 AG CC AA 
19 GG CC AG 
 
55 AG CC AA 
20 GG ? AG 
 
56 AG CC AA 
21 GG CC AG 
 
57 AG CC AA 
22 AA CC AG 
 
58 AA CC AA 
23 GG CC AG 
 
59 AG CT AA 
24 AG CC AA 
 
60 GG CC AG 
25 AG TT AA 
 
61 GG CT AA 
26 GG CT AG 
 
62 AG CT AA 
27 GG CT AG 
 
63 GG CC AA 
28 AA CT AG 
 
64 GG CC GG 
29 GG CT AG 
 
65 GG CT GG 
30 AG CC AG 
 
66 AG CC AA 
31 AA CC AG 
 
67 AA TT AA 
32 AG CC AG 
 
68 GG CC AA 
33 AG CC AA 
 
69 AG CC AA 
34 GG CC AG 
 
70 AA CT AA 
35 AG CC AA 
 
71 GG CC AG 
36 AG CT AA 
 
72 AG CC AA 
 
Table 5.1: Genotypes of a panel of breast cancer tissues  
A panel of ER positive breast cancer tissues was genotyped, for both marker SNPs and 
rs2981578. Orange shaded positions indicate heterozygous samples. Grey shaded 
positions indicate ambiguous results, where the SNP status could not be determined. In 
red are the samples used for analysis and in green the ones used as controls.  
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rs2981578   
 
rs1047100   
 
rs755793   
A (T) 0.382 
 
T 0.163 
 
A 0.687 
G (C) 0.612 
 
C 0.812 
 
G 0.319 
 
 
rs2981578 (1000 Genomes) 
 
 
rs1047100 (1000 Genomes) 
 
 
rs755793 (1000 Genomes) 
 
 
Figure 5.3: Allelic frequency in Barts Breast Tissue Bank samples 
Allele frequencies measured in 72 ER positive breast cancer samples, compared to 1000 
Genome data set. The three letters codes are Super population codes that regroup data 
from several populations: AFR: African, AMR: Ad Mixed American, ASN: East Asian, EUR: 
European. When the code ALL is used this means that all individuals from that the data set 
are being considered. 
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Figure 5.4: FGFR2 allelic imbalance in breast cancer samples 
Absolute differences between cDNA and gDNA Ct values as measured by SNP genotyping 
Taqman assay for SNP rs1047100. Samples were assayed in triplicate. Mann Whitney test 
was performed using Prism software, error bars represent SEM. Five test samples were 
analysed and compared to three homozygous controls with the major allele (A;A) and 
seven homozygous controls with the minor, or risk allele (G;G).  
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Real time PCR using allele specific Taqman probes was performed for each sample, 
using genomic (gDNA) and complementary DNA (cDNA) templates. Imbalanced 
allelic expression is detected when the heterozygous allele ratio in mRNA (cDNA) 
differs from the corresponding 1:1 ratio in genomic DNA. Cycle threshold (Ct) 
values obtained for both alleles of rs1047100 in cDNA were normalised to Ct 
values obtained from gDNA to correct for errors coming from potential copy 
number variations. The absolute differences between Ct values from cDNA and 
gDNA, were calculated (Fig. 5.4) (Appendix 9). Mann Whitney test (p=0.1645) 
indicated that the results did not show any significant difference in absolute levels 
of expression (i.e. allelic imbalance) in the heterozygous samples compared to 
controls (A;A and G;G genotypes). Surprisingly, the controls homozygous for the 
non-disease associated allele of rs2981578 were the ones that displayed the 
greater difference between expression of each allele. 
5.2.3. Selection pressure: polyclonal population expansion 
FGFR2 has been reported to act as an oncogene in breast cancer and increased 
FGF signalling might promote cancer initiation or progression by protecting the 
cells from apoptosis (Hishikawa et al, 2004) and stimulating growth and 
proliferation (Turner et al, 2010).  
In order to test this hypothetical advantage, three heterogeneous populations 
(ZFN1, ZFN2, ZFN3) composed of a mixture of wild-type MCF7 (A;A) and ZFN-
modified cells (A;G or G;G) were cultured over a period of 20 passages. The 
relative amount of each rs2981578 allele was measured over time using allele 
specific Taqman probes to monitor any changes in the proportion of the two 
different genotypes. 
The Ct values revealed, as expected after ZFN genome editing, a predominant 
proportion of wild-type cells (with Ct values around 30 cycles), with a slight 
increase (2 cycles difference) in G alleles post ZFN transfection, that persisted for 3 
passages (Fig. 5.5). However, the Ct values returned to the level of the control, 
untransfected cells rapidly and no additional changes in Ct values were observed. 
The apparent increase in G allele frequency at passage 17 was an artefact caused
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Figure 5.5: Ct values of each allele of rs2981578 (A or G) over 20 passages of ZFN-edited 
MCF7 cells 
Three independent cultures (ZFN1, ZFN2 and ZFN3) of MCF7 cells were transfected with 
ZFN mRNA and MCF7 repair template (containing the risk allele) and kept in culture over a 
period of 20 passages. Genomic DNA was extracted every three passages and used for SNP 
genotyping Taqman assay, to monitor the levels of each allele of rs2981572. Results are 
represented as Ct values for each allele over time. Untransfected MCF7 cells were used as 
control.   
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by the poor quality of the genomic DNA samples, as this drop in Ct values was 
observed for both G and A alleles. The conclusion from this experiment indicates 
that the presence of the G allele in the FGFR2 haplotype does not give a 
measurable growth advantage to the modified MCF7 cells in 2D culture.  
5.3. Discussion 
Two independent GWAS studies have identified FGFR2 as a risk factor for breast 
cancer (Easton et al, 2007; Hunter et al, 2007). It was established that the disease 
associated alleles were inherited as a haplotype of eight SNPs in European 
populations, in which rs2981578 might constitute the causal variant (Meyer et al, 
2008).  In this chapter, the effect of the risk allele of rs2981578 on FGFR2 
expression was investigated. Measuring the relative expression of mRNA 
molecules originating from different copies of the same gene is a useful method to 
determine allelic imbalance caused by a cis-acting heterozygous polymorphism 
(Milani et al, 2007). The hypothesis under test was that the single nucleotide 
polymorphism, rs2981578, considered to be functional by allowing the de novo 
binding of transcription factors on the DNA molecule carrying the disease 
associated allele of the SNP, would regulate FGFR2 expression.  
Panels of ERα positive breast cancer samples and cell lines were genotyped to 
identify heterozygous SNPs (rs2981578, rs1047100 and rs755793). None of the 
breast cancer cell lines harboured the correct combination of heterozygous SNPs 
and were thus excluded from the study (Fig. 5.1B). Overall the allele frequencies 
measured in the breast cancer samples (Fig. 5.3) were very similar to those of the 
AMR (Ad mixed American), ASN (East Asian) or EUR (European) populations of the 
1000 Genomes project, except for SNP rs755793, in which the G allele was 
represented at a high level in the samples (0.319) but was completely absent in the 
EUR populations. The limited information available on SNP allele frequencies of 
south Asian population (Indians, Bangladeshi and Pakistani individuals), 
constituting 10% of the data set in this study, might partly explain the discrepancy 
in the data. In the future, rs755793 might become useful as a marker SNP in similar 
studies of allelic imbalance in individuals of African descent, as its minor allele 
frequency reaches 36% in African population data. African descent population 
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(American or British alike) are a very singular group to study in relation to breast 
cancer risk as it was established that breast cancer presents itself at a younger age 
with distinct disease characteristics in this population (Bowen et al, 2008). 
The allelic imbalance data showed that no significant difference in allelic 
expression levels could be observed in patient samples. This indicates that 
variation in allelic expression, if present,  may manifest itself in a cell type or state 
specific manner, or that environmental conditions and/or physiological feedback 
mechanisms may mask the impact of subtle cis-acting variants on expression 
levels. An important consideration is the makeup of the tissue samples used for 
RNA and DNA extraction. The genetic material used for this experiment was 
actually a mixture of epithelial cancer cells, surrounded by stroma and blood 
vessels. One can therefore hypothesise that if the allele specific binding affects 
transcript production and consequent expression is cell type specific, any small 
effect would be diluted down by the presence of other cell types. Indeed, a study 
by Huijts and colleagues (2011) showed that FGFR2 mRNA levels were only 
increased in primary fibroblasts, but not primary epithelial cells from 98 breast 
cancer patients with rs2981578 risk allele (Huijts et al, 2011). Although the primary 
fibroblasts used were isolated from the skin of the patients and not the breast or 
tumour site, this indicates that the risk is mediated through a stroma-specific 
phenotype. Interestingly, it was demonstrated by Yan and colleagues (2002) that a 
smaller than anticipated number of normal individuals display ASE. They examined 
a normal population of 96 individuals, and interrogated heterozygous SNPs in 13 
genes (Yan et al, 2002). Among all the heterozygous individual tested (from 17 to 
37 depending on the genes), only a small minority showed ASE (3% to 30%). They 
also observed, by studying their pedigree, that altered allelic expression was an 
heritable trait.  Additional patient samples that carry heterozygous functional and 
marker SNPs are therefore required to increase the power of this experiment as 
well as laser micro-dissection of tumour samples to obtain nucleic acids originating 
exclusively from a single cell population. 
Observing an increase in the level of expression of an oncogene, here FGFR2, has 
little importance in terms of elucidating its impact on cancer incidence or 
progression without a concomitant phenotypic advantage for the cancer cells that 
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show such an increase. This advantage could be an increase in cell proliferation, as 
FGFR2 pathway stimulation is known to increase cell proliferation and migration in 
cancer cells by signalling via the MAPK signalling pathway (Ropiquet et al, 1999). 
However, no increase in the number of the cells carrying the risk allele of FGFR2 
SNP was observed in a population of cells composed of non-risk allele and risk 
allele genotypes, indicating that the risk is not mediated through an advantage in 
cellular proliferation, at least not in the context of cancer cells growing in 2D 
cultures without any other cell type present. Future refinements to this line of 
investigation could be to test behaviour in more physio-mimetic 3D culture models 
(Chioni and Grose, 2009) or testing response to cellular stress or insult, for 
example following serum starvation or chemotherapeutic challenge.  
Identifying a true regulatory variant is complicated when a SNP shows very high 
linkage disequilibrium (LD) with other variants in close proximity. It is also possible 
that changes in chromatin structure, by epigenetic mechanisms, might also be an 
important factor to consider (Tirosh et al, 2008). It was shown by Zhu and 
colleagues that breast cell lines, harbouring the disease associated allele displayed 
histone acetylation at three SNP loci including rs2981578, hypothesising that this 
chromatin modification would modulate access to transcription factor binding 
sites and splicing sites (Zhu et al, 2009). 
In conclusion, the phenotypic effect of rs2981578 remains unclear and might 
involve a cell type specific FGFR2 regulation that could not be measured in tissue 
samples with mixed cell populations.  
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GENERAL DISCUSSION 
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6. General discussion 
6.1. Introduction 
The development of breast cancers that are not the result of mutations in high 
penetrance susceptibility genes like BRCA1 and BRCA2, are caused by a multitude 
of genetic factors, each conferring a small increase in the overall risk. This was 
demonstrated by multiple genome wide association studies and the FGFR2 second 
intron was one of the most significant loci identified in ER positive breast cancers 
(Easton et al, 2007; Hunter et al, 2007). This locus was characterised by a 
haplotype composed of several SNPs in linkage disequilibrium within the large 
second intron of the gene. An early functional study hypothesised that rs2981578 
was the functional SNP and that the risk was mediated via allele specific 
expression of FGFR2, as the result of differential binding of a trans-acting enhancer 
(Meyer et al, 2008). This enhancer was identified as the Runx2/Oct1 complex that 
has previously been shown to act in a similar fashion in β-casein, a mammary gland 
specific gene. The overall aim of this work was to create a set of isogenic breast 
epithelial cell lines to study the role played by rs2981578 in mediating breast 
cancer risk. To this end, ZFN technology was used as a means of editing rs2981578 
in breast cancer cells. The second objective was to characterise the cell lines 
created and study the impact of rs2981578 in vitro in 2D cell culture models, thus 
deciphering the role played by trans-acting factors in mediating the breast cancer 
risk. Finally an alternative approach to study this mechanism was adopted, by 
using breast tissues from cancer patients with ER positive breast malignancy to 
study the allele specific expression of FGFR2 in vivo.  
6.2. Creation of ZFN-edited breast cancer cell lines 
Conventional methods for the study of gene function can be challenging and often 
use indirect approaches; for instance overexpressing the gene in a mammalian 
expression vector or knocking it down transiently using siRNA (Ahmed et al, 2010). 
For the study of cis-regulatory sequences, similar indirect methods are commonly 
used, such as reporter assays. ZFN-mediated genome editing presents several 
advantages over these conventional methods for generating modifications at the 
endogenous genomic DNA sequence, but can prove challenging.  
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The selection of a suitable candidate cell line for ZFN-mediated genome editing 
was a crucial step with potential repercussions during the entire editing process. 
The biological variability associated with the use of different human cancer cell 
lines might in part explain the differences in transfection efficiency, targeted DNA 
repair and also response to single cell cloning, all encountered in the genome 
editing process.  
Additionally, the choice of potential ZFN binding sites was restricted to the 
immediate vicinity of the target SNP, which meant that the optimal ZFN pair was 
less efficient than they could have been, had the whole FGFR2 locus been available 
for targeting. This resulted in a low efficiency of genome editing in the breast 
cancer cell lines tested. The initial optimisation process was therefore one of the 
most crucial steps in obtaining the model cell lines, and this, inevitably, took a 
considerable period of time. Several methods for transfection were tested, with 
Amaxa nucleofection being found to be the most suitable technique in MCF7 cells, 
further optimised by the introduction of a GFP control plasmid, co-transfected 
with the ZFNs and used for FACS enrichment of the GFP positive cells (Soldner et 
al, 2011). However, the ‘cold shock’ technique, that reportedly increased ZFNs 
cutting efficiency (Doyon et al, 2010), was not successful with FGFR2 ZFNs. The 
problem of relative low efficiency of gene editing is common to many other studies 
and a lot of efforts are now being put into improving  ZFN technology, as 
exemplified by recent reports suggesting the use of the proteasome inhibitor 
MG132 during the editing process as a way to increase the half-life of ZFN proteins 
(Ramakrishna et al, 2013), or the use of surrogate reporters that express GFP only 
when the reporter has been cleaved by the ZFN and a consequent frame shift 
mutation has occurred (Kim et al, 2011).  
The choice of candidate cell lines was important not only for genome editing 
purposes, but also to provide the adequate phenotypic context in which to study 
the FGFR2 SNP. As mentioned previously, ERα positivity was the single most 
important factor associated with the breast cancer risk mediated by FGFR2 SNP, 
making the use of an ER positive cell line essential. Additionally, the increase in risk 
conferred by the FGFR2 SNP was relatively small (1.63 for homozygous risk allele 
carriers) and was hypothesised to be easily masked by other major genetic 
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alterations commonly found in classic breast cancer cell lines. The immortalised 
but otherwise normal MCF10A cells (Soule et al, 1990) appeared to be the ideal 
cell line, but unfortunately lacked ERα expression. However, a study by Zhao and 
colleagues suggested that the MCF10A cell line had the potential to express ERα 
protein in an inducible fashion (Zhao et al, 2008). The results obtained in the Zhao 
study are in contradiction to the results presented in Chapter 3. It was 
demonstrated that the lack of ERα expression in the MCF10A cell line was not due 
to the presence of miR221 and miR222, as this cell line (and other derived cell 
lines) lacked ERα mRNA. MCF7 cells, which express high levels of ERα, were 
therefore selected as an alternative cell line for use in the study.  
Three clones carrying one copy of the rs2981578 risk allele were obtained (none 
had a biallelic change after the first round of ZFN editing) and three other non-
modified clones were selected as controls. A final attempt to edit the two copies of 
FGFR2, to obtain the final set of cell lines, using a different repair template 
(ssODN), failed. The potential off-target effect of the FGFR2 ZFN was evaluated and 
considered non significant as sequencing of seven potential off-target binding sites 
failed to show deletions due to NHEJ. 
 Cell-based assays showed that there was no change in cell cycle progression, nor 
any apparent advantage in cell growth or migration/invasion in cells carrying the 
risk allele of rs2981578 (heterozygous versus non-modified controls). Crucially, it 
was established that Runx2 was not the key transcription factor that mediated the 
rs2981578 risk, but instead, it was the pioneer factor FOXA1 that appeared more 
important in these studies. The FOXA1 chromatin immunoprecipitation 
experiment showed that there was a reduced binding of FOXA1 to the SNP locus in 
two out of three of the heterozygous clones, whereas a very strong binding was 
observed in two out of three control cell lines. It has now been established that 
FOXA1 is crucial in mediating the binding of ERα to its target genes, and whole 
genome ChIP-seq screening has demonstrated that FOXA1 plays a role in the 
reprogramming of ERα binding sites during breast cancer progression (Ross-Innes 
et al, 2012) (Cowper-Sal lari et al, 2012).  The role of each individual SNP forming 
the FGFR2 haplotype, or their collaborative effect, remains to be elucidated.  
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Finally, the assay that could have shed more light on the potential differential 
allelic binding of FOXA1 was the rs2981578 Taqman assay. The identification of 
which rs2981578 allele in an heterozygous sample that was pulled down 
predominantly after chromatin immunoprecipitation would have been very 
informative, but failed due to technical problems with the assay (discussed in 
Chapter 4). 
6.1. Study of allele specific expression in a cohort of patient tumour samples 
The cohort of patient samples collected at Barts Hospital, and examined in Chapter 
5, did not show any allelic imbalance in FGFR2 expression. However, as pointed 
out in the chapter, the heterogeneous nature of the tumour samples used might 
explain the lack of allelic imbalance if that phenomenon is cell type specific. The 
examination of the patient genotype, and the fact that ASE is not present in every 
heterozygous individual, emphasised the importance of increasing the cohort of 
patients studied (Yan et al, 2002). Additionally, the composition of our patient 
cohort has revealed  that genetic data on population originating from central and 
western Asia, such as India, Bangladesh and Pakistan, are currently missing from 
the main publicly available data bases such as the 1000 Genomes project, and that 
little information is available in term of SNP allele frequencies for these 
populations (Table 6.1).  
6.2. Future work 
6.2.1. FGFR2 haplotype study 
It has now become apparent that the breast cancer risk, in the context of FGFR2 
mediated risk, is attributable to a group of SNPs, called risk haplotype, rather than 
a single one (personal communication, Dr Kerstin Meyer, CRUK-CRI). Indeed, an 
unpublished genetic study conducted in Prof Bruce Ponder’s lab has validated the 
importance of rs2981578 but only in association with other SNPs alleles. Further 
work on this risk haplotype could be made by the further modification of other 
SNPs such as rs35054928, 123 bp away from rs2981578. This SNP is in fact an 
insertion of a C risk allele (-/C), in which C is present 83% of the time in populations 
of European descent. 
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% 
Black 
Black British 3 
0.083333 Caribbean 1 
Other Black 2 
    
Asian 
Pakistani 2 
0.097222 
Bangladeshi 2 
Indian 2 
Other Asian 1 
    
White 
Eng/Scot/Welsh 39 
0.680556 
Irish 2 
Greek 3 
Other White 5 
    
 
unknown 10 0.138889 
    
 
total 72 1 
    Table 6.1: Ethnicity of breast cancer samples  
Proportion of each ethnicity within the 72 breast cancer samples obtained from the Breast 
Tissue Bank. 
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The risk allele is, however, not carried by the MCF7 cell line (Appendix 14). ZFNs 
could again be used in our modified MCF7 clones, along with ssODN repair 
templates to create an array of model cell lines with all the possible SNP 
combinations from that risk haplotype. The mechanism underlying the risk might 
be more complex than anticipated, and affect other genetic loci. For instance, a 
new study showed that SNPs at 16q12 (near the TOX3 gene), associated with 
breast cancer risk, were located in enhancer regions and altered the binding 
affinity for FOXA1. This FOXA1 binding site on the chromatin was able to form a 
binding loop to reach the distant TOX3 promoter, indicating that the role of trans-
acting factors and the disruption of their binding site had an effect at very long 
range (Cowper-Sal lari et al, 2012).  
Additional information also is required to characterise further the ZFN-modified 
clones, which may explain the divergent phenotypic appearances observed and 
identify additional mutations that might have occurred and that are not related to 
potential ZFN off-target effects. To this end, spectral karyotyping and SNP array (to 
assess copy number variation) should be conducted in each clone.  
Isolating a true regulatory variant is complicated by linkage disequilibrium (LD) 
phenomena in the human genome. This is exemplified by studies of lactose 
intolerance, a common monogenic trait caused by cis-acting regulatory variants. 
Genetic studies in the Finnish population have shown a perfect correlation 
between the persistence of Lactase expression and the T allele of C/T-13910 
variant (Enattah et al, 2002), further supported by in vitro studies showing 
functional differences between the alleles (Olds and Sibley, 2003). However, 
subsequent studies identified individuals who were heterozygous for the 
persistent allele but showed equal expression of Lactase alleles (Poulter et al, 
2003), suggesting that this variant was actually in LD with the true causative 
regulatory variant. 
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6.2.2. FGFR2 expression and ASE 
Additional results from the patient samples study did not establish clearly if the 
risk associated with rs2981578 is mediated via epithelial or mesenchymal cell 
types, with respect to which cell type was responsible for initiating or driving of 
tumour development. It would therefore be very interesting to look at the impact 
of rs2981578 in the tumour microenvironment, in particular in fibroblasts and 
myoepithelial cells (that support the epithelial cells in the breast lobules and 
ducts). The ZFN-genome editing process could be applied to mammary gland 
fibroblasts in order to create similar cell lines to those obtained for epithelial cells. 
The use of an organotypic model to study invasion could be extended to a 3D 
model of co-cultures of different cell types (epithelial and mesenchymal), as 
developed by Prof Louise Jones group in the Centre for Tumour Biology, at Barts 
Cancer Institute (Holliday et al, 2009). Ultimately, these cell lines could also be 
injected into immune-deficient mice to test the tumourigenicity of the cell models 
in an in vivo environment in the presence or absence of oestrogens. In parallel to 
the initial in vitro and animal studies, the levels of FGFR2 expression could be 
quantified by immunohistochemistry in an extended cohort of breast cancer 
patients.  
6.2.3. GFP-tagged FGFR2 construct 
The FGFR2 ZFNs are very specific genomic scissors and their function cannot be 
extended to target any other areas of the genome. They can, however, be 
employed to introduce a transgene at the endogenous FGFR2 locus. The ZFN 
cutting site, in the second intron, after the ATG start codon that initiates FGFR2 
translation, would conveniently introduce that transgene under the control of the 
endogenous FGFR2 promoter. This would constitute an obvious advantage 
compared to other strategies, since the trans and cis acting factors controlling 
FGFR2 expression, for the most part, would still be present. A construct was 
created for such a purpose, containing the FGFR2-b isoform cDNA tagged with 
green fluorescent protein, the splicing acceptor sequence upstream of exon 3 of 
FGFR2 (sA)  and a neomycin resistance cassette (Appendix 10 and 11). 
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Figure 6.1: Endogenous expression of the FGFR2 tagged construct in T47D cells 
T47D cells observed under transmission and UV light microscopy 19 days post transfection 
with ZFN mRNA and FGFR2-GFP-Neo construct (scale bar = 50 microns. The cells were 
cultured in medium containing 600 µg/ml of Geneticin (G418) from day 11 post-
transfection (as estimated by a Kill curve experiment, bottom plate). G418 concentration 
required for Neomycin resistant cell selection. T47D cells were exposed to different 
concentrations of G418 (200 µg/ml to 1 mg/ml) over a period of one week. The surviving 
cells were stained with Coomassie blue to visualise the effect of the drug on this particular 
cell line. 600 µg/ml was the chosen concentration for antibiotic selection in the T47D cells. 
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A polyadenylation signal was also introduced after the GFP sequence in order to 
short-cut the expression of the endogenous FGFR2, and substitute the tagged 
protein instead (Appendix 10 and 11) (Gutschner et al, 2011).  
Preliminary results showed that the FGFR2b-GFP/neo construct was successfully 
introduced and expressed in T47D cells treated with G418 drug (Fig. 6.1). T47D 
cells were chosen for this application, being  one of the breast cancer cell lines 
expressing high levels of FGFR2 (as determined by publicly available expression 
microarray data (CCLE, 2012)).  GFP expression was observed two weeks after ZFN 
mediated genome editing, however, the cell culture presented bacterial 
contamination before clones could be isolated. Although not included in the 
Results chapters, this was nevertheless a proof of concept that the tagged FGFR2 
construct was successfully expressed by these cells. It remains to be demonstrated 
that the construct successfully integrated at the FGFR2 endogenous locus. The 
applications for this construct are long ranging: from study of the cellular 
localisation of the receptor to the co-culture of cancer cells stably expressing 
either a green IIIb receptor isoform with other cells expressing a red (RFP) IIIc 
isoform. Another possibility is the modification of the wild-type receptor using Site 
Directed Mutagenesis to study the importance of known oncogenic or inherited 
mutations of the protein signalling cascade or cellular localisation under different 
conditions. For instance, S252W is an activating mutation, located in the acid box 
of the receptor, which is often present in FGFR2-dependent skeletal disorders and 
also is seen in breast and uterine cancer (Pollock et al, 2007). Because the ZFN 
editing method usually targets one allele of a gene at a time, we could also insert 
two different tagged constructs of FGFR2 isoforms (b and c) in the same individual 
diploid cell, at each endogenous locus, and observe their behaviour in situ using 
fluorescence microscopy.  It may of course be possible that the tagged GFP alters 
the function and cellular localisation of FGFR2, by modifying its size or preventing 
adaptor proteins to bind to its intracellular tail. The bi-cistronic expression of 
FGFR2 and GFP could therefore be obtained by including an internal ribosome 
entry site (IRES) between the two cDNA sequences (Gurtu et al, 1996).  
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6.3. Conclusion 
To conclude, ZFN-mediated genome editing showed the promising perspective of 
studying the role of risk SNP alleles in cancer cell lines. The collective data from 
this study showed that rs2981578 was not alone in mediating the breast cancer 
risk and that a combination of other SNP alleles might be required to confer a pre-
carcinogenic state to the mammary gland cells via a mechanism involving FGFR2, 
ERα and the pioneer factor FOXA1.   
159 
    
 
 
 
 
 
 
 
 
CHAPTER 7 
 
APPENDICES   
160 
    
7. Appendices 
Appendix 1: STR profiling of MCF7 cells and spectral karyotyping 
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Appendix 2: STR profiling of MCF10A cells and spectral karyotyping 
  
162 
    
Appendix 3: ZFN primers and target site location relative to rs2981578  
ZFN primers binding sites are underlined with a thick black line. The ZFN binding (upper 
case) and cutting (lower case) site is in the grey box. The SNP rs2981578 is circled in black.  
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Appendix 4: Map of the ZFN plasmid CompoZr (Sigma) and quality of synthesized ZFN 
mRNA 
A) The constructs, PZFN1 and PZFN2, containing both CMV and T7 promoters for use 
directly in eukaryotic cells and in an in vitro transcription reaction, respectively. All ZFNs 
are triple FLAG-peptide tagged (AspTyrLysAspAspAspAspLys) at the N-terminus, for 
protein detection by western blot. The restriction enzyme Xba I cuts just after the stop 
codon and was be used to linearise the template for mRNA production. The construct 
confers Kanamycin resistance to bacteria. B) NanoChIP RNA quality assay showing three 
different batch of synthesized ZFN mRNA.  
 
 
 
 
A 
B 
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Appendix 5: Centificate of Analysis CompoZr custom ZFN 
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Appendix 6: ChIP-seq data for ERα and FOXA1 in breast cancer patients and breast 
cancer cell lines, at the FGFR2 locus 
Data from (Ross-Innes et al, 2012) visualised using IGV2.2 software (Broad-Novartis 
Institute). FOXA1 and ERα ChIP seq data were available on the Carroll lab website 
(http://www.carroll-lab.org.uk/data). SNP rs2981578 is located on chr10:123330300 in the 
NCBI36/hg18 build of the human genome assembly. 
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Appendix 7: FGFR2 ZFN off-target binding sites and their genomic context 
Red dot represents the ZFN off-target binding site 
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Appendix 8: Sequencing results of FGFR2 ZFN off-target loci  
http://genome.ucsc.edu/cgi-bin/hgBlat 
Matching bases in cDNA and genomic sequences are colored blue and capitalized. Light 
blue bases mark the boundaries of gaps in either sequence (often splice sites). 
 
 
Intergenic 1 (PRKCε promoter) 
 
E4 (Ctr 1) 
  
ccttgggcca agctcaagca agtagcattc ctggaatctg ttgtttatta  46429669 
gcagggatga gaggacagga caccacttgc tggttaaacc atctctagac  46429719 
CTTATCTCTG cCCAGCACCT TTAAaCACAA ACTTTGCCCT GGGGCTGCAG  46429769 
CCCTCTGAAG CCACCGGAGC TAAATGAGGT GCATTTGGGT TTTGAGCCTG  46429819 
TTGATTCACA CTTATCTCCA GAGAGTTCTC CTTCCTCCCC TAAAGCTCCC  46429869 
TCTAGAAACT TCCCTCAGGA CCCAAGAGGG AACCTCTGCC AAACCAGCTC  46429919 
AACCTCCACC ATCTAATTCC ACTGGTATGG ATAAAGCTCA CATCATCCCA  46429969 
GGCCTCAAAA CTCACAAGAC AAGGAGTTCA GATGGTAGTT TAAAATGTTT  46430019 
CCCTTCTCCT AGCCCTGCCC AAGAGACTAA Ttccctgtta cttcagcctt  46430069 
caccagaagc ccagagtcct ccagggtctt actgctctga tccatccagg  46430119 
cctagtttta tctaaccccc tacctattcc c 
 
F4 (Ctr 2) 
gattgttcct tgggccaagc tcaagcaagt agcattcctg gaatctgttg  46429662 
tttattagca gggatgagag gacaggacac cacttgctgg ttaaaccatc  46429712 
TCTAgACCTT ATCTCTGCCC AGCACCTTta AACACAAACT TTGCCctGGG  46429762 
GCTGCAgCCC TCTGAAGCCA CCGGAGCTAA aTGAgGTGCA TTTGGGTTTT  46429812 
GAGCCTGTTG ATTCACACTT ATCTCCaGAG AGTTCTCCTT CCTCCCCTAA  46429862 
AGCTCCCTCT AGAAACTTCC CTCAGgACCC AagagGGAAC CTCTGCCAAA  46429912 
CCAGCTCAAC CTCCACCATC TAATTCCACT GGTATGGATA AAGCTCACAT  46429962 
CATCCCAGGC CTCAAAACTC ACAAgaCAAG GAGTTCAGAT GGtagTTTAA  46430012 
AATGTTTCCC TTCTCCTAGC CCTGCCCAaG AGACTAATtc cctgttactt  46430062 
cagccttcac cagaagccca gagtcctcca gggtcttact gctctgatcc  46430112 
atccaggcct agttttatct aaccccctac ctattccc 
 
E11 (Ctr 3) 
ccttgggcca agctcaagca agtagcattc ctggaatctg ttgtttatta  46429669 
gcagggatga gaggacagga caccacttgc tggttaaacc atctctagac  46429719 
CTTATCTCTG cCCAGCACCT TTAAaCACAA ACTTTGCCCT GGGGCTGCAg  46429769 
CCCTCTGAAG CCACCGGAGC TAAATGAGGT GCATTTGGGT TTTGAGCCTG  46429819 
TTGATTCACA CTTATCTCCa GAGAGTTCTC CTTCCTCCCC TAAAGCTCCC  46429869 
TCTAGAAACT TCCCTCAGgA CCCAAgagGG AACCTCTGCC AAACCAGCTC  46429919 
AACCTCCACC ATCTAATTCC ACTGGTATGG ATAAAGCTCA CATCATCCCA  46429969 
GGCCTCAAAA CTCACAaGAC AAGGAGTTCA GATGGtAGTT TAAAATGTTT  46430019 
CCCTTCTCCT AGCCCTGCCC AAGAGACTAA Ttccctgtta cttcagcctt  46430069 
caccagaagc ccagagtcct ccagggtctt actgctctga tccatccagg  46430119 
cctagtttta tctaaccccc tacctattcc c 
 
A8 (Het 1) 
ccttgggcca agctcaagca agtagcattc ctggaatctg ttgtttatta  46429669 
gcagggatga gaggacagga caccacttgc tggttaaacc atctctagac  46429719 
CTTATCTCTG cCCAGCACCT TTAAACACAA ACTTTGCCCT GGGGCTGCAg  46429769 
CCCTCTGAAG CCACCGGAGC TAAATGAGGT GCATTTGGGT TTTGAGCCTG  46429819 
TTGATTCACA CTTATCTCCa GAGAGTTCTC CTTCCTCCCC TAAAGCTCCC  46429869 
TCTAGAAACT TCCCTCAGGA CCCAAgAGGG AACCTCTGCC AAACCAGCTC  46429919 
AACCTCCACC ATCTAATTCC ACTGGTATGG ATAAAGCTCA CATCATCCCA  46429969 
GGCCTCAAAA CTCACAAGAC AAGGAGTTCA GATGGTAGTT TAAAATGTTT  46430019 
CCCTTCTCCT AGCCCTGCCC AAGAGACTAA Ttccctgtta cttcagcctt  46430069 
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caccagaagc ccagagtcct ccagggtctt actgctctga tccatccagg  46430119 
cctagtttta tctaaccccc tacctattcc c 
 
C4 (Het 2) 
ccttgggcca agctcaagca agtagcattc ctggaatctg ttgtttatta  46429669 
gcagggatga gaggacagga caccacttgc tggttaaacc atctctagac  46429719 
CTTATCTCTG cCCAGCACCT TTAAaCACAA ACTTTGCCCT GGGGCTGCAG  46429769 
CCCTCTGAAG CCACCGGAGC TAAATGAGGT GCATTTGGGT TTTGAGCCTG  46429819 
TTGATTCACA CTTATCTCCa GAGAGTTCTC CTTCCTCCCC TAAAGCTCCC  46429869 
TCTAGAAACT TCCCTCAGGA CCCAAgagGG AACCTCTGCC AAACCAGCTC  46429919 
AACCTCCACC ATCTAATTCC ACTGGTATGG ATAAAGCTCA CATCATCCCA  46429969 
GGCCTCAAAA CTCACAAGAC AAGGAGTTCA GATGGTAgTT TAAAATGTTT  46430019 
CCCTTCTCCT AGCCCTGCCC AAGAGACTAA Ttccctgtta cttcagcctt  46430069 
caccagaagc ccagagtcct ccagggtctt actgctctga tccatccagg  46430119 
cctagtttta tctaaccccc tacctattcc c 
 
G11 (Het 3) 
ccttgggcca agctcaagca agtagcattc ctggaatctg ttgtttatta  46429669 
gcagggatga gaggacagga caccacttgc tggttaaacc atctctagac  46429719 
CTTATCTCTG CCcAGCACCT TTaAACACAA ACTTTGCCCT GGGGCTGCAG  46429769 
CCCTCTGAAG CCACCGGAGC TAAATGAGGT GCATTTGGGT TTTGAGCCTG  46429819 
TTGATTCACA CTTATCTCCa GAGAGTTCTC CTTCCTCCCC TAAAGCTCCC  46429869 
TCTAGAAACT TCCCTCAGGA CCCAAGAGGG AACCTCTGCC AAACCAGCTC  46429919 
AACCTCCACC ATCTAATTCC ACTGGTATGG ATAAAGCTCA CATCATCCCA  46429969 
GGCCTCAAAA CTCACAAGAC AAGGAGTTCA GATGGTAGTT TAAAATGTTT  46430019 
CCCTTCTCCT AGCCCTGCCC AAGAGACTAA Ttccctgtta cttcagcctt  46430069 
caccagaagc ccagagtcct ccagggtctt actgctctga tccatccagg  46430119 
cctagtttta tctaaccccc tacctattcc c 
 
 
 
Intergenic 2 (TGFβRAP1 promoter) 
 
 
E11(Ctr3) 
gtttaatcac tgatgaagtg ctcatgggca agcaccttgt ctatcaggaa  105945134 
ggaaggcagc tgcgggtgtg attgtggtgg caagttaagg cactgagaag  105945084 
GTGTGCAGGG aAGATCCTAC TGCGTTGTGT GTGTTGGCTT GGTTGGAGTC  105945034 
AGGATGAACG AATGTAGAGG GACTGTGTGG TGGCTGCTAC TCTCTCATGG  105944984 
TGGACATGCT TCTCTCTGTT GGTCAGCCGG AAGCTGGCAg ACAACTGAgA  105944934 
GCTCGCAGTT CCaTGGTcag tcagAAGGAA CATTTGgtCA gCTGCTTCCT  105944884 
TtTCTTTTTC CTTCCATTTC TGCCagcCgA gcaGCCTCAA CaGtCaTTGC  105944834 
AgCTGCTTCT GTgATGTGTA GCAAAacgct gcctggagta ctagaaagtc  105944784 
tactggctgg AATCTGCTGG AACCTGTCca taactagcct gccccaggtc  105944734 
atctatgaaa tgggagtgat gctctgtggt ggtaatgaat gtggagtgtg  105944684 
ggttcaaatc ctgcctctgc catttcct 
 
F4 (Ctr2) 
gtttaatcac tgatgaagtg ctcatgggca agcaccttgt ctatcaggaa  105945134 
ggaaggcagc tgcgggtgtg attgtggtgg caagttaagg cactgagaag  105945084 
GTGTGCAGGg aAGATCCTAC TGCGTTGTGT GTGTTGGCTT gGTTGGAGTC  105945034 
AGGATGAACG AATGTAGAGG GACTGTGTGG TGGCTGCTAC TCTCTCATGG  105944984 
TgGACATGCT TCTCTCTGTT GGTCAgCCGG AAGCTGGCAg ACAACTGAgA  105944934 
GCTCGCAGTT CCaTGGTcag tcagAAGGAA CAtTTGgtCA gCTGCTTCCt  105944884 
TTTCTTTTTC CTTCCATTTC TGCCagcCgA gcaGCCTCAA CAGtCaTTGc  105944834 
agCTGCTTCT GTgATGTGTA gCAAAacgct gcctggagta ctagaaagtc  105944784 
tactggctgg aatctgctgg aacctgtcca taactagcct gccccaggtc  105944734 
atctatgaaa tgggagtgat gctct 
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E4 (Ctr 1) 
ttaatcactg atgaagtgct catgggcaag caccttgtct atcaggaagg  105945132 
aaggcagctg cgggtgtgat tgtggtggca agttaaggca ctgagaaggt  105945082 
GTGCAGGGAa gatCCTACTG CGTTGTGTGT GTTGGCTTgG TTGGAGTCAG  105945032 
GATGAACGAA TGTAGAGGGA CTGTGTGGTG GCTGCTACTC TCTCATGGTG  105944982 
GACATGCTTC TCTCTGTTGG TCAgCCGGAA GCTGGCAgAC AACTGAgAGC  105944932 
TCGCAgTTCC ATGGTCAgTC AgAAGGAACA TTTGGTCagC TGCTTCCtTT  105944882 
TCTTTTTCCT TCCATTTCTG CCAgccgagc AGCCTCAACA GtCATTGCAg  105944832 
CTGCTTCTGT GATGTGTAgC AAAACGCTGC CTGGAgTACT AgAAAgTCTA  105944782 
CTGGctggaa tctgctggaa cctgtccata actagcctgc cccaggtcat  105944732 
ctatgaaatg ggagtgatgc tctgtggtgg taatgaatgt ggagtgtggg  105944682 
ttca 
 
C4 (Het 2)  
ttaatcactg atgaagtgct catgggcaag caccttgtct atcaggaagg  105945132 
aaggcagctg cgggtgtgat tgtggtggca agttaaggca ctgagaaggt  105945082 
GTGCAGGGaA GATCCTACTG CGTTGTGTGT GTTGGCTTGG TTGGAGTCAG  105945032 
GATGAACGAA TGTAGAGGGA CTGTGTGGTG GCTGCTACTC TCTCATGGTG  105944982 
GACATGCTTC TCTCTGTTGG TCAGCCGGAA GCTGGCAGAC AACTGAgAGC  105944932 
TCGCAGTTCC ATGGtCAgTC AGAAGgAACA TTTGGTCAgC TGCTTCCTTT  105944882 
TCTTTTTCCT TCCATTTCTG CCagCCgAgc AGCCTCAACA GtCaTTGCAG  105944832 
CTGCTTCTGT GATGTGTAgC AAAACGCTGC CTGGAgTACT AgAAAgTCTA  105944782 
CTGgCTGgAA TCTGCTGGAA CCTGTCcata actagcctgc cccaggtcat  105944732 
ctatgaaatg ggagtgatgc tctgtggtgg taatgaatgt ggagtgtggg  105944682 
ttcaaatcct gcctctgcca tttcct 
 
A8 (Het 1) 
agtgctcatg ggcaagcacc ttgtctatca ggaaggaagg cagctgcggg  105945118 
tgtgattgtg gtggcaagtt aaggcactga gaaggtgtgc agggaagatc  105945068 
CTACTGCGTT GTGTGTGTTG GCTTgGTTGG AGTCAGGATG AACGAATGTA  105945018 
GAGGGACTGT GTGGTGGCTG CTACTCTCTC ATGGTGGACA TGCTTCTCTC  105944968 
TGTTGGTCAg CCGGAAGCTG GCAgACAACT GAgaGCTCGC AGTTCCaTGG  105944918 
TcagtcagAA GGAACATTTG gtCAgCTGCT TCCTTTTCTT TTTCCTTCCA  105944868 
TTTCTGCCag cCgAgcaGCC TCAACaGtCa TtgcagCTGC TTCTGTgATG  105944818 
TGTAgCAAAa cgctgcctgg agtactagaa agTCTACTGg cTggAATCTG  105944768 
CTGGAACCTG TCcataacta gcctgcccca ggtcatctat gaaatgggag  105944718 
tgatgctctg tggtggtaat gaatgtggag tgtgggttca aatcctgcct  105944668 
ctgccatttc ct 
 
G11 (Het 3) 
ttaatcactg atgaagtgct catgggcaag caccttgtct atcaggaagg  105945132 
aaggcagctg cgggtgtgat tgtggtggca agttaaggca ctgagaaggt  105945082 
GTGCAGGgaA GATCCTACTG CGTTGTGTGT GTTGGCTTGg tTgGAGTCAG  105945032 
GATGAACGAA TGTAGAGGGA CTGTGTGGTG GCTGCTACTC TCTCATGGTg  105944982 
GACATGCTTC TCTCTGTTGG TCAgCCGGAA GCTGGCAgAC AACTGAgAGC  105944932 
TCGCAGTTCC ATGGtcagtc agAAGGAACA TTTGgtcagC TGCTTCCTTT  105944882 
TCTTTTTCCT TCCATTTCTG CCAgcCgAgc AGCCTCAACA GtCATTGCAg  105944832 
CTGCTTCTGT GATGTGTAgC AAAACgctgc ctggagtact agaaagTCTA  105944782 
CTGgcTGgAA TCTGCTGGAA CCTGTCcata actagcctgc cccaggtcat  105944732 
ctatgaaatg ggagtgatgc tctgtggtgg taatgaatgt ggagtgtggg  105944682 
ttcaaatcct gcctctgcca tttcct 
 
 
WWC2 
 
E4 (Ctr 1) 
attctcctcc accacagtat tggagctttc gggaagatgt gatgttactg  184190947 
tttaaagcaa tatgacattt aaatgctaca gcagaagact tcacagttaa  184190997 
CTAAtTGTGA GTttaATACa CTGTTGTGCG TaATAACCAg AAAACCATTA  184191047 
TGTCCCAGTA AAGTTACATA AgTATTcaaa tgcAGGCATC TAgAGATGTG  184191097 
CCATGTGTTC AgAAAACAAT GTGAGTCTCC AATTGAgCTT TTCTCTGcag  184191147 
TCCAgTGGGA AGCACAgAAA CACATGTTTC ATGATGAACA AAGTTTAAgA  184191197 
GGGGtAGGTT TCTTCTTAAT TTTTCTTCTT GTTTTCTTTA CTTGAAAAAA  184191247 
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ATATCTGATG ATaTTGTCTG ACAATAAAGT TAGAAAGAAG CAgagctaac  184191297 
agactcgtta ggctatcaga aaggctttag tatcatagat gtcatattta  184191347 
gtataataga tgtcagaggc tcccacaaag ttcataaata tt 
 
F4 (Ctr 2) 
cctccaccac agtattggag ctttcgggaa gatgtgatgt tactgtttaa  184190952 
agcaatatga catttaaatg ctacagcaga agacttcaca gttaactaat  184191002 
TGTGAGTTTa ATACACTGTT GTGCGTAATA ACCAgAAAAC CATTATGTCC  184191052 
CAGTAAAGTT ACATAAGTAT TCAAATGCAG GCATCTAgAG ATGTGCCATG  184191102 
TGTTCAgAAA ACAATGTGAG TCTCCAATTG AGCTTTTCTC TGCAGTCCAG  184191152 
TGGGAAGCAC AgAAACACAT GTTTCATGAT GAACAAAGTT TAAgAGGGGT  184191202 
AGGTTTCTTC TTAATTTTTC TTCTTGTTTT CTTTACTTGA AAAAAATATC  184191252 
TgATGATaTT GTCTGACAAT AAAGTTAgaa agaagcagag ctaacagact  184191302 
cgttaggcta tcagaaaggc tttagtatca tagatgtcat atttagtata  184191352 
atagatgtca gaggctccca caaagtt 
 
E11 (Ctr 3) 
cctccaccac agtattggag ctttcgggaa gatgtgatgt tactgtttaa  184190952 
agcaatatga catttaaatg ctacagcaga agacttcaca gttaactaat  184191002 
TGTGAGTTta ATACaCTGTT GTGCGTaATA ACCAgAAAAC CATTATGTCC  184191052 
CAGTAAAGTT ACATAAgTAT TCAAATGCAG GCaTCTAgAG ATGTGCCATG  184191102 
TGTTCAgAAA acAATGTGAG TCTCCAATTG AgCTTTTCTC TGcagTCCAG  184191152 
TGGGAAGCAC AgAAACACAT GTTTCATGAT GAACAAAGTT TAAgAGGGGT  184191202 
AGGTTTCTTC TTAATTTTTC TTCTTGTTTT CTTTACTTGA AAAAAATATC  184191252 
TGATGATaTT GTCTGACAAT AAAGTTAgAA AGAAGCAgag CTAACAgACT  184191302 
CGTtaggcta tcagaaaggc tttagtatca tagatgtcat atttagtata  184191352 
atagatgtca gaggctccca caaagttcat aaatattata ttgatagcct  184191402 
taa 
 
A8 (Het 1) 
cctccaccac agtattggag ctttcgggaa gatgtgatgt tactgtttaa  184190952 
agcaatatga catttaaatg ctacagcaga agacttcaca gttaactaat  184191002 
TGTGAGTTta ATACaCTGTT GTGCGTAaTA ACCAgAAAAC CATTATGTCC  184191052 
CAGTAAAGTT ACATAAGTAT TcaAAtGCAG GCaTCTAGAG ATGTGCCATG  184191102 
TGTTCAgAAA ACAATGTGaG TCTCCAATTG AGCTTTTCTC TGCAGTCCAG  184191152 
TGGGAAGCAC AgAAACACAT GTTTCATGAT GAACAAAGTT TAAgAGGGGT  184191202 
AGGTTTCTTC TTAATTTTTC TTCTTGTTTT CTTTACTTGA AAAAAATATC  184191252 
TgATGATaTT GTCTGACAAT AAAGTTAgaa agaagcagag ctaacagact  184191302 
cgttaggcta tcagaaaggc tttagtatca tagatgtcat atttagtata  184191352 
atagatgtca gaggctccca caaagtt 
 
C4 (Het 2) 
cctccaccac agtattggag ctttcgggaa gatgtgatgt tactgtttaa  184190952 
agcaatatga catttaaatg ctacagcaga agacttcaca gttaactaat  184191002 
TGTGAGTTta ATACACTGTT GTGCGTAATA ACCAgAAAAC CATTATGTCC  184191052 
CAGTAAAGTT ACATAAGTAT TCAAATGCAG GCaTCTAgAG ATGTGCCATG  184191102 
TGTTCAgAAA ACAATGTGAG TCTCCAATTG AGCTTTTCTC TGCAGTCCAG  184191152 
TGGGAAGCAC AgAAACACAT GTTTCATGAT GAACAAAGTT TAAgAGGGGT  184191202 
AGGTTTCTTC TTAATTTTTC TTCTTGTTTT CTTTACTTGA AAAAAATATC  184191252 
TgATGATaTT GTCTGACAAT AAAGTTAgaa agaagcagag ctaacagact  184191302 
cgttaggcta tcagaaaggc tttagtatca tagatgtcat atttagtata  184191352 
atagatgtca gaggctccca caaagt 
 
G11 (Het 3) 
cctccaccac agtattggag ctttcgggaa gatgtgatgt tactgtttaa  184190952 
agcaatatga catttaaatg ctacagcaga agacttcaca gttaactaat  184191002 
TGTGAGTTta ATACACTGTT GTGCGTAATA ACCAgAAAAC CATTATGTCC  184191052 
CAGTAAAGTT ACATAAGTAT TCAAATGCAG GCaTCTAgAG ATGTGCCATG  184191102 
TGTTCAgAAA ACAATGTGAG TCTCCAATTG AGCTTTTCTC TGCAGTCCAG  184191152 
tGGGAAGCAC AgAAACACAT GTTTCATGAT GAACAAAGTT TAAgAGGGGT  184191202 
AGGTTTCTTC TTAATTTTTC TTCTTGTTTT CTTTACTTGA AAAAAATATC  184191252 
TgATGATaTT GTCTGACAAT AAAGTTAgaa agaagcagag ctaacagact  184191302 
cgttaggcta tcagaaaggc tttagtatca tagatgtcat atttagtata  184191352 
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atagatgtca gaggctccca caaagtt 
 
 
LFNG (intron) 
 
E11 (Ctr 3) 
cccttctccc agcgtcctgt ccacttctgg tttgccacgg gcggcgctgg  2565356 
cttctgcatc agccgtgggc tggctctgaa gatgagcccg tgggccaggt  2565406 
GAGTGCCctg caCAGGTTAG GCCAGCCCGG TCCCAGGCTC CTCGCCACTG  2565456 
TGGGGCCTGG CTTAGTTCAT CTTCCCAGCC ATGGGGTGTC CCCAGCCTCC  2565506 
TGTGTGGcAC TGCCCACTTA CTTCCTATAT TCCACTTCCC TCTgGGTTTC  2565556 
AgAGGGCAGc TGTGTTTACG gCGGCTGCCC CCAAGcCTGA CCTGCTCAGA  2565606 
GcAGcCAgGG GGGCGATGAg CACCCCAGGC ACCATCCggc aGGACTCTTC  2565656 
CCTGcaCCCA gATTCCCTCC ACAgAGAGcC ACGGAGcACA gGAGCTGTGc  2565706 
AGGGAGTGTG ccctggctgt ggccagggga ggcagaggga gctgcagccc  2565756 
agagctctcc tcagggctcc tctccctgag gagtgcagcg cctttgcctg  2565806 
gtggggcctc  
 
F4 (Ctr 2) 
cgtcctgtcc acttctggtt tgccacgggc ggcgctggct tctgcatcag  2565368 
ccgtgggctg gctctgaaga tgagcccgtg ggccaggtga gtgccctgca  2565418 
CAGGTTAGGC CAGCCCGGTC CCAGGCTCCT CGCCACTGTG GGGCCTGGCT  2565468 
TAGTTCATcT TCCCAGCCAT GGGGTGtCCC CAGCCTCCTG TGTGGcACTG  2565518 
CCCACTTACT TCCTATATTC CACTTCCCTC TGGGTTTCAg AGGGCAGcTG  2565568 
TGTTTACgGC GGCTGCCCCC AAGcCTGACC TGCTCAGAGc AGcCAgGGGG  2565618 
GCGATGAGCA CCCCAGGCAC CATCCGGCAG GACTCTTCCC TGCACCCAgA  2565668 
TTCCCTCCAC AgAGAGCCAC GgAGCACAGg AGCTGTGCAG GgAGTGTGcc  2565718 
ctggctgtgg ccaggggagg cagagggagc tgcagcccag agctctcctc  2565768 
agggctcctc tccctgagga gtgcagcgcc tttgcctggt ggggcctc 
 
E4 (Ctr 1) 
cccagcgtcc tgtccacttc tggtttgcca cgggcggcgc tggcttctgc  2565363 
atcagccgtg ggctggctct gaagatgagc ccgtgggcca ggtgagtgcc  2565413 
CTGCAcAGGT TAGGCCAGCC CGGTCCCAGG CTCCTCGCCA CTGTGGGGCC  2565463 
TGGCTTAgTT CATCTTCCCA GCCATGGGGT GTCCCCAGCC TCCTGTGTGG  2565513 
CACTGCCCAC TTACTTCCTA TATTCCACTT CCCTCTGGGT TTCAgAGGGC  2565563 
AGcTGTGTTT ACGgCGGCTG CCCCCAAGcC TGACCTGCTC AGAGcagcca  2565613 
gGGGGGCGAT GAgCACCCCA GGCACCATCC GGcaGGACTC TTCCCTGCAC  2565663 
CCAgATTCCC TCCACAgaga gccacggagc acaggagctg tgcagggagt  2565713 
gtgccctggc tgtggccagg ggaggcagag ggagctgcag cccagagctc  2565763 
tcctcagggc tcctct 
 
C4 (Het 2) 
ccttctccca gcgtcctgtc cacttctggt ttgccacggg cggcgctggc  2565357 
ttctgcatca gccgtgggct ggctctgaag atgagcccgt gggccaggtg  2565407 
AGTGcCCTGC AcAGGTTAGG CCAGCCCGGT CCcAGGCTCC TCGCCACTGT  2565457 
GGGGCCTGGC TTAgTTCATC TTCCCAGCCA TGGGGTGTCC CCAGCCTCCT  2565507 
GTGTGGCACT GCCCACTTAC TTCCTATATT CCACTTCCCT CTGGGTTTCA  2565557 
gAGGGCAgCT GTGTTTACgG CGGCTGCCCC CAAGCCTGAC CTGCTCAGAG  2565607 
cAGCCAGGGG GgCGATGAgC ACCCCAGGCA CCATCCgGCA GGACTCTTCC  2565657 
CTGCACCCAg atTCCCTCCA CAgagagcca cgGAGCACAG gagCTGTGCa  2565707 
GGGAGTGTGc cctggctgtg gccaggggag gcagagggag ctgcagccca  2565757 
gagctctcct cagggctcct ctccctgagg agtgcagcgc ctttgcctgg  2565807 
tggggcctc 
 
A8 (Het 1) 
cccttctccc agcgtcctgt ccacttctgg tttgccacgg gcggcgctgg  2565356 
cttctgcatc agccgtgggc tggctctgaa gatgagcccg tgggccaggt  2565406 
GAGTGcCCTG CAcAGGTTAG GCCAGCCCGG TCCCAGGCTC CTCGCCACTG  2565456 
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TGGGGCCTGG CTTAgTTCAT CTTCCCAGCC ATGGGGTGTC CCCAGCCTCC  2565506 
TGTGTGGcAC TGCCCACTTA CTTCCTATAT TCCACTTCCC TCTGGGTTTC  2565556 
AgAGGGCAGc TGTGTTTACG gCGGCTGCCC CCaAGcCTGA CCTGCTCAGA  2565606 
GcAGcCAgGG GGGCGATGAg CACCCCAGGC ACCATCCGGc aGGACTCTTC  2565656 
CCTGCACCCA gATTCCCTCC ACAgagagcc acggagcaca ggagctgtgc  2565706 
agggagtgtg ccctggctgt ggccagggga ggcagaggga gctgcagccc  2565756 
agagctctcc tcagggctcc tct 
 
G11 (Het 3) 
cccagcgtcc tgtccacttc tggtttgcca cgggcggcgc tggcttctgc  2565363 
atcagccgtg ggctggctct gaagatgagc ccgtgggcca ggtgagtgcc  2565413 
CTGCAcAGGT TAGGCCAGCC CGGTCCcAGG CTCCTCGCCA CTGTGGGGCC  2565463 
TGGCTTAgTT CATCTTCCCA GCCATGGGGT GTCCCCAGCC TCCTGTGTGG  2565513 
cACTGCCCAC TTACTTCCTA TATTCCACTT CCCTCTGGGT TTCAgAGGGC  2565563 
AgCTGTGTTT ACgGCGGCTG CCCCCAAGCC TGACCTGCTC AGAGcAGCCa  2565613 
gGGGGGCGAT GAgCACCCCA GGCACCATCC GGcAGGACTC TTCCCTGCAC  2565663 
CCAgATTCCC TCCACAgaga gccacgGAGC ACAGgagctg tgcagGGAGT  2565713 
GTGccctggc tgtggccagg ggaggcagag ggagctgcag cccagagctc  2565763 
tcctcagggc tcctctccct gaggagtgca gcgcctttgc ctggtggggc  2565813 
ctc 
 
 
DPP6 (intron) 
 
E11 (Ctr 3) 
tttacattag caattacatt gaattaggga ttataagtag tctagaggtg  154445827 
gcttaaagga tacgggagga tgtgcttaca ttatatgcaa ataccacaca  154445877 
TTTTATATca AGGACTTGAG CATCTGTGGA TTTTGGTATC TGCAGGGGTG  154445927 
TCCCGGAACC AATCTTCCAT GGATACCAAG GATGACTGTG CTCATATTTG  154445977 
TGATCATATA TGTTAAAAGC ATCTCTCTGA ATTAgAGAGG GAATCTGTcA  154446027 
CATCTGTCAC TAATATTTTA GAACAGGCCA CCCCGATCCA TCTTtagTGA  154446077 
GTGGAGCATC TCTGCCTgAA AACATCTATA TCCAAATCTt TCTTTCTTTC  154446127 
TTTCtttctt tctttttttg atacagcgtc tcgccctatt gcccaggctg  154446177 
gagtgcagtg acgtgatctc ggctcactgc aacctctgcc tcccaggttc  154446227 
aggc 
 
F4 (Ctr 2) 
cagctgttta cattagcaat tacattgaat tagggattat aagtagtcta  154445821 
gaggtggctt aaaggatacg ggaggatgtg cttacattat atgcaaatac  154445871 
CACACATTTT ATATCAaGGA CTTGAGCATC TGTGGATTTT GGTATCTGCA  154445921 
GGGGTGTCCC GGAACCAATC TTCCATGGAT ACCAAGGATG ACtGTGCTCA  154445971 
TATTTGTGAT CATATATGTT AAAAGCATCT CTCTGAATTA gAGAGGGAAT  154446021 
CTGTCACATC TGTCACTAAT ATTTTAGAAC AGGCCACCCC GATCCATCtT  154446071 
TAgTGAGTGG AGCATCTCTG CCTgAAAACA TCTATATCCA AATCTtTCTT  154446121 
tCTTTCTTTC TTTCtttctt tttttgatac agcgtctcgc cctattgccc  154446171 
aggctggagt gcagtgacgt gatctcggct cactgcaacc tctgcctccc  154446221 
aggttcaggc gatt 
 
E4 (Ctr 1) 
acagctgttt acattagcaa ttacattgaa ttagggatta taagtagtct  154445820 
agaggtggct taaaggatac gggaggatgt gcttacatta tatgcaaata  154445870 
CCACACATTT TATATCAAGG ACTTGAGCAT CTGTGGATTT TGGTATCTGC  154445920 
AGGGGTGTCC CGgAACCAAT CTTCCATGGA TACCAAGGAT GACTGTGCTC  154445970 
ATATTTGTGA TCATATATGT tAAAAGCATC TCTCTGAATT AgAGAGGGAA  154446020 
TCTGTCACAT CTGTCACTAA TATTTTAGAA CAGGCCACCC CGATCCATCt  154446070 
ttagtGAGTG GAGCATCTCT GCCTgAAAAC ATCTATATCC AAATCTttCT  154446120 
TTCTTTCTTT CTTtctttct ttttttgata cagcgtctcg ccctattgcc  154446170 
caggctggag tgcagtgacg tgatctcggc tcactgcaac ctctgcctcc  154446220 
caggttcagg cga 
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C4 (Het 2) 
tttacattag caattacatt gaattaggga ttataagtag tctagaggtg  154445827 
gcttaaagga tacgggagga tgtgcttaca ttatatgcaa ataccacaca  154445877 
TTTTATATCA AGGACTTGAG CATCTGTGGA TTTTGGTATC TGCAGGGGTG  154445927 
TCCCGGAACC AATCTTCCAT GGATACCAAG GATGACTGTG CTCATATTTG  154445977 
TGATCATATA TGTtAAAAGC ATCTCTCTGA ATTAgAGAGG GAATCTGTCa  154446027 
CATCTGTCAC TAATATTTTA GAACAGGCCA CCCCGATCCA TCtTTAgTGA  154446077 
GTGGAGCATC TCTGCCTgAA AACATCTATA TCCAAATCTT TCTTTCTTTC  154446127 
TTTCTTtctt tctttttttg atacagcgtc tcgccctatt gcccaggctg  154446177 
gagtgcagtg acgtgatctc ggctcactgc aacctctgcc tcccaggttc  154446227 
aggcga 
 
A8 (Het 1) 
tagcaattac attgaattag ggattataag tagtctagag gtggcttaaa  154445834 
ggatacggga ggatgtgctt acattatatg caaataccac acattttata  154445884 
TCAAGGACTT GAGCATCTGT GGATTTTGGT ATCTGCAGGG GTGTCCCGGA  154445934 
ACCAATCTTC CATGGATACC AAGGATGACT GTGCTCATAT TTGTGATCAT  154445984 
ATATGTTAAA AGCATCTCTC TGAATTAgAG AGGGAATCTG TCaCATCTGT  154446034 
CACTAATATT TTAGAACAGG CCACCCCGAT CCATCTTTAg TGAGTgGAGC  154446084 
ATCTCTGCCT gAAAACATCT ATATCCAAAT CTTTCTTTCT TTCTTTCttt  154446134 
ctttcttttt ttgatacagc gtctcgccct attgcccagg ctggagtgca  154446184 
gtgacgtgat ctcggctcac tgcaacctct gcctcccagg ttcaggc 
 
G11 (Het 3) 
gctgtttaca ttagcaatta cattgaatta gggattataa gtagtctaga  154445823 
ggtggcttaa aggatacggg aggatgtgct tacattatat gcaaatacca  154445873 
CACATTTTAT ATCAAGGACT TGAGCATCTG TGGATTTTGG TATCTGCAGG  154445923 
GGTGTCCCGG AACCAATCTT CCATGGATAC CAAGGATGAC TGTGCTCATA  154445973 
TTTGTGATCA TATATGTTAA AAGCATCTCT CTGAATTAgA GAGGGAATCT  154446023 
GTCaCATCTG TCACTAATAT TTTAGAACAG GCCACCCCGA TCCATCtTTA  154446073 
gTGAGTgGAG CATCTCTGCC TgAAAACATC TATATCCAAA TCTTTCTTTC  154446123 
TTTCtttctt tctttctttt tttgatacag cgtctcgccc tattgcccag  154446173 
gctggagtgc agtgacgtga tctcggctca ctgcaacctc tgcctcccag  154446223 
gttc 
 
 
IGSF9B (intron) 
 
E11 (Ctr 3)  
Failed 
 
F4 (Ctr 2) 
actgggcttt ggtaggatac atagtctctc tggcactgac agcaggactg  133814804 
ggaggggacc ctagcatcct ggaccccagc ctgccttccc tctgccctag  133814754 
AGAGGGAAGC TGGGtgagcc agtagTCCTG GAAATGCTGc tgggataggg  133814704 
atattgctca gcctgaatgg aggtgctCCC GGGTGCGCTg GAGACCCCCC  133814654 
ACCcATCCTC TTCTGTTGGC aCTTTTtCAT TcTCTCTTtC ATCTCttcac  133814604 
agctctgtat ccatcatgcc ttacttttgt ctcaggagac ctccaaaaga  133814554 
atgagagtat tctagggaac tgaggctgct ctcaatgcca agtgc 
 
E4 (Ctr 1) 
ggcttctgca cctctggcct cctcattgcc acatgtgaga cacagatggc  133814973 
atcctactgg ggcaggggat tagagctgag gaagggtgcc tccaggatgt  133814923 
TTGCTCTGAT GGCCAaCCCA TTCCTTGTTC TCaGGCTTCt GGGCCCTGCT  133814873 
GCCCTCATCT CCTGGGGTCA CTGGGCTTTG gtagGATACA TAgTCTCTCT  133814823 
GGCACTGACa gcagGACTGG GAgGGGACCC TAgCATCCTG gACCCCAGCC  133814773 
TGCCTTCCCT CTGCCCTAgA GAGGGAAGCT GGgtgagcca gtagTCCTgG  133814723 
AAATGCTGCT GGgATAgGGA TATTGCTCAG CCtGAATGGA gGTGCTCCCg  133814673 
GGTGCGCTGG AGACCCCCCA CCCaTCCtCT TCTGTTGGCA CTTTTtCaTT  133814623 
CTCTCTTTCA TCTCTtcaca gctctgtatc catcatgcct tacttttgtc  133814573 
tcaggagacc tccaaaagaa tgagagtatt ctagggaact gaggctgctc  133814523 
tcaatgccaa gtgca 
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C4 (Het 2) 
tgtgagacac agatggcatc ctactggggc aggggattag agctgaggaa  133814940 
gggtgcctcc aggatgtttg ctctgatggc caacccattc cttgttctca  133814890 
GGCTTCTGGG CCCTGCTGCC CTCATCTCCT GGGGTCACTG GGCTTTGGTA  133814840 
GgATACATAg TCTCTCTGGC ACTGACAgCA gGACTGGGAG GGGACCCTAg  133814790 
CATCCTGgAC CCCAGCCTGC CTTCCCTCTG CCCTagAGAG GGAAGCTGGg  133814740 
tgagccagta gtcctggaaa tgctgctggg atagggATAT TGCTCAGcct  133814690 
gaatggaggt GCTCCCgGGT GCGCTGGAGA CCCCCCACcc atcctcttct  133814640 
gttggcactt tttcattctc tctttcatct cttcacagct ctgtatccat  133814590 
catgccttac ttttgtctca ggagacctcc aaaagaat 
 
A8 (Het 1) 
gaggcttctg cacctctggc ctcctcattg ccacatgtga gacacagatg  133814975 
gcatcctact ggggcagggg attagagctg aggaagggtg cctccaggat  133814925 
GTTTGCTCtG ATGGCCaACC CATTCCTTGT tctcaGGCTT CTGGGCCCTG  133814875 
CTGCCCTCAT CTCCTGGGGT CACTGGGCTT TGGTAGgATA CATAgTCTCT  133814825 
CTGGCACTGA CagcagGACT GGGAGGGGAC CCTAgCATCC TGgACCCcAG  133814775 
CCTGCCTTCC CTCTGCCCTA gAGAGGGAAG CTGGgtgagc cagtagTCCT  133814725 
GgAAATGCTG CTGGgATAgG GATATTGCTC AGCCtgaatG GAgGtGCTCC  133814675 
CgGGTGCGCT GGAGACCCCC CACCCaTCCT CTTctGTTGG CaCTTTTtCa  133814625 
TTCTCTCTTt CATCTCttca cagctctgta tccatcatgc cttacttttg  133814575 
tctcaggaga cctccaaaag aatgagagta ttctagggaa ctgaggctgc  133814525 
tctcaatgcc aagtgc 
 
G11 (Het 3) 
ggcttctgca cctctggcct cctcattgcc acatgtgaga cacagatggc  133814973 
atcctactgg ggcaggggat tagagctgag gaagggtgcc tccaggatgt  133814923 
TTGCTCTGAT GGCCaACCCA TTCCTTGTTC TCAGGCTTCT GGGCCCTGCT  133814873 
GCCCTCATCT CCTGGGGTCA CTGGGCTTTG GTAGGATACA TAGTCTCTCT  133814823 
GGCACTGACA GCAGGACTGG GAGGGGACCC TAGCATCCTG GACCCCAGCC  133814773 
TGCCTTCCCT CTGCCCTAGA GAGGGAAGCT GGGTGAGCCA GTAGTCCTGG  133814723 
AAATGCTGCT GGGATAGGGA TATTGCTCAG CCTGAATGGA GGTGCTCCCG  133814673 
GGTGCGCTGG AGACCCCCCA CCCATCCTCT TCTGTTGGCA CTTTTTCATT  133814623 
CTCTCTTTCA TCTCTTCACA GCTCTGTATC CATCATGCCT tacttttgtc  133814573 
tcaggagacc tccaaaagaa tgagagtatt ctagggaact gaggctgctc  133814523 
tcaatgccaa gtgcattgag ttgccttgca ggctggggca  
 
 
TSPAN11 
 
E11 (Ctr 3) 
ccccgggcac gctggacggc acgaggccct cagaggccca gagctctctc  31080020 
ccaaggcaca agtgcagaaa ggcagactca tgcgcatagt tatggacacc  31079970 
GTGTTGCGTG TccCATGCAG ACACCAATAc CTGCTCACAT GCCCCGCGAG  31079920 
TGTcCCAGGC ATTCCTGCCT CCTCCACTCC tcatccccag ccggcttccc  31079870 
tctgcccgcc cgggggAAGC TCGGgacaGT CTAGCTCGGG ACTGCcGGCG  31079820 
gggcgggcag cgGAGGtGGA GGCGcCTCTC CtGGACCCCC AgCCCCCTCC  31079770 
CGCggcGCCC CCACTCCTCG GGCGCGCTTC TGCACTTACC CTGCCAgGGG  31079720 
CTCCggaagc ggcgaaggga gctgcgccta gagagactga gagcggcggc  31079670 
tcccggggcc gcccagccgc ccaccgcccg cagccagcgc tcctccctcc  31079620 
cagc 
 
F4 (Ctr 2) 
ccccgggcac gctggacggc acgaggccct cagaggccca gagctctctc  31080020 
ccaaggcaca agtgcagaaa ggcagactca tgcgcatagt tatggacacc  31079970 
GTGTTGCGTG TcCCATGCAG ACACCAATAC cTGCTCaCAT GCCCCGCgAG  31079920 
TGTCcCAGGC ATTCCTGCCT CCTCCACTCC TCATCCCCAG CCGGCTTCCC  31079870 
TCTGCCCGcC cgGGGGAaGC TCGGGAcagT CTAGCTCGGG ACTGCCGgcg  31079820 
gggcgggcag cggaggtgGA GGCGCCTCTC CTGgACCCCC AGCCCCCTCC  31079770 
CGCGGCGCCC CCACTCCTCG GGCGCGCTTC TGCACTTACC CTGCCAGGGG  31079720 
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CTCCggaagc ggcgaaggga gctgcgccta gagagactga gagcggcggc  31079670 
tcccggggcc gcccagccgc ccaccgcccg cagccagcgc tcctccctcc  31079620 
cagc 
 
E4 (Ctr 1) 
tgccccgggc acgctggacg gcacgaggcc ctcagaggcc cagagctctc  31080022 
tcccaaggca caagtgcaga aaggcagact catgcgcata gttatggaca  31079972 
CCGTGTTGCG TGTCCCATGC AGACACCAAT AcCTGCTCAC ATGCCCCGCG  31079922 
AGTGTCCCAG GCATTCCTGC CTCCTCCACT CCTCATCCCC AGCCGGCTTC  31079872 
CCTCTGCCCG CcCGGGGGAA GCTCGGGACA GTCtaGCTCG GGACTGCCGG  31079822 
CGgggcgggc agcgGAGGtG GAGGCGCCTC TCCTGgACCC cCAgCCCCCT  31079772 
CCCGCGGCGC CCCCACTCCT CGGGCGCGCT TCTGCACTTA CCCTGCCAGG  31079722 
GGCTCCggaa gcggcgaagg gagctgcgcc tagagagact gagagcggcg  31079672 
gctcccgggg ccgcccagcc gcccaccgcc cgcagccagc gctcctccct  31079622 
cccagc 
 
C4 (Het 2) 
gccccgggca cgctggacgg cacgaggccc tcagaggccc agagctctct  31080021 
cccaaggcac aagtgcagaa aggcagactc atgcgcatag ttatggacac  31079971 
CGTGTTGCGT GTcCCATGCA GACACCAATA cCTGCTCACA TGCCCCGCGA  31079921 
GTGtcCCAGG CATTCCTGCC TCCTCCACTC CTCATCCCCA GCCgGCTTCC  31079871 
CTCTGCCCGc cCGGGGGAAG CTCGGGAcag tCtaGCTCGG GACTGCCGgc  31079821 
ggggcgggca gcgGAGGtGG AGGCGCCTCT CCTGgACCCc CAgCCCCCTC  31079771 
CCGCGGCGCC CCCACTCCTC GGGCGCGCTT CTGCACTTAC CCTGCCAGGG  31079721 
GCTCCGGAAg CGGCgAAGGg AGCTGCgCCT Agagagactg agagcggcgg  31079671 
ctcccggggc cgcccagccg cccaccgccc gcagccagcg ctcctccctc  31079621 
ccagcccggg aaggtcagcg tgtgggcagc c 
 
A8 (Het 1) 
gccccgggca cgctggacgg cacgaggccc tcagaggccc agagctctct  31080021 
cccaaggcac aagtgcagaa aggcagactc atgcgcatag ttatggacac  31079971 
CGTGTTGCGT GTcCCATGCA GACACCAATA CCTGCTCACA TGCCCCGCGA  31079921 
GTGTcCCAGG CATTCCTGCC TCCTCCACTC CTCATCCCCA GCCGGCTTCC  31079871 
CTCTGCCCGc ccgggggaaG CTCGGGAcag tctagctCGG GACTGCCGgc  31079821 
ggggcgggca gcggaggtgg aggcgcCTCT CCTGgACCCc CAGCCCCCTC  31079771 
CCGCGGCGCC CCCACTCCTc GGGCGCGCTT CTGCACTTAC CCTGCCAGGG  31079721 
GCTCCGGAAg CGgcgaaggg agctgcgcct agagagactg agagcggcgg  31079671 
ctcccggggc cgcccagccg cccaccgccc gcagccagcg ctcctccctc  31079621 
ccagcccggg aaggtcagcg tgtgggcagc ccggcccgcg cccctgcgcc  31079571 
 
G11 (Het 3) 
ccccgggcac gctggacggc acgaggccct cagaggccca gagctctctc  31080020 
ccaaggcaca agtgcagaaa ggcagactca tgcgcatagt tatggacacc  31079970 
GTGTTGCGTG TcCCATGCAG ACACCAATAc CTGCTCACAT GCCCCGCGAG  31079920 
TGTCcCAGGC ATTCCTGCCT CCTCCACTCC TCATCCCCAG CCGGCTTCCC  31079870 
TCTGCCCgCc CGGGGGAAGC TCGGGAcagt CtaGCTCGGG ACTGCCGGCG  31079820 
GGgcgggcag cgGAGGtGGA GGCGCCTCTC CTGgaCCCcC AGCCCCCTCC  31079770 
CGCGGCGCCC CCACTCCTCG GGCGCGCTTC TGCACTTACC CTGCCAGGGG  31079720 
CTCCGGAAgC GGCgAAGGga gctgcgccta gagagactga gagcggcggc  31079670 
tcccggggcc gcccagccgc ccaccgcccg cagccagcgc tcctccctcc  31079620 
cagcccggga aggtcagc 
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Appendix 9: Allelic Imbalance table, raw data 
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Appendix 10: FGFR2b-GFP construct 
The construct was assembled from two Gene Art plasmids Gene ART project for GFP-
tagged FGFR2b construct. The 2 fragment were synthesised by Invitrogen and provided as 
two vectors.  
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Appendix 11: FGFR2b-GFP/neo construct targeted integration 
Diagram showing the structure of the FGFR2b-GFP construct and the insertion locus in the 
second intron of the FGFR2 gene. 
 
 
 
FGFR2b-GFP construct 
The coding region of the GFP-tagged FGFR2b construct was synthesised by 
Invitrogen (GeneART project) as two distinct inserts cloned into PMK-RQ vector. 
The vector FGFR2b_A was opened by a double digestion using EcoRI and PacI and 
purified. The insert FGFR2b_B was excised from the vector using double digestion 
with EcoRI and PacI. This generated compatible ends for cloning the second insert 
into the first vector (1:3 ratio) in the following ligation reaction, carried out 
overnight at 4°C: 
T4 Ligase..................................................1 µl 
10X Ligase buffer (with ATP)...................1 µl 
Vector FGFR2b_A.....................................2 µl 
Insert FGFR2b_B.......................................6 µl 
Insert A+B was lifted out of PMK-RQ using SpeI restriction enzyme digestion and 
cloned in MCF7 repair template with a unique SpeI site in the middle of the 2kb 
homology region, previously created by site-directed mutagenesis (SDM). In a later 
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stage, a neomycin resistance cassette was added (from PGKneolox2DTA.2 vector, 
Addgene) after the poly(A) tail of the cDNA using a BamHI restriction site. 
Transfection in T47D cells 
ZFN-edited T47D cells were seeded in 96 well plates at a concentration of 4 
cells/ml, with 100 µl of complete medium containing 600 µg/ml of G418 antibiotic 
(Sigma) in each well. After the single cell colonies reached 50 to 100 cells, they 
were detached by trypsination and transferred to a new 96 well plate and 
duplicated. A duplicate of each plate containing monoclonal MCF10A and MCF7 
cells was made 7 days later and sent to the Genome Centre (Barts Cancer Institute, 
QMUL) for gDNA extraction and Taqman SNP genotyping assay for rs2981578, 
once the cells were confluent. The edited T47D cells were screened for GFP 
expression, as observed under UV light microscopy.  
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Appendix 12: Culture media used for each cell lines 
 
 
Cell line Culture media 
AU561 RPMI, 10% FBS 
BT20 DMEM, 10%FBS 
BT474 RPMI, 10% FBS 
Cal51 RPMI, 10% FBS 
H3396 DMEM, 10%FBS 
HFF2 DMEM, 10%FBS 
MCF10A DMEM, F12* 
MCF7 DMEM, 10%FBS 
MDA-MB-231 DMEM, 10%FBS 
MDA-MB-453 DMEM, 10%FBS 
MDA-MB-468 L15, 10% FBS 
SKBR3 RPMI, 10% FBS 
SUM159 Ham's F12, 5%FBS, IH# 
T47D RPMI, 10% FBS 
ZR-75-1 RPMI, 10% FBS 
β4-1089 DMEM, 10%FBS 
 
* DMEM/F12 media supplemented with 5% horse serum, 20 ng/ml EGF, 100 ng/ml 
cholera enterotoxin, 0.01 mg/ml insulin and 500 ng/ml hydrocortisone. 
# Ham’s F12 media supplemented with 5% FBS, insuling (0.01 mg/ml) and hydrocortisone 
(500 ng/ml) 
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Appendix 13: FACS GFP sorting 
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Appendix 14: rs35054928 genotype in MCF7 cells 
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Appendix 15: Previous publication 
 
Fibroblast growth factor 22 is not essential for skin development and repair but 
plays a role in tumorigenesis. 
Jarosz M, Robbez-Masson L, Chioni AM, Cross B, Rosewell I, Grose R. 
PLoS One. 2012;7(6):e39436. doi: 10.1371/journal.pone.0039436.  
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